CARIM
SELF EVALUATION
2007 2012
ADDENDA
Faculty of Health, Medicine and Life Sciences, Maastricht University
Maastricht University Medical Centre
ADDENDUM I
GRANTS SUPPORTING RESEARCH IN MAIN THEME I
<table>
<thead>
<tr>
<th>YEAR</th>
<th>TITLE</th>
<th>TYPE</th>
<th>COMPANY BASE/ ORGANISATION</th>
<th>COUNTRY</th>
<th>SUPPORT (K€) from:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NWO/STW foundations</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>contracts</td>
</tr>
<tr>
<td>2007</td>
<td>Consultancy agreement</td>
<td>Contract</td>
<td>Baxter</td>
<td>Austria</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Study of Protein S antagononists</td>
<td>Contract</td>
<td>Baxter</td>
<td>Austria</td>
<td>420</td>
</tr>
<tr>
<td></td>
<td>Donation agreement</td>
<td>Contract</td>
<td>CSL</td>
<td>Belgium</td>
<td>110</td>
</tr>
<tr>
<td></td>
<td>Research agreement</td>
<td>Contract</td>
<td>BRACCO</td>
<td>Italy</td>
<td>221</td>
</tr>
<tr>
<td></td>
<td>Research and collaboration agreement</td>
<td>Contract</td>
<td>CSL Behring GmbH</td>
<td>Germany</td>
<td>46</td>
</tr>
<tr>
<td></td>
<td>Collaboration in studies on platelet inhibition, direct</td>
<td>Contract</td>
<td>AstraZeneca</td>
<td>Sweden</td>
<td>344</td>
</tr>
<tr>
<td></td>
<td>thrombin inhibition and atherosclerotic disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Predictors of recurrent myocardial ischemia in patients after an</td>
<td>Contract</td>
<td>Pfizer BV</td>
<td>The Netherlands</td>
<td>90</td>
</tr>
<tr>
<td></td>
<td>acute myocardial infarction</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consultancy agreement Philips</td>
<td>Contract</td>
<td>Philips Electronics</td>
<td>The Netherlands</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Healthcare Incubator</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phase III Study to Evaluate the Efficacy and Safety of ARIXTRA etc</td>
<td>Contract</td>
<td>CTCM</td>
<td>The</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>Once-daily oral direct factor Xa inhibitor rivaroxaban in the long-</td>
<td>Contract</td>
<td>CTCM</td>
<td>Netherlands</td>
<td>117</td>
</tr>
<tr>
<td></td>
<td>term prevention of recurrent symptomatic venous thromboembolism etc</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral direct factor Xa inhibitor rivaroxaban in patients with acute</td>
<td>Contract</td>
<td>CTCM</td>
<td>The</td>
<td>118</td>
</tr>
<tr>
<td></td>
<td>symptomatic deep-vein thrombosis or pulmonary embolism</td>
<td></td>
<td>Netherlands</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Recover study</td>
<td>Contract</td>
<td>CTCM</td>
<td>The</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Biointerface</td>
<td>Grant</td>
<td>DFG</td>
<td>Germany</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>Surface plasmon resonance as tool in the analysis of biomolecular</td>
<td>Grant</td>
<td>ZonMw</td>
<td>The</td>
<td>291</td>
</tr>
<tr>
<td></td>
<td>interactions that play a role in the</td>
<td></td>
<td></td>
<td>Netherlands</td>
<td></td>
</tr>
<tr>
<td></td>
<td>biology of cardiovascular disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Whitaker International Fellow grant - MA Berny</td>
<td>Grant</td>
<td>Whitaker International USA</td>
<td>USA</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>Thrombus formation on rutured plaques</td>
<td>Grant</td>
<td>NHS</td>
<td>The</td>
<td>68</td>
</tr>
<tr>
<td></td>
<td>Protein S/tissue factor pathway inhibitor (TFPI) in cardiovascular</td>
<td>Grant</td>
<td>NHS</td>
<td>The</td>
<td>240</td>
</tr>
<tr>
<td></td>
<td>disease: physiological implications of a novel anticoagulant</td>
<td></td>
<td></td>
<td>Netherlands</td>
<td></td>
</tr>
<tr>
<td></td>
<td>mechanism?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Identification and characterization of new compounds that are directed</td>
<td>Grant</td>
<td>tUL</td>
<td>The</td>
<td>200</td>
</tr>
<tr>
<td></td>
<td>against selected coagulation proteins</td>
<td></td>
<td>Netherlands</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td>309 548 1,507</td>
</tr>
</tbody>
</table>

<p>| 2008 | Collaboration agreement                                              | Contract     | MosaMedix                  | The         | 80                |
|      | Consultancy agreement Philips Healthcare Incubator                   | Contract     | Philips Electronics        | The         | 10                |
|      | Multicenter, Randomized, parallel, Group Efficacy                    | Contract     | CTCM                       | The         | 121               |
|      | superiority study in hospitalized medically ill patients etc         |              |                            |            |                   |
|      | Antithemophilic Factor (Recombinant) Plasma/ Albumin-Free Method      | Contract     | CTCM                       | The         | 25                |
|      | (AHF-PFM): A Phase 3/4 etc                                          |              |                            |            |                   |
|      | Consultancy agreement                                                | Contract     | Baxter AG                  | Austria     | 10                |
|      | Biointerface                                                         | Grant        | DFG                        | Germany     | 18                |
|      | Novel flow chamber technology to establish the haemostatic of        | Grant        | Sanquin                    | The         | 318               |
|      | stored platelets pre- and posttransfusion                            |              |                            | Netherlands |                   |
|      | Working mechanisms of activated protein C in a mouse model for        | Grant        | Thrombosis Foundation      | The         | 157               |
|      | myocardial ischemia/ reperfusion injury                              |              |                            | Netherlands |                   |
|      | The impact of coagulation factor XII on mechanisms of thrombosis in  | Grant        | NHS                        | The         | 200               |
|      | patients with cardiovascular disease                                 |              |                            | Netherlands |                   |
|      | Total                                                                |              |                            |            | 18 675 246        |</p>
<table>
<thead>
<tr>
<th>YEAR</th>
<th>TITLE</th>
<th>TYPE</th>
<th>COMPANY BASE/ ORGANISATION</th>
<th>COUNTRY</th>
<th>SUPPORT (K€) from: foundations contracts</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>Study of Protein S antagononists</td>
<td>Contract</td>
<td>Baxter INNOVATIONS GMBH</td>
<td>Austria</td>
<td>210</td>
</tr>
<tr>
<td></td>
<td>Collaboration agreement</td>
<td>Contract</td>
<td>MosaMedix</td>
<td>The Netherlands</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td>Can combined measurement of thrombin potential and thrombo-elastography predict the risk of severe bleeding in surgery and trauma?</td>
<td>Contract</td>
<td>CSL Behring GmbH</td>
<td>Germany</td>
<td>86</td>
</tr>
<tr>
<td></td>
<td>Services Agreement</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>ASPASIA E. Castoldi Funtional interactions of genetic defects affecting the protein C pathway in familial thrombophilia</td>
<td>Grant</td>
<td>ZonMw</td>
<td>The Netherlands</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>Trombose Expertise Centre</td>
<td>Grant</td>
<td>Academic Hospital Maastricht</td>
<td>The Netherlands</td>
<td>250</td>
</tr>
<tr>
<td></td>
<td>Discovery and optimalization of biologically active molecules that inhibit the functions of activated protein C</td>
<td>Grant</td>
<td>Bayer HealthCare</td>
<td>United Kingdom</td>
<td>200</td>
</tr>
<tr>
<td></td>
<td>BMM IDDAS</td>
<td>Grant</td>
<td>BMM</td>
<td>The Netherlands</td>
<td>427</td>
</tr>
<tr>
<td></td>
<td>CTMM INCOAG Innovative coagulation diagnostics</td>
<td>Contract</td>
<td>CTMM</td>
<td>The Netherlands</td>
<td>652</td>
</tr>
<tr>
<td></td>
<td>CTMM INCOAG</td>
<td>Contract</td>
<td>CTMM</td>
<td>The Netherlands</td>
<td>935</td>
</tr>
<tr>
<td></td>
<td>CTMM TRIUMPH</td>
<td>Contract</td>
<td>CTMM</td>
<td>The Netherlands</td>
<td>333</td>
</tr>
<tr>
<td></td>
<td>Interreg Va- program “Grensregio Vlaanderen-Nederland&quot; project “Euregional Pact II”</td>
<td>Grant</td>
<td>Interreg Vlaanderen-Nederland</td>
<td>Belgium</td>
<td>650</td>
</tr>
<tr>
<td></td>
<td>Student travel grant</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td></td>
<td><strong>100</strong></td>
</tr>
<tr>
<td>2010</td>
<td>Research agreement</td>
<td>Contract</td>
<td>Novartis</td>
<td>Italy</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>The practical application of antithrombotic and thrombolytic therapy in the hospital environment Translation of the ACCP (American College of Chest Physicians) and relating guidelines into practically applicable workflows</td>
<td>Contract</td>
<td>Philips Electronics Nederland BV</td>
<td>The Netherlands</td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>Ultrasound accelerated catheter-directed thrombolysis combined with standard anticoagulant etc (IFDVT).</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>249</td>
</tr>
<tr>
<td></td>
<td>Study for evaluation of efficacy and safety of (LMW) heparin/edoxaban versus (LMW) heparin/ warfarin in subjects with deep-vein thrombosis and/or pulmonary embolism</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>161</td>
</tr>
<tr>
<td></td>
<td>Can combined measurement of thrombin potential and thrombo-elastography predict the risk of severe bleeding in surgery and trauma?</td>
<td>Contract</td>
<td>CSL Behring GmbH</td>
<td>Germany</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>The Global Anticoagulation Registry in the FIELD (GARFIELD)</td>
<td>Contract</td>
<td>Thrombosis research institute</td>
<td>United Kingdom</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>CTMM EMINENCE</td>
<td>Contract</td>
<td>CTMM</td>
<td>The Netherlands</td>
<td>426</td>
</tr>
<tr>
<td></td>
<td>Trombose Expertise Centre</td>
<td>Grant</td>
<td>Academic Hospital Maastricht</td>
<td>The Netherlands</td>
<td>250</td>
</tr>
<tr>
<td></td>
<td>Student travel grant NHS</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Dynamic fibrin clot formation: a haemostatic process involving multiple blood components and a possible surrogate end point for transfusion</td>
<td>Grant</td>
<td>LSBR</td>
<td>The Netherlands</td>
<td>256</td>
</tr>
<tr>
<td></td>
<td>Trombograph (Pieken in de Delta)</td>
<td>Grant</td>
<td>SenterNovem</td>
<td>The Netherlands</td>
<td>126</td>
</tr>
<tr>
<td></td>
<td>Beta2-glycoprotein I: A novel player in VWF-dependent Haemostasis</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>140</td>
</tr>
<tr>
<td></td>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td></td>
<td><strong>0</strong></td>
</tr>
<tr>
<td>YEAR</td>
<td>TITLE</td>
<td>TYPE</td>
<td>COMPANY BASE/ ORGANISATION</td>
<td>COUNTRY</td>
<td>SUPPORT (K€) from: NWO/STW foundations contracts</td>
</tr>
<tr>
<td>------</td>
<td>-------</td>
<td>------</td>
<td>---------------------------</td>
<td>---------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>2011</td>
<td>Collaboration agreement</td>
<td>Contract</td>
<td>PAREXEL Nederland bv</td>
<td>The Netherlands</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>Study of Protein S and TFPI Antagononists</td>
<td>Contract</td>
<td>Baxter INNO-VATIONS GMBH</td>
<td>Austria</td>
<td>154</td>
</tr>
<tr>
<td></td>
<td>Development research haemostasis</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Sponsoring agreement</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>250</td>
</tr>
<tr>
<td></td>
<td>Co-financiering CAVA</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>176</td>
</tr>
<tr>
<td></td>
<td>The role of blood platelet in tumor angiogenesis and cancer progression</td>
<td>Grant</td>
<td>NWO</td>
<td>The Netherlands</td>
<td>200</td>
</tr>
<tr>
<td></td>
<td>Trombose Expertise Centre</td>
<td>Grant</td>
<td>Academic Hospital Maastricht</td>
<td>The Netherlands</td>
<td>250</td>
</tr>
<tr>
<td></td>
<td>C Hemker Foundation</td>
<td>Grant</td>
<td>SWOL</td>
<td>The Netherlands</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>BioMIMedecs, cross border collaboration on BioMaterials &amp; Life Sciences</td>
<td>Grant</td>
<td>EU/Interreg IV</td>
<td>Belgium</td>
<td>1,302</td>
</tr>
<tr>
<td></td>
<td>Modulation of thrombin generation and activity by total fibrinogen and fibrinogen γ</td>
<td>Grant</td>
<td>Thrombosis Foundation</td>
<td>The Netherlands</td>
<td>141</td>
</tr>
<tr>
<td></td>
<td>Unraveling the role of platelet-derived matrix metalloproteinases in the repair of healthy and diseased arteries</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>279</td>
</tr>
<tr>
<td></td>
<td>Beta2-glycoprotein I: A novel player in VWF-dependent Haemostasis</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>235</td>
</tr>
<tr>
<td></td>
<td>Cytron II</td>
<td>Grant</td>
<td>Agentschap NL (Life Sciences &amp; Health)</td>
<td>The Netherlands</td>
<td>938</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td><strong>200</strong></td>
</tr>
<tr>
<td>2012</td>
<td>The effect of Xa inhibition on atherosclerotic plaque development and progression in normal and pro-thrombotic mice</td>
<td>Contract</td>
<td>Bayer Pharma AG</td>
<td>Germany</td>
<td>104</td>
</tr>
<tr>
<td></td>
<td>Reversal of dabigatran activity with B1655075 in situations of hemodilution and trauma injury in pigs</td>
<td>Contract</td>
<td>Boehringer Ingelheim</td>
<td>Germany</td>
<td>400</td>
</tr>
<tr>
<td></td>
<td>The effect of thrombin inhibition on atherosclerotic plaque development in normal and pro-thrombotic mice</td>
<td>Contract</td>
<td>Boehringer Ingelheim</td>
<td>Germany</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>Comparative study of effects of Dabigatran and Warfarin on atherosclerotic plaque calcification</td>
<td>Contract</td>
<td>Boehringer Ingelheim</td>
<td>Germany</td>
<td>70</td>
</tr>
<tr>
<td></td>
<td>Research agreement</td>
<td>Contract</td>
<td>AstraZeneeca</td>
<td>Sweden</td>
<td>47</td>
</tr>
<tr>
<td></td>
<td>TRACS study</td>
<td>Contract</td>
<td>AstraZeneeca</td>
<td>The Netherlands</td>
<td>45</td>
</tr>
<tr>
<td></td>
<td>Real life observations on innohep thrombosis management in oncology patients</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Open label trial investigating safety and efficacy of on-demand and prophylactic treatment with BAY 94-9027 in severe hemophilia A</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>Psychiatric analysis varous pathology</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>55</td>
</tr>
<tr>
<td></td>
<td>Collaboration agreement</td>
<td>Contract</td>
<td>MosaMedix</td>
<td>The Netherlands</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>Consultancy agreement</td>
<td>Contract</td>
<td>Zin Medical Europe BV</td>
<td>The Netherlands</td>
<td>120</td>
</tr>
<tr>
<td></td>
<td>Study of Protein S and TFPI Antagononists</td>
<td>Contract</td>
<td>Baxter INNO-VATIONS GMBH</td>
<td>Austria</td>
<td>68</td>
</tr>
<tr>
<td></td>
<td>VIDI R Koenen Propellants of atherosclerosis Molecular aspects of RANTES- and PF4-release by activated platelets</td>
<td>Grant</td>
<td>ZonMw</td>
<td>The Netherlands</td>
<td>800</td>
</tr>
<tr>
<td></td>
<td>Improved design of novel therapeutics and idioanalytics for the treatment of cardiovascular disease by use of microcalorimetry</td>
<td>Grant</td>
<td>ZonMw</td>
<td>The Netherlands</td>
<td>178</td>
</tr>
<tr>
<td></td>
<td>Interreg Vfa- program &quot;Grensregio Vlaanderen-Nederland&quot; project &quot;Euregional Pact II&quot;</td>
<td>Grant</td>
<td>Interreg Vlaanderen-Nederland</td>
<td>Belgium</td>
<td>175</td>
</tr>
<tr>
<td></td>
<td>Trombose Expertise Centre</td>
<td>Grant</td>
<td>Academic Hospital Maastricht</td>
<td>The Netherlands</td>
<td>250</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td><strong>978</strong></td>
</tr>
</tbody>
</table>
C_
ADDENDUM II
OUTPUT OF
MAIN THEME I
IN 2007-2012

1. LIST OF PHD THESSES 2007 – 2012
2. LIST OF PUBLICATIONS 2007 – 2012
# PHD THESES 2007

**Boelen E** – Novel radiopaque biomaterials for spinal surgery. 
Promotores: Prof. L Koole, Prof. S Bulstra.  
Maastricht University, April 4, 2007

**Cauwenberghs S** – Platelet responsiveness and function during storage. 
Promotor: Prof. J Rosing. Co-promotores: Dr J Heemskerk, Dr J Curvers.  
Maastricht University, June 20, 2007

**Van Genderen H** – Dynamics of the phosphatidylinerse-expressing cell surface during endocytosis of Annexin A5. 
Promotor: Prof. C Hemker. Co-promotores: Dr W van Heerde, Dr C Reutelingsperger.  
Maastricht University, October 18, 2007

**Hansen H** – Blood coagulation and diabetic vascular complications. 
Promotores: Prof. H ten Cate, Prof. P Reitsma. Co-promotor: Dr H Sproink.  
Maastricht University, February 9, 2007

**Munnik I** – Platelet signalling to procoagulant activity and heterogeneity in thrombus formation. 
Maastricht University, December 17, 2007

**Vanschoonbeek K** – Haemostatic variation in subjects with atherothrombotic risk: modulation by dietary fish oil. 
Maastricht University, December 13, 2007

**Vrij A** – Inflammatory bowel disease and haemostasis: clinical and biochemical studies. 
Maastricht University, February 16, 2007

---

# PHD THESES 2008

**Boelen E** – Novel radiopaque biomaterials for spinal surgery. 
Promotores: Prof. L Koole, Prof. S Bulstra.  
Maastricht University, April 4, 2007

**Cauwenberghs S** – Platelet responsiveness and function during storage. 
Promotor: Prof. J Rosing. Co-promotores: Dr J Heemskerk, Dr J Curvers.  
Maastricht University, June 20, 2007

**Van Genderen H** – Dynamics of the phosphatidylinerse-expressing cell surface during endocytosis of Annexin A5. 
Promotor: Prof. C Hemker. Co-promotores: Dr W van Heerde, Dr C Reutelingsperger.  
Maastricht University, October 18, 2007

**Hansen H** – Blood coagulation and diabetic vascular complications. 
Promotores: Prof. H ten Cate, Prof. P Reitsma. Co-promotor: Dr H Sproink.  
Maastricht University, February 9, 2007

**Munnik I** – Platelet signalling to procoagulant activity and heterogeneity in thrombus formation. 
Maastricht University, December 17, 2007

**Vanschoonbeek K** – Haemostatic variation in subjects with atherothrombotic risk: modulation by dietary fish oil. 
Maastricht University, December 13, 2007

**Vrij A** – Inflammatory bowel disease and haemostasis: clinical and biochemical studies. 
Maastricht University, February 16, 2007

---

# PHD THESES, EXTERNALLY PREPARED

**Van Summeren M** – Vitamin K requirement in children... beyond coagulation. 
Promotores: Prof. W Kuis, Prof. C Vermeer, Prof. M Lilien.  
University Utrecht, December 12, 2007

**Maurissen L** – Characterization of anticoagulant functions of protein S. 
Promotores: Prof. J Rosing, Prof. T Hackeng.  
Maastricht University, February 18, 2009

**Prinzén L** – Bimodal imaging of molecular targets associated with plaque vulnerability. 
Promotores: Prof. D Slaaf, Prof. M van Zandvoort (RWTH, Aachen), Prof. C Reutelingsperger.  
Maastricht University, September 17, 2009

**Tchaikovsky S** – Hormone-induced changes in the coagulation system. 
Maastricht University, December 6, 2009

**Wolfs J** – Generation of procoagulant activity in blood cells. 
Maastricht University, September 10, 2009

---

# PHD THESES 2009

**Boelen E** – Novel radiopaque biomaterials for spinal surgery. 
Promotores: Prof. L Koole, Prof. S Bulstra.  
Maastricht University, April 4, 2007

**Cauwenberghs S** – Platelet responsiveness and function during storage. 
Promotor: Prof. J Rosing. Co-promotores: Dr J Heemskerk, Dr J Curvers.  
Maastricht University, June 20, 2007

**Van Genderen H** – Dynamics of the phosphatidylinerse-expressing cell surface during endocytosis of Annexin A5. 
Promotor: Prof. C Hemker. Co-promotores: Dr W van Heerde, Dr C Reutelingsperger.  
Maastricht University, October 18, 2007

**Hansen H** – Blood coagulation and diabetic vascular complications. 
Promotores: Prof. H ten Cate, Prof. P Reitsma. Co-promotor: Dr H Sproink.  
Maastricht University, February 9, 2007

**Munnik I** – Platelet signalling to procoagulant activity and heterogeneity in thrombus formation. 
Maastricht University, December 17, 2007

**Vanschoonbeek K** – Haemostatic variation in subjects with atherothrombotic risk: modulation by dietary fish oil. 
Maastricht University, December 13, 2007

**Vrij A** – Inflammatory bowel disease and haemostasis: clinical and biochemical studies. 
Maastricht University, February 16, 2007

---

# PHD THESES 2010

**Afrasiabi A** – Molecular Genetic Analysis of Patients with Rare Bleeding; disorders in South Iran. 
Maastricht University, March 17, 2010

**Di Castelnuovo A** – The protective effect of Moderate Alcohol Consumption against Cardiovascular disease and total Mortality: Epidemiological evidence. 
Promotores: Prof. C Hemker and Prof. G de Gaetano (Italy). Co-promotor: Dr M Donati (Campobasso, Italy).  
Maastricht University, June 2, 2010

**Di Giuseppe R** – A nutritional approach to prevent cardiovascular disease: from single foods to complex dietary pattern. 
Promotores: Prof. C Hemker and Prof. G de Gaetano (Italy). Co-promotor: Dr L Iacoviello (Campobasso, Italy).  
Maastricht University, June 2, 2010

**Napoleone E** – Modulation of tissue factor expression in vascular cells. 
Promotores: Prof. C Hemker and Prof. G de Gaetano (Italy). Co-promotor: Dr R Lorenzet (Campobasso, Italy).  
Maastricht University, June 2, 2010

**Schols S** – Thrombin generation and fibrin formation in diolitional coagulopathy: towards improved periproperative transfusion protocols. 
Promotor: Prof. H ten Cate Co-promotores: Prof. J Heemskerk and Dr L van Pampus.  
Maastricht University, February 19, 2010
PHD TESIS 2011

Cranenburg E –
Circulating Matrix Fla-protein: a biomarker for vascular disease.
Promotor: Prof. J Rosing. Co-promotores: Dr C Vermeer, Dr L Schurgers.
Maastricht University, March 17, 2011

Duckers C –
Modulators of bleeding tendency in severe factor V deficiency.
Maastricht University, March 24, 2011

Kilinc E –
Effects of air pollution on haemostasis and atherosclerosis.
Promotor: Prof. H ten Cate. Co-promotor: Dr H Spronk.
Maastricht University, December 22, 2011

Nergiz-Unal R –
Platelets in atherothrombosis - roles of CD36 and P2Y12 receptors.
Maastricht University, June 23, 2011

Rennenberg R –
Vascular Calcifications and Matrix Gla Protein in Hypertensive Subjects.
Promotor: Prof. P de Leeuw. Co-promotores: Dr A Kroon, Dr L Schurgers.
Maastricht University, July 6, 2011

Stevens KNJ –
Blood-contacting biomaterials for critical clinical applications.
Promotores: Prof. J Maessen, Prof. L Koole.
Maastricht University, December 15, 2011

Costanzo S –
Alcohol Consumption in Relation to Cardiovascular Risk and Mortality.
Promotores: Prof. C Hemker; Prof. G de Gaetano, Campobasso, Italy; Prof. H ten Cate.
Maastricht University, January 26, 2012

Gilio K –
All roads to thrombus formation; demystifying platelet signaling pathways.
Promotor Prof. J Heemskerk. Co-promotor: Dr J Cosemans.
Maastricht University, November 12, 2012

Groote O –
Effects of haemostatic agents on trauma induced bleeding.
Promotores: Prof. H ten Cate; Prof. R Rossaint, Aachen; Dr H Spronk
Maastricht University, November 1, 2012

Knotternus I –
Vascular endothelial function and genetic epidemiology in lacunar stroke subtypes.
Promotores: Prof. RJ van Oostenbrugge, Prof. H ten Cate, Prof. J Lodder.
Maastricht University, March 2, 2012

Panova-Noeva M –
Platelet-associated hypercoagulability in patients with Essential Thrombocythemia and Polycythemia Vera.
Promotor: Prof. H ten Cate. Co-promotores: Dr A Falanga, Dr M Marchetti.
Maastricht University, November 29, 2012

Ruiter M –
Reactivity, recruitment and remodeling of collateral arteries in diabetes.
Promotores: Prof. N Schaper, Prof. C Stehouwer. Co-promotores: Dr M Huijberts; Dr J van Golde.
Maastricht University, September 6, 2012

PHD TESIS 2012

Klem TMAL –
Venous cry surgery of the leg.
Promotor: Prof. C Wittens. Co-promotor: Dr A van der Ham.
Maastricht University, September 29, 2011

Sarabi A –
Structural and functional characterization of the interactions of platelet-derived chemokines CCL5, CXCL4 and CXCL4L1.
RWTH Aachen, January 31, 2011

Stevens KNJ –
Blood-contacting biomaterials for critical clinical applications.
Promotores: Prof. J Maessen, Prof. L Koole.
Maastricht University, December 15, 2011

Costanzo S –
Alcohol Consumption in Relation to Cardiovascular Risk and Mortality.
Promotores: Prof. C Hemker; Prof. G de Gaetano, Campobasso, Italy; Prof. H ten Cate.
Maastricht University, January 26, 2012

Gilio K –
All roads to thrombus formation; demystifying platelet signaling pathways.
Promotor Prof. J Heemskerk. Co-promotor: Dr J Cosemans.
Maastricht University, November 12, 2012

Groote O –
Effects of haemostatic agents on trauma induced bleeding.
Promotores: Prof. H ten Cate; Prof. R Rossaint, Aachen; Dr H Spronk
Maastricht University, November 1, 2012

Knotternus I –
Vascular endothelial function and genetic epidemiology in lacunar stroke subtypes.
Promotores: Prof. RJ van Oostenbrugge, Prof. H ten Cate, Prof. J Lodder.
Maastricht University, March 2, 2012

Panova-Noeva M –
Platelet-associated hypercoagulability in patients with Essential Thrombocythemia and Polycythemia Vera.
Promotor: Prof. H ten Cate. Co-promotores: Dr A Falanga, Dr M Marchetti.
Maastricht University, November 29, 2012

Ruiter M –
Reactivity, recruitment and remodeling of collateral arteries in diabetes.
Promotores: Prof. N Schaper, Prof. C Stehouwer. Co-promotores: Dr M Huijberts; Dr J van Golde.
Maastricht University, September 6, 2012


Cranenburg ECM, Schurgers LJ, Vermeer C - Vitamin K the coagulation vitamin that became a bone vitamin. J Thromb Haemost 2007; 97(6): 938-43 IF 2.803

Frederik K, Chauhan AK, Kisucka J, Zhao BQ, Hoff EI, Spronk HMH, ten Cate H, Wagner DD - Platelet adhesion receptors do not modulate infarct volume after a photochemically induced stroke in mice. Brain Res 2007; 1185: 239-45 IF 2.341

Van Gestel MA, Reitsma S, Slaaf DW, Heijnen VVT, Feige MAH, van Zandvoort MAMJ, Elg M, Reneman RS, Heemskerk JWM, Oude Egbrink MGA - Both ADP and thrombin regulate arterial thrombus stabilization and embolization but are not involved in initial hemostasis as induced by micro puncture. Microcirculation 2007; 14: 193-205 IF 2.405


IF 4.655


IF 4.498


IF 4.986

KNAPEN MJH, SCHURGERS LJ, VERMEER C. Vitamin K2 supplementation improves bone geometry and bone strength indices in postmenopausal women. Osteoporosis Int 2007; 18: 963-972

IF 3.718


IF 2.497


IF 5.138

KROH HK, TANS GMH, NICOLEAS GAF, ROSING J, BOCK PE. Expression of allosteric linkage between the sodium ion binding site and exosite I of thrombin during prothrombin activation. J Biol Chem 2007; 282(22): 16095-104

IF 5.808


IF 9.643


IF 5.032


IF 2.803


IF 4.890


IF 1.370


IF 6.883


IF 2.212


IF 5.032


IF 9.701


IF 4.498


IF 5.196


IF 10.370


IF 5.138


IF 10.370


IF 5.808

SEGERS K, DÄHLBÄCK B, NICOLEAS GAF. Coagulation factor V and thrombophilies - background and mechanisms. Thrombosis and Haemostasis 2007; 98(3): 530-542

IF 2.803


IF 9.843


IF 10.370

SELF-EVALUATION 2007-2012

CARIM 11


Tchaikovsky-Chernushchev S, van Vliet HA, Christella M, Thomassen MCLGD, Bertina RM, Tchaikovski-Chernushevich S, van Vliet HA, Bernardi F – Letter to the editor


Publications in scientific journals (wi-2)


Letter to the editor


Publications in scientific journals 2008


Brouwers MC, Govers-Rijmerslag J, Schalkwijk CG, van Greevenbroek MMJ, van der Kallen CJH, Bekkers O, van Dijen-Visser MP, ten Oever J, de Bruin T, ten Cate H, Stehouwer CDA - Plasma PAI-1 levels are independently related to fatty liver and hypertriglyceridaemia in familial combined hyperlipidaemia involvement of apolipoprotein E. Thromb Res 2008; 122(4): 466-72 IF 0


Ten Cate H, Falanga A - Overview of the postulated mechanisms linking cancer and thrombosis. Pathophysiology of Haemostasis and Thrombosis 2008; 363-4; 122-130 IF 1.129
IF 1.129

IF 3.501

IF 0

IF 16.915

IF 5.947

IF 2.463

IF 5.516

IF 5.947

IF 10.896

IF 10.896

Folkeringa N, Coppens M, Veeger NJ, Bom VJ, Middeldorp S, Hamuluyk K, Prins MH, Büller HR – Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activated fibrinolysis inhibitor (TAFI) levels. Thromb Haemostasis 2008; 100(1): 38-44
IF 3.501

IF 0

IF 2.604

IF 4.374

IF 8.261

IF 4.287

IF 5.947

IF 5.947

IF 4.282

IF 6.273

IF 1.342

IF 2.905

IF 4.333

IF 3.501

Lijfering WM, Coppens M, Veeger NJ, Middeldorp S, Hamuluyk K, Prins MH, üller HR, van der Meer J – Hyperhomocysteinemia is not a risk factor for venous and arterial thrombosis and is associated with evated factor VIII levels. Thromb Res 2008; 123(2): 244-50
IF 0

Lindhout MJ, Wielders S, Hamuluyk K, Bevers EM, ten Cate H – Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase does not inhibit the platelet procoagulant response. J Thromb Haemost 2008; 6(8): 1424-6
IF 5.947

IF 16.915

Maas C, Schiks B, Strangi RD, Hackeng TM, Bouma BN, Gobblink MF, Bouma B – Hyperhomocysteinemia is not a risk factor for venous and arterial thrombosis and is associated with evated factor VIII levels. Thromb Res 2008; 123(2): 244-50
IF 0

IF 10.896

IF 10.896


Munnix ICA, Gilo K, Siljander PR, Raynal N, Feijge MA, Hackeng TM, Deckmyn H, Smethurst PA, Heemskerk JWM – Collagen-mimetic peptides mediate flow-dependent thrombus formation by high- or low-affinity binding of integrin αVβ3 and glycoprotein VIJ. Thromb Haemost 2008; 100: 2174-1751 IF 5.947


Publications in scientific journals (wi-2)


Letter to the editor


Publications in scientific journals 2009

Publications in scientific journals (wi-1)


Daissermont ITMN, Kraaijeveld AO, Biessen EAL – Chemonkines as therapeutic targets for atherosclerotic plaque destabilization and rupture. Future Cardiol 2009; 5: 273-284 IF 0


SELF-EVALUATION 2007-2012


Xanthoulea S, Thelen M, Potgotts CCH, Gijbels MJ, Lutgens E, de With to MPJ – Absence of p55 TNF receptor reduces atherosclerosis, but has no major effect on angiotensin II induced aerylossus in LDL receptor deficient mice. Plos One 2009; 4(7): e6113 IF 0


SELF-EVALUATION 2007-2012
Letter to the editor

IF 7.188

IF 3.087

IF 0

Publications in scientific journals 2010

Publications in scientific journals (wi-1)

Al Dieri R, Hemker HC – Monitoring new oral antithrombotics: what we should know before we can decide. Journal of Thrombosis and Haemostasis 2010; 8(12): 2833-2835
IF 6.069

IF 1.385

IF 7.235

IF 4.351

IF 3.541

IF 1.351

IF 14.816

IF 6.069

IF 10.555

IF 1.503

IF 6.416

IF 6.069

IF 6.069

IF 2.406

IF 6.069

IF 6.069

IF 4.451

IF 2.406

IF 3.06

IF 2.622

IF 10.555

IF 0.642

IF 6.069

IF 6.069

IF 4.988

Erkens PMG, Prins MH – Fixed dose subcutaneous low molecular weight heparin versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database of Systematic Reviews 2010; (9): 97
IF 5.653
IF 5.228

IF 10.555

IF 3.431

IF 4.502

IF 1.189

Scholz SEM, Heemskerk JWM, van Pampus ECM – Correction of Coagulation in Dilutional Coagulopathy: Use of Kinetic and Capacitive Coagulation Assays to Improve Hemostasis. Transfusion Medicine Reviews 2010; 24(1): 44-52
IF 3.614

IF 4.451

Schurgers LJ, Barreto DV, Barreto FC, La Heij EC – The Circulating Inactive Form of Matrix Gla Protein is a Surrogate Marker for Vascular Calcification in Chronic Kidney Disease: A Preliminary Report. Laboratory Investigation 2010; 90(6): E517-E531
IF 4.370

IF 1.78

IF 7.689

Siegerink B, Govers-Rijnsdorp JWP, Rosendaal FR, ten Cate H, Algra A – Intrinsic Coagulation Activation and the Risk of Arterial Thrombosis in Young Women Results From the Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) Case-Control Study. Circulation 2010; 122(18): 1854-1861
IF 14.816

IF 3.517

IF 7.543

IF 3.214

IF 1.78

IF 2.013

IF 2.183

IF 1.333

IF 1.925

IF 4.35

IF 2.360

Vanakker OM, Martin L, Schurgers LJ, Quaglini D, Costrop L, Vermeer C, Pasquali-Ronchetti I, Coucke PJ, De Paepe A – Low serum vitamin K in PXE results in defective carboxylation of mineralization inhibitors similar to the GGCX mutations in the PXE-like syndrome. Laboratory Investigation 2010; 90(8): 895-905
IF 4.602

IF 2.456


Publications in scientific journals 2011

Publications in scientific journals (wi-1)


Shoham MS, Shalev DE, Adriaens W, Merkx M, Hackeng TM, Taha H – Characterization of a (Glu)-bound peptide model of copper metalloproteases: Insights on the role of methane. Chemical Communications 2011; 4722: 6407-6409 IF 5.787


Wittens C, Theuwissen E – Osteoporosis and Degenerative Diseases of Aging. Menopause Int 2011; 17: 19-23

Letter to the editor


Castoldi E, Collins PW, Williamson PL, Bevers EM - Compound heterozygosity for 2 novel TMEM16F mutations in a patient with Scott syndromeBlood (Letter) 2011; 117(16): 4399-4400

De Smedt E, Hemker HC - Thrombin generation is extremely sensitive to preheating conditionsJournal of Thrombosis and Haemostasis (Letter) 2011; 9(1): 234-234


Publications in scientific journals (wi-2)


Vermeer C, Theuwissen E – Osteoporosis and Degenerative Diseases of Aging. Menopause Int 2011; 17: 19-23

IF 4.701
IF 5.731

IF 2.093

IF 2.805

IF 2.516

Kleinegris MC, ten Cate-Hoek AJ, ten Cate H – Coagulation and the vessel wall in thrombosis and atherosclerosis. Polskie Archiwum Medycyny Wewntrznej-Polish Archives of Internal Medicine 2012; 122(11): 557-565
IF 1.367

IF 3.013

IF 11.08

IF 5.895

IF 4.092

IF 0.528


Ninivaggi M, Kelchtermans H, Lindhout T, de Laat B – Conformation of beta2glycoprotein I and its effect on coagulation. Thrombosis Research 2012; 130: S33-S36 IF 2.072


Trappenberg MG, van Schilfgaarde M, Freniches FCP, Sprook HMH, ten Cate H, de Fijter CWH, Terpstra WE, Uytter H – Chronic renal failure is accompanied by endothelial activation and a large increase in microparticle numbers with reduced procoagulant capacity. Nephrology Dialysis Transplantation 2012; 27(4): 1446-1453 IF 3.396


Pisters R, ten Cate H, Crins HJ – Challenges in Atrial Fibrillation. Antiplatelet Therapy in Acs and a-Fib 2012; 47: 155-164


Theuwissen E, Vermeer C, Smit E – Health benefits of vitamin K2 are presently underestimated. Nutracs 2012; 11: 2-6


Vermeer C – Vitamin K: the effect on health beyond coagulation. Food Nutr Res 2012; 56: 5329 - DOI: 10.3402/fnr.v56i0.5329

Letter to the editor

Bloemen S, Pieters M, Hemker HC, Al Dieri R - No Effect of Ethanol Intake on Thrombin Generation ParametersThrombosis Research (Letter) 2012; 129(4): 530-531


ADDENDUM I
GRANTS SUPPORTING RESEARCH IN MAIN THEME II
### 2007

<table>
<thead>
<tr>
<th>YEAR</th>
<th>TITLE</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>In-vivo mechanisms of drug-induced Torsades de Pointes</td>
<td>Contract</td>
<td>Janssen Pharmaceutica, Div. Johnson &amp; Johnson</td>
<td>Belgium</td>
<td>81</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Effect of AVE 1231 on atrial contractility in normal and electrically remodelled atria in goat</td>
<td>Contract</td>
<td>Sanofi-Aventis</td>
<td>Germany</td>
<td>81</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Educational grant agreement</td>
<td>Contract</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Collaboration agreement</td>
<td>Contract</td>
<td>Medtronic Bakken Research Center</td>
<td>The Netherlands</td>
<td>70</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study on the use of intermittent ventricular pacing for the prevention of heart failure</td>
<td>Contract</td>
<td>Cardiac Pacingmakers/ Boston Scientific</td>
<td>USA</td>
<td>145</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clinical evaluation of a new continuous ECG Antyrhythmia Monitor: the gain of long-term event monitoring</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Surface vs Subcutaneous ECG study</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vernakalant (oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>56</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Optimize RV. Selective site pacing clinical trial</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>109</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>XPECT: Reveal XT Performance Trial</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study of the effects of KW-39021V Injectable Emulsion on heart failure signs and symptoms etc</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>60</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Evaluation of EmBlocker™</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>32</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Subcellular trafficking of CD36 as target for restoring cardiac dysfunction in type-2 diabetes</td>
<td>Grant</td>
<td>Diabetes Foundation Netherlands</td>
<td>The Netherlands</td>
<td>270</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Leducq European-North American atrial fibrillation research alliance</td>
<td>Grant</td>
<td>Fondation Leducq</td>
<td>France</td>
<td>647</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Support stage UK</td>
<td>Grant</td>
<td>Hein Wellens Foundation</td>
<td>The Netherlands</td>
<td>18</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hustinx chair S. Dimmelere</td>
<td>Grant</td>
<td>Hustinx Foundation</td>
<td>The Netherlands</td>
<td>23</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Student travel grant</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Control of cardiac growth by kruppel-like factor 15</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>240</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Genetic modulation of protein kinase-D in the heart: a novel target to restore metabolism and function in diabetic cardiomyopathy</td>
<td>Grant</td>
<td>IUL</td>
<td>The Netherlands</td>
<td>200</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kootstra Fellowship M. Constlen</td>
<td>Grant</td>
<td>UM / FHMI</td>
<td>The Netherlands</td>
<td>18</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kootstra Fellowship M. Schellings</td>
<td>Grant</td>
<td>UM / FHMI</td>
<td>The Netherlands</td>
<td>25</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The role of myocardial reactive oxygen species in the onset and maintenance of atrial fibrillation</td>
<td>Grant</td>
<td>British Heart Foundation via University of Oxford</td>
<td>United Kingdom</td>
<td>55</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>2008</strong></td>
<td>Evaluation of the antifibrillatory effects of DHA and F 16915 in the goat</td>
<td>Contract</td>
<td>IRPF</td>
<td>France</td>
<td>62</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Further studies on the effect of LV endocardial pacing in a canine LBBB model</td>
<td>Contract</td>
<td>EBR-systems Delaware</td>
<td>Delaware</td>
<td>84</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chronic alternate site pacing in canine hearts</td>
<td>Contract</td>
<td>Medtronic BRC</td>
<td>The Netherlands</td>
<td>75</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The influence of AV-node stimulation on ventricular rate during atrial fibrillation</td>
<td>Contract</td>
<td>Medtronic Bakken Research Center B.V.</td>
<td>The Netherlands</td>
<td>33</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consultancy agreement ATHENA study</td>
<td>Contract</td>
<td>Sanofi-Aventis</td>
<td>France</td>
<td>40</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Collaboration agreement: Feasibility study to evaluate the use of a new technique for real time cardiac dimension measurement from regular intra cardiac electrodes</td>
<td>Contract</td>
<td>Medtronic Bakken Research Center B.V.</td>
<td>The Netherlands</td>
<td>37</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Studies on the use of glucocorticoids after myocardial infarction</td>
<td>Contract</td>
<td>Durect</td>
<td>USA</td>
<td>76</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Funded post/fellowship agreement</td>
<td>Contract</td>
<td>St. Jude Medical Netherlands</td>
<td>The Netherlands</td>
<td>180</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Telmisartan for the treatment of viral heart disease, a preclinical study</td>
<td>Contract</td>
<td>Boehringer Ingelheim</td>
<td>Germany</td>
<td>84</td>
<td></td>
<td></td>
</tr>
<tr>
<td>YEAR</td>
<td>TITLE</td>
<td>TYPE</td>
<td>COMPANY/ORGANISATION</td>
<td>COUNTRY</td>
<td>SUPPORT (K€) from: foundations contracts</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>-----------------------------------------------------------------------</td>
<td>------------</td>
<td>------------------------</td>
<td>---------------------------------</td>
<td>-----------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2008</td>
<td>Rheos CVRx Diastolic Heart Failure Trial</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>23</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Randomized Clinical Evaluation of LeGoo Internal Vessel Occluder vs. Traditional Vessel Loops</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>30</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study to assess the effects of intravenous BIG8829 on body weight etc</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>81</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study of the effects of KW3902 injectable emulsion on heart failure signs and symptoms etc</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>63</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>RELY-ABLE long term multi-center extension of dabigatran treatment in patients with atrial fibrillation etc</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>52</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Heart Beat Survival Program</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>139</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The electro-pathological substrate of persistent atrial fibrillation: taking AF to the 3rd dimension</td>
<td>Grant</td>
<td>ZonMw</td>
<td>The Netherlands</td>
<td>406</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>VENI B. Schroen MicroRNAs - dissection of their regulation and function using a genetical genomics strategy</td>
<td>Grant</td>
<td>ZonMw</td>
<td>The Netherlands</td>
<td>208</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>VIDI S. Heymans The cardiac matrix protects the heart against harmful inflammation during viral aggression</td>
<td>Grant</td>
<td>ZonMw</td>
<td>The Netherlands</td>
<td>600</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PRIMA study</td>
<td>Grant</td>
<td>ICIN (KNAW)</td>
<td>The Netherlands</td>
<td>25</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Importance and treatment of viral cardiomyopathy</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>220</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Improved detection of electrical abnormalities in inherited loss-function sodium channelopathies of the heart NHB dr E. Dekker programma: junior staffid R. Volders</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>248</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Facilitating therapy of congenital heart diseases by computer modeling of the heart and circulation, e.g. hypoplastic left heart syndrome (HLHS)</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>180</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hein Wellens Visiting Professorship Prof Y. Rudy</td>
<td>Grant</td>
<td>St. Sint Annadal</td>
<td>The Netherlands</td>
<td>23</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SPARC: (osteonectin) keeps the heart together. A protective role for SPARC against heart failuretoekenning 2006; start 2009</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>170</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Atrial specific potassium channels as new drug targets in atrial fibrillation</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>108</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fellow M. Gawrysiak European Rythm Association</td>
<td>Grant</td>
<td>European Rythm Association</td>
<td>The Netherlands</td>
<td>25</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Unraveling the vesicular trafficking machinery controlling cardiac fatty acid metabolism to understand the molecular etiology of diabetic cardiomyopathy</td>
<td>Grant</td>
<td>FHML</td>
<td>The Netherlands</td>
<td>180</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Student travel grant</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td></td>
<td><strong>1,239 1,157 1,059</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td>Cardiac Electrophysiological Characteristics of AZD1305 in Anesthetized Mongrel Dogs</td>
<td>Contract</td>
<td>AstraZeneca</td>
<td>Sweden</td>
<td>30</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Service agreement</td>
<td>Contract</td>
<td>AstraZeneca</td>
<td>Sweden</td>
<td>21</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Enhanced prediction and prevention of drug-induced Torsades de Pointes</td>
<td>Contract</td>
<td>AstraZeneca</td>
<td>United Kingdom</td>
<td>45</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsoring agreement</td>
<td>Contract</td>
<td>Boehringer Ingelheim</td>
<td>Germany</td>
<td>31</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clinical evaluation of pacing during the onset of revascularization</td>
<td>Contract</td>
<td>Guidant Europe / Boston Scientific</td>
<td>Belgium</td>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Collaboration agreement: Feasibility of using AV-node vagal stimulation as a protective measure against life-threatening arrhythmias and against infarct size expansion</td>
<td>Contract</td>
<td>Medtronic Bakken Research Center B.V.</td>
<td>The Netherlands</td>
<td>110</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consultancy agreement</td>
<td>Contract</td>
<td>Medtronic Bakken Research Center BV</td>
<td>The Netherlands</td>
<td>48</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cardiovascular Grand Rounds</td>
<td>Contract</td>
<td>Medtronic Trading NL BV</td>
<td>The Netherlands</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>YEAR</td>
<td>TITLE</td>
<td>TYPE</td>
<td>COMPANY/ORGANISATION</td>
<td>COUNTRY</td>
<td>SUPPORT (K€) from: foundations contracts</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>-----------------------------------------------------------------------</td>
<td>----------</td>
<td>-----------------------</td>
<td>---------------</td>
<td>------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td>Study agreement</td>
<td>Contract</td>
<td>Merck Eprova AG</td>
<td>Switzerland</td>
<td>170</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Two-day training course in arrhythmology</td>
<td>Contract</td>
<td>Sanofi-Aventis</td>
<td>France</td>
<td>20</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Educational grant</td>
<td>Contract</td>
<td>Meda Pharma</td>
<td>The Netherlands</td>
<td>28</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsoring agreement</td>
<td>Contract</td>
<td>BMEYE BV</td>
<td>The Netherlands</td>
<td>15</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cardiofl Vagus Nerve STIMulation for treatment of heart failure patients with preserved ejection fraction</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>92</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study of celivarone at 50, 100 and 300 mg OD with amiodarone as calibrator for the prevention of ICD interventions or death</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>94</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>F Artery Coronary T Syndrome</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Routine versus Aggressive upstream rhythm Control for prevention of Early atrial fibrillation in heart failure</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>75</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cardiomyopathy and endomyocardial parovirus B19 persistence etc</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>157</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Effect of acadesine on clinically significant adverse cardiovascular etc CABG</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>83</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rocket AF and ENGAGE</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>64</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Treatment after conversion with loading dose of a Miodarone in patients with persistent Atrial Fibrilliation requiring conversion of AF (ARTEMIS)</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>40</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Evaluation of the Safety and Efficacy of Apixaban in Subjects with a Recent Acute Coronary Syndrome</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>66</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Trial to compare the efficacy of otamixaban with Unfractionated Heparin + epilfibrate etc</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>90</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Micro RNA function in heart failure</td>
<td>Grant</td>
<td>ZonMw</td>
<td>The Netherlands</td>
<td>47</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>VIDI P. Volders Dying suddenly of excitement; New perspectives on the role of the sympatich nervous system in cardiac ventricular repolarization and arrhythogenesis</td>
<td>Grant</td>
<td>ZonMw</td>
<td>The Netherlands</td>
<td>717</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NFAT, a transcriptional platform for heart failure</td>
<td>Grant</td>
<td>ZonMw/Netherlands Genomics Initiative</td>
<td>The Netherlands</td>
<td>211</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MicroRNAs as hallmarks of susceptibility to viral heart disease</td>
<td>Grant</td>
<td>ZonMw/Netherlands Genomics Initiative</td>
<td>The Netherlands</td>
<td>100</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>VIDI A. Moens Specific targeting eNOS-dependent superoxide by modulating eNOS-uncoupling, a new therapeutic strategy to support the failing heart</td>
<td>Grant</td>
<td>ZonMw</td>
<td>The Netherlands</td>
<td>800</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Magnetic resonance perfusion imaging in patients from the Euregio with stable angina pectoris (EUREGIO-AP)</td>
<td>Grant</td>
<td>Academic Hospital Maastricht</td>
<td>The Netherlands</td>
<td>172</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CTMM TRIUMPH</td>
<td>Contract</td>
<td>CTMM</td>
<td>The Netherlands</td>
<td>1023</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CTMM PREDICCI WP 3</td>
<td>Contract</td>
<td>CTMM</td>
<td>The Netherlands</td>
<td>501</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CTMM TRIUMPH WP 1</td>
<td>Contract</td>
<td>CTMM</td>
<td>The Netherlands</td>
<td>84</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CTMM biomarker COPHAR</td>
<td>Contract</td>
<td>CTMM</td>
<td>The Netherlands</td>
<td>2122</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Research agreement Leducq</td>
<td>Grant</td>
<td>Foundation Leducq</td>
<td>France</td>
<td>407</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>mIR-155 protects against heart failure</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>240</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prevention of doxorubicin-induced acute cardiotoxicity and chronic ventricular dysfunction by modulating eNOS-uncoupling.</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>250</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td></td>
<td><strong>1,675</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>4,799</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>1,296</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>YEAR</td>
<td>TITLE</td>
<td>TYPE</td>
<td>COMPANY BASE/ ORGANISATION</td>
<td>COUNTRY</td>
<td>SUPPORT (K€)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>-------</td>
<td>------</td>
<td>-----------------------------</td>
<td>---------</td>
<td>--------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td>Grant Agreement</td>
<td>Contract</td>
<td>TERUMO Europe Nv</td>
<td>Belgium</td>
<td>150</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consultancy agreement</td>
<td>Contract</td>
<td>Sanofi-Aventis Netherlands</td>
<td>The Netherlands</td>
<td>40</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consulting agreement</td>
<td>Contract</td>
<td>Schering-Plough</td>
<td>The Netherlands</td>
<td>1,5</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tissue in-growth evaluation of various defibrillation coil subassemblies</td>
<td>Contract</td>
<td>Medtronic Bakken Research Center B.V.</td>
<td>The Netherlands</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>International registry on cardioversion of atrial fibrillation RHYTHM-AF</td>
<td>Contract</td>
<td>MSD - UPTOYOU</td>
<td>The Netherlands</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study on the use of intermittent ventricular pacing for the prevention of heart failure</td>
<td>Contract</td>
<td>Cardiac Pacemakers/ Boston Scientific</td>
<td>USA</td>
<td>22</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Research agreement</td>
<td>Contract</td>
<td>AtriCure</td>
<td>USA</td>
<td>55</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consultancy agreement</td>
<td>Contract</td>
<td>Sanofi-Aventis</td>
<td>France</td>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consultancy agreement</td>
<td>Contract</td>
<td>Roche Diagnostics Ltd.</td>
<td>Switzerland</td>
<td>92</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clinical study agreement</td>
<td>Contract</td>
<td>Sanofi-Aventis</td>
<td>The Netherlands</td>
<td>11</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Physician training laboratories for the WISE-CRT study</td>
<td>Contract</td>
<td>EBR-systems Delaware</td>
<td>USA</td>
<td>27</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Septum pacing for AF termination</td>
<td>Contract</td>
<td>Medtronic Bakken Research Center B.V.</td>
<td>The Netherlands</td>
<td>85</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cardiovascular Grand Rounds</td>
<td>Contract</td>
<td>Boehringer Ingelheim</td>
<td>The Netherlands</td>
<td>2,5</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsoring agreement</td>
<td>Contract</td>
<td>Boehringer Ingelheim</td>
<td>The Netherlands</td>
<td>65</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cardiovascular Grand Rounds</td>
<td>Contract</td>
<td>Sanofi-Aventis/ Sanofi-BMS</td>
<td>The Netherlands</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The feasibility of electrically stimulating carotid baroreceptor nerve fibers to lower blood pressure</td>
<td>Contract</td>
<td>Medtronic Bakken Research Center B.V.</td>
<td>The Netherlands</td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Collaboration agreement</td>
<td>Contract</td>
<td>Bioterics</td>
<td>Switzerland</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TRanslational Initiative on Unique and novel strategies for Management of Patients with Heart failure etc</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>59</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phase 3 study to demonstrate the efficacy and safety of ACT-293987 in patients with pulmonary arterial hypertension</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>47</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study, to assess the safety and tolerability of ACT-293987 in patients with pulmonary arterial hypertension</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>31</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>INcrease Of VAgal TonE in chronic Heart Failure (INOVATE-HF)</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>171</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Next generation INCEPTA ICD and CRT-D Field Following Study: Respiratory Rate Trend Evaluation in Heart Failure Patients</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>15</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Source Registry XT: Edwards Sapien Aortic Bioprosthesis Multi-Region Outcome Registry XT</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>227</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Safety, Efficacy, and Pharmacodynamics of the REG1 Anticoagulation System Compared etc</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Multicenter Automatic Defibrillator Implantation Trial: Reduce Inappropriate Therapy</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>29</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Left Ventricular Lead Acute Clinical Study</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>11</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study to Evaluate the Safety and efficacy of Vernakalant Hydrochloride Injection in Patients with Recent Onset Symptomatic Atrial Fibrillation</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>41</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>51</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The prevention of thrombotic events with ticagrelor compared with placebo on a background of acetylsalicylic acid (ASA) therapy in patients with history of myocardial infarction</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>58</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The clinical benefit of Dronedarone 400 mg BID on top of standard therapy in patients with permanent atrial fibrillation and additional risk factors</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>191</td>
<td></td>
<td></td>
</tr>
<tr>
<td>YEAR</td>
<td>TITLE</td>
<td>TYPE</td>
<td>COMPANY BASE/ ORGANISATION</td>
<td>COUNTRY</td>
<td>SUPPORT (K€) from foundations contracts</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>-------</td>
<td>------</td>
<td>-----------------------------</td>
<td>---------</td>
<td>-----------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td>To evaluate cardiovascular safety of linagliptin versus glimepiride etc</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>438</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>DELUX registry - Drug Eluting Panthera LUX Catheter Registry</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ASPASIA VIDI A. Moens Specific targeting eNOS-dependent superoxide by modulating eNOS-uncoupling, a new therapeutic strategy to support the failing heart</td>
<td>Grant</td>
<td>ZonMW</td>
<td>The Netherlands</td>
<td>50</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Visual sonsics echo scanner</td>
<td>Grant</td>
<td>ZonMW</td>
<td>The Netherlands</td>
<td>300</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The spacemaker: a novel multipurpose platform that facilities manoeuvrability for endoscopic instruments</td>
<td>Grant</td>
<td>STW / NWO</td>
<td>The Netherlands</td>
<td>494</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hein Wellens Visiting Professorship Prof Raymond J. Kim</td>
<td>Grant</td>
<td>St. Sint Annadal - Hein Wellens Foundation</td>
<td>The Netherlands</td>
<td>23</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Support for training and career development of researchers (Marie Curie) Optimization of noninvasive assessment of the substrate for atrial fibrillation - ASAP</td>
<td>Grant</td>
<td>EU</td>
<td>Belgium</td>
<td>75</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Research agreement</td>
<td>Grant</td>
<td>Boston Scientific Corporation</td>
<td>The Netherlands</td>
<td>118</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CardiaBase: Alphee study</td>
<td>Grant</td>
<td>CardiaBase</td>
<td>France</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Assessment of the substrate for atrial fibrillation using tissue velocity imaging of the fibrillating atrial wall</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>161</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The embryonic transcription factor HAND2 (dHAND) regulates left and right ventricular remodeling towards dilated cardiomyopathy</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>240</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Importance of the KCNQ1 transmembrane segment S6 for the adrenergic control of cardiac repolarization</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>236</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The European network for Translational Research in Atrial Fibrillation</td>
<td>Grant</td>
<td>EU / EUTRAF</td>
<td>Belgium</td>
<td>1400</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ESC research grant Dr Miren David Transatlantic Career Development Award P. da costa Martins MFR-216: a cell death regulating MicroRNAs during myocardial repair</td>
<td>Grant</td>
<td>ESC</td>
<td>France</td>
<td>20</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Blocking Wnt/frizzled signalling: a novel therapeutic approach to prevent heart failure development after myocardial infarction</td>
<td>Grant</td>
<td>Fondation Leducq</td>
<td>France</td>
<td>225</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Towards better pacing therapies in patients with congenital heart disease</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>220</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>dr E. Dekker program - junior staff member W. Vanagt</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>136</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td>1,981</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<p>| 2011 | Educational Grant Agreement -postdoctoral fellowship Dr J. Lumens in Centre Hospitalier Universitaire de Bordeaux | Contract | Pfizer | The Netherlands | 10 |
|      | Consultancy agreement | Contract | Merck | USA | 3 |
|      | Antihypertensive and antihypertrofie effecten van LeadPharmaHolding stoffen in de spontaan hypertensive rat | Contract | Lead Pharma Holding | The Netherlands | 59 |
|      | Collaboration agreement | Contract | Merck Sharp &amp; Dohme ( MSD) | USA | 87 |
|      | Research agreement for TIME-CHF Safety Analysis | Contract | Roche Diagnostics Ltd. | Switzerland | 26 |
|      | Linagliptin for the inhibition of cardiac inflammation, fibrosis and dysfunction in pressure overloaded hearts | Contract | Boehringer Ingelheim | Germany | 95 |
|      | Research agreement | Contract | Roche Diagnostics Nederland | The Netherlands | 16 |
|      | Does AV-node stimulation induce a decrease in cardiac inflammation | Contract | BRC / Medtronic | The Netherlands | 6 |
|      | Collaboration agreement | Contract | Merck Sharp &amp; Dohme ( MSD) | The Netherlands | 65 |</p>
<table>
<thead>
<tr>
<th>YEAR</th>
<th>TITLE</th>
<th>TYPE</th>
<th>COMPANY</th>
<th>BASE/COUNTRY</th>
<th>SUPPORT (K€)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>Effect of NCX1 Blocker on stability of atrial fibrillation</td>
<td>Contract</td>
<td>Bayer HealthCare</td>
<td>Germany</td>
<td>45</td>
</tr>
<tr>
<td></td>
<td>Determining the Feasibility of Spinal Cord Neurmodulation for the Treatment of Chronic Heart Failure</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>74</td>
</tr>
<tr>
<td></td>
<td>MALT Meeting</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>Trial to Assess the OMEGA Coronary Stent System for the Treatment of a Single De Novo Coronary Artery Lesion</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>Clinical trial for the assessment of coronary plaque changes with RVX002222, as determined by intravascular ultrasound</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>94</td>
</tr>
<tr>
<td></td>
<td>Global Registry on Long-Term Oral Antithrombotic Treatment in patients with Atrial Fibrillation</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>Alternate Site Cardiac ReSYNChronization (ALSYNC)</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>39</td>
</tr>
<tr>
<td></td>
<td>Trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>153</td>
</tr>
<tr>
<td></td>
<td>Regulated sugar for my sweetheart! Glycogen-targeting of AMP-activated protein kinase</td>
<td>Grant</td>
<td>NWO</td>
<td>The Netherlands</td>
<td>800</td>
</tr>
<tr>
<td></td>
<td>Synchronous ventricular pacing using novel left ventricular septum pacing site</td>
<td>Grant</td>
<td>ZonMw</td>
<td>The Netherlands</td>
<td>160</td>
</tr>
<tr>
<td></td>
<td>Development of microRNA medicines for cardiac metabolic diseases; a targeted European Exchange Programme</td>
<td>Grant</td>
<td>EU/CardiomiR</td>
<td>Belgium</td>
<td>967</td>
</tr>
<tr>
<td></td>
<td>Markers for Sub-Clinical Cardiovascular Risk Assessment FP7 EU MASCARA</td>
<td>Grant</td>
<td>EU/MASCARA</td>
<td>Belgium</td>
<td>271</td>
</tr>
<tr>
<td></td>
<td>Collaboration agreement</td>
<td>Grant</td>
<td>CRP-SANTE</td>
<td>Luxemburg</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>The METabolic Road to DIAstolic Heart Failure</td>
<td>Grant</td>
<td>EU/MEDIA</td>
<td>The Netherlands</td>
<td>1,050</td>
</tr>
<tr>
<td></td>
<td>Research agreement</td>
<td>Grant</td>
<td>Boston Scientific</td>
<td>The Netherlands</td>
<td>118</td>
</tr>
<tr>
<td></td>
<td>CTMM COPHAR</td>
<td>Grant</td>
<td>CTMM COHFAR</td>
<td>The Netherlands</td>
<td>334</td>
</tr>
<tr>
<td></td>
<td>Biomarkers to predict cardiac failure, arrhythmias and success of treatment</td>
<td>Grant</td>
<td>CTMM COHFAR</td>
<td>The Netherlands</td>
<td>700</td>
</tr>
<tr>
<td></td>
<td>Cytron II</td>
<td>Grant</td>
<td>Agentschap NL (Life Sciences &amp; Health)</td>
<td>The Netherlands</td>
<td>360</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td>960 3,800 830</td>
</tr>
</tbody>
</table>

<p>| 2012 | Cardiovascular Grand Rounds | Contract | Medtronic Bakken Research Center | The Netherlands | 5 |
|      | Consulting agreement | Contract | AstraZeneca | Sweden | 2 |
|      | Material Transfer agreement | Contract | Enverdis | Germany | 12 |
|      | Collaboration agreement | Contract | Merck Sharp &amp; Dohme (MSD) | USA | 24 |
|      | Consultancy agreement | Contract | Bristol-Myers Squibb BV | The Netherlands | 1 |
|      | Consultancy Agreement | Contract | SHIRE AG | Switzerland | 8 |
|      | Consultancy service agreement | Contract | Bristol-Myers Squibb BV | France | 15 |
|      | With top cyclists to a more specific troponin assay | Contract | CTCM | The Netherlands | 100 |
|      | Impact of airflow limitation in chronic heart failure | Contract | CTCM | The Netherlands | 124 |
|      | Study to evaluate the hemodynamic responses to intravenous RLX030 infusion in subjects with acute heart failure | Contract | CTCM | The Netherlands | 76 |
|      | Study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction | Contract | CTCM | The Netherlands | 88 |
|      | System safety and efficacy in treatment of patients diagnosed with NYHA Class II-III Heart Failure | Contract | CTCM | The Netherlands | 27 |
|      | Gloria-AF: Global registry on long-term oral anti-thrombotic treatment in patients with atrial fibrillation | Contract | CTCM | The Netherlands | 11 |</p>
<table>
<thead>
<tr>
<th>YEAR</th>
<th>TITLE</th>
<th>TYPE</th>
<th>COMPANY BASE/ ORGANISATION</th>
<th>COUNTRY</th>
<th>SUPPORT (K€) from: foundations contracts</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>Study exploring the efficacy and safety of once-daily oral rivaroxaban (BAY 59-7939) compared with that of dose-adjusted oral vitamin K antagonists (VKA) etc</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>29</td>
</tr>
<tr>
<td></td>
<td>Group study to evaluate the effect of Ranolazine and Dronedarone when given alone and in combination on atrial fibrillation burden in subjects with Paroxysmal atrial fibrillation</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>31</td>
</tr>
<tr>
<td></td>
<td>Study of the Effects of Once-Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations etc</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>72</td>
</tr>
<tr>
<td></td>
<td>Integrated chronic care program at specialized AF clinic versus usual care in patients with atrial fibrillation, a multicenter randomized controlled clinical trial - RACE-4</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>154</td>
</tr>
<tr>
<td></td>
<td>Attain performa quadripolar lead clinical study</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>48</td>
</tr>
<tr>
<td></td>
<td>Study to evaluate the safety and pharmacokinetics of oral, Dabigatran etoxilate in patients after heart valve replacement</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>47</td>
</tr>
<tr>
<td></td>
<td>Increased arterial stiffness in formerly preeclamptic women characterizes reduced vascular reserves and relates to imminent chronic hypertension (personal grant C. Ghoesen, Mozaik beurs)</td>
<td>Grant</td>
<td>NWO</td>
<td>The Netherlands</td>
<td>200</td>
</tr>
<tr>
<td></td>
<td>YourRhythmics Non-invasively Classifying Atrial Fibrillation (Pre-Seed Grant U. Schotten)</td>
<td>Grant</td>
<td>ZonMw / NGI</td>
<td>The Netherlands</td>
<td>250</td>
</tr>
<tr>
<td></td>
<td>CVON-ARENA Approaching Heart Failure by Translational research of RNA Mechanisms</td>
<td>Grant</td>
<td>ZonMw / NWO</td>
<td>The Netherlands</td>
<td>1,120</td>
</tr>
<tr>
<td></td>
<td>Regionalcare Portals. Innovative solutions for chronic diseases</td>
<td>Grant</td>
<td>EU / Interreg IVB</td>
<td>Belgium</td>
<td>280</td>
</tr>
<tr>
<td></td>
<td>Cell Line models CM</td>
<td>Grant</td>
<td>Academic Hospital Maastricht Clin Genomics</td>
<td>The Netherlands</td>
<td>175</td>
</tr>
<tr>
<td></td>
<td>RNA-based regulation of signal transduction</td>
<td>Grant</td>
<td>EU / CALMIRS</td>
<td>Belgium</td>
<td>1500</td>
</tr>
<tr>
<td></td>
<td>Regulation of calcineurin/NFAT signalling by microRNA-based mechanisms</td>
<td>Grant</td>
<td>EU / HOMAGE</td>
<td>France</td>
<td>925</td>
</tr>
<tr>
<td></td>
<td>Noninvasive patient-specific Cardiovascular simulation to optimize diagnosis and pacemaker treatment of heart failure</td>
<td>Grant</td>
<td>EU / MANASH</td>
<td>Belgium</td>
<td>184</td>
</tr>
<tr>
<td></td>
<td>NHS Dr Dekker junior postdoctoral fellow J. Lumens</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>279</td>
</tr>
<tr>
<td></td>
<td>Ontrafeleng van de genetische oorzaken bij sporadische mitochondriale aandoeningen</td>
<td>Grant</td>
<td>Metakids</td>
<td>The Netherlands</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>Student travel grant NHS</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Heart ‘omics in AGEing’ for the validation of ‘omics-based biomarkers for diseases affecting the elderly</td>
<td>Grant</td>
<td>EU / HOMAGE</td>
<td>France</td>
<td>925</td>
</tr>
<tr>
<td></td>
<td>Marie Curie fellowship D. Chanda Exploiting the MSP-AMPK pathway for amelioration of NASH</td>
<td>Grant</td>
<td>EU / MANASH</td>
<td>Belgium</td>
<td>184</td>
</tr>
<tr>
<td></td>
<td>Post-transcriptional regulation of autophagy: MIR-216a as a cell death-regulating microRNA during myocardial repair</td>
<td>Grant</td>
<td>NWO MEERVOUD</td>
<td>The Netherlands</td>
<td>222</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1,570 3,618 874</td>
</tr>
</tbody>
</table>
C_
ADDENDUM II
OUTPUT OF
MAIN THEME II
IN 2007-2012

1. LIST OF PHD THESIS 2007 – 2012
2. LIST OF PUBLICATIONS 2007 – 2012
PHD THESES 2007

Heijmans J –
Promotores: Prof. M van Kleef, Prof. J Maessen.
Co-promotor: Dr P Roekaerts.
Maastricht University, November 29, 2007

Moreira W –
Atrial Flutter/Atrial Fibrillation: Long term follow-up of cryoablation with new pathophysiological insights.
Promotor: Prof. M Daemen. Co-promotores: Dr L Rodriguez, Dr C Timmermans.
Maastricht University, December 6, 2007

Nieuwlaat R –
Management of atrial fibrillation in Europe.
Promotor: Prof. H Crijns.
Maastricht University, September 21, 2007

Op den Buijsch R –
Pharmacokinetics and pharmacogenetics of tacrolimus in renal transplant patients.
Maastricht University, October 25, 2007

Peppelenbosch A –
Endovascular treatment in elective and ruptured abdominal aortic aneurysms.
Promotor: Prof. M van Dieijen-Visser. Co-promotor: Dr G Schurink, Dr J Buith.
Maastricht University, September 28, 2007

Pullen J –
Pharmacokinetics and dosing of antibiotics in neonates.
Promotor: Prof. L Zimmerman. Co-promotores: Dr C Neef, Dr L Stolk, Dr P Degraeuwe.
Maastricht University, April 28, 2007

Schellings M –
Matricellular proteins: essential modulators of cardiac remodeling.
Promotor: Prof. M Jacobs. Co-promotores: Dr G Schurink, Dr J Buith.
Maastricht University, November 23, 2007

Vanagt W –
Pacing-induced dyssynchrony, blessing or curse?
Promotor: Prof. G van der Vusse. Co-promotores: Dr F Prinzen, Dr T Delhaas.
Maastricht University, December 21, 2007

Willigers H –
Anesthesiological strategies to modulate the surgical stress response; a focus on the cardiovascular consequences.
Promotor: Prof. M van Kleef. Co-promotores: Dr F Prinzen, Dr P Roekaerts.
Maastricht University, October 18, 2007

PHD THESES, EXTERNALLY PREPARED

Van Empel V –
Apoptosis-Inducing Factor in cardiac cell death and cell survival.
Promotores: Prof. H Crijns, Prof. P Doevendans.
Utrecht University, September 13, 2007

PHD THESES 2008

Donker D –
Cardiac mechanoncropyathy.
Promotores: Prof. H Crijns, Prof. M Vos. Co-promotor: Dr P Volders.
Maastricht University, September 11, 2008

Driesen R –
Adaptive remodeling of cardiomyocytes under stress.
Promotores: Prof. F Ramaekers, Prof. M Borgers.
Co-promotor: Dr F Verheyen.
Maastricht University March 20, 2008

Gamboa Vilela D –
Analysis of gene expression in the Leishmania Life Cycle:Leishmania (Viannia) braziliensis and Leishmania (Vianna) peruviana model.
Promotor: Prof. C Bruggeman. Co-promotor: Dr G van Eys.
Maastricht University, September 4, 2008

De Graaf R –
Promotores: Prof. C Bruggeman, Prof. P Kitaal.
Co-promotor: Dr F Stassen.
Maastricht University, November 15, 2008

Habets D –
Regulation of cardiac long-chain fatty acid and glucose utilization: studies with cardiomyocytes from genetically manipulated mice.
Promotores: Prof. J Glazt, Prof. A Bonen.
Co-promotor: Dr J Luiken.
Maastricht University, December 8, 2008

Kietselaer B –
The Annexin Code; Revealing Cardiovascular Disease.
Promotor: Prof. H Crijns. Co-promotor: Dr L Hofstra.
Maastricht University, June 19, 2008

Michielsen E –
Implications of cardiac troponin T degradation.
Promotor: Prof. M van Dieijen-Visser. Co-promotor: Dr K Wodzig.
Maastricht University, February 29, 2008

Smeets P –
PPARs as Modulators of cardiac remodeling.
Promotor: Prof. G van der Vusse. Co-promotor: Dr M van Bilsen.
Maastricht University, December 4, 2008

Tack F –
Post translational gene silencing and peptide microarray as a way to perform drug target validation.
Promotores: Prof. F Ramaekers, Prof. M Borgers.
Co-promotor: Dr M Janicot.
Maastricht University, June 12, 2008

Wouters K –
Non-Alcoholic Steatohepatitis: Second Hit or Strike Out?
Promotor: Prof. M Hofker. Co-promotores: Dr M van Bilsen, Dr R Sverdlov.
Maastricht University, December 3, 2008

PHD THESES, EXTERNALLY PREPARED

El Azzouzi H –
Peroxisome proliferators-activated receptor (PPAR) regulation in cardiac metabolism and disease.
Promotor: Prof. H Clevers. Co-promotores: Dr L de Windt, Dr M van Bilsen.
Utrecht University, January 13, 2009

Rojiers R –
Element analysis with a proton microprobe of early atherosclerotic lesions.
Promotor: Prof. G van der Vusse. Eindhoven Technical University, January 14, 2009

Borne van den S –
Myocardial infarct healing: Rupture and remodeling.
Maastricht University, April 24, 2009

Gelsomino S –
New insights in the Surgical Treatment of Chronic ischemic mitral regurgitation.
Promotor: Prof. J Maessen. Co-promotores: Dr R Lorusso, Dr F van der Veen.
Maastricht University, April 24, 2009

Kroon JW –
Mechanoccontrol of cardiac growth and remodeling.
Promotor: Prof. T Arts. Co-promotores: Dr T Delhaas, Dr P Bovendeerd (Eindhoven University of Technology).
Maastricht University, May 14, 2009

Mastrigt van G –
Outcome assessment and economic evaluation of short stay intensive care for coronary artery bypass patients.
Maastricht University, September 25, 2009

Sauren L –
Cerebral microembolic signals in cardiac interventions.
Promotores: Prof. J Maessen, Prof. W Mess. Co-promotor: Dr F van der Veen.
Maastricht University, December 15, 2009

Schans van de V –
Wnt signaling and Cardiac hypertrophy.
Promotores: Prof. J Smits, Dr M Blanksteijn.
Maastricht University, January 22, 2009
<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>University</th>
<th>Date</th>
<th>Promotores</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greiser M</td>
<td>Remodeling of intracellular calcium handling in fibrillating atria.</td>
<td>Maastricht University</td>
<td>June 3, 2010</td>
<td>Prof. F van der Brandt, Prof. V Courtes, Prof. J Maessen</td>
</tr>
<tr>
<td>Lauermanns H</td>
<td>Discovery of ligands for Frizzled and their promises for the diagnosis of cardiovascular disease.</td>
<td>Maastricht University</td>
<td>May 19, 2010</td>
<td>Prof. J Maessen, Prof. L Koole, Prof. T Delhaas</td>
</tr>
<tr>
<td>Lumens J</td>
<td>Patient-specific cardiovascular modeling in pulmonary hypertension. Assessment of hemodynamic and mechanical ventricular interaction.</td>
<td>Maastricht University</td>
<td>July 2, 2010</td>
<td>Prof. T Arts and Prof. E Oomen, Prof. J Maessen</td>
</tr>
<tr>
<td>Merry A</td>
<td>Coronary heart disease in the Netherlands: Incidence etiology and risk prediction.</td>
<td>Maastricht University</td>
<td>November 19, 2010</td>
<td>Prof. J Maessen, Prof. T Delhaas, Prof. J Maessen</td>
</tr>
<tr>
<td>Rademakers L</td>
<td>Resynchronization of the ischemic asynchroneous heart.</td>
<td>Maastricht University</td>
<td>December 10, 2010</td>
<td>Prof. J Maessen, Prof. T Delhaas, Prof. J Maessen</td>
</tr>
<tr>
<td>Simons A</td>
<td>To drain or not to drain; quantification of drainable intravascular venous volume during extracorporeal life support.</td>
<td>Maastricht University</td>
<td>June 23, 2010</td>
<td>Prof. J Maessen, Prof. E Oomen, Prof. J Maessen, Prof. T Delhaas</td>
</tr>
<tr>
<td>Van Straten B</td>
<td>Outcome following ten years coronary artery bypass surgery; risk factors for early and late mortality and morbidity.</td>
<td>Maastricht University</td>
<td>April 8, 2010</td>
<td>Prof. J Maessen, Prof. E Oomen, Prof. J Maessen, Prof. T Delhaa</td>
</tr>
<tr>
<td>Swinnen M</td>
<td>Matricellular Proteins: crucial regulators of cardiac remodeling.</td>
<td>Maastricht University</td>
<td>March 31, 2010</td>
<td>Prof. J Maessen, Prof. E Oomen, Prof. J Maessen, Prof. T Delhaa</td>
</tr>
<tr>
<td>Bekkers SCAM</td>
<td>Assessment of injury in reperfused acute myocardial infarction using cardiovascular magnetic resonance imaging.</td>
<td>Maastricht University</td>
<td>June 1, 2011</td>
<td>Prof. J Maessen, Prof. E Oomen, Prof. J Maessen, Prof. T Delhaa</td>
</tr>
<tr>
<td>Dennert R</td>
<td>Idiopathic cardiomyopathies: the role of virus persistence and immune-mediated disease.</td>
<td>Maastricht University</td>
<td>February 25, 2011</td>
<td>Prof. J Maessen, Prof. E Oomen, Prof. J Maessen, Prof. T Delhaa</td>
</tr>
<tr>
<td>Houben F</td>
<td>Nucleo-cytoskeletal interactions in the mechanical functioning of the cell.</td>
<td>Maastricht University</td>
<td>December 20, 2011</td>
<td>Prof. J Maessen, Prof. E Oomen, Prof. J Maessen, Prof. T Delhaa</td>
</tr>
<tr>
<td>Kubben N</td>
<td>Lamin interA/CTors: from the premature to senescence.</td>
<td>Maastricht University</td>
<td>July 7, 2011</td>
<td>Prof. J Maessen, Prof. E Oomen, Prof. J Maessen, Prof. T Delhaa</td>
</tr>
<tr>
<td>Nabben M</td>
<td>Uncoupling protein 3 and the protection of skeletal muscle mitochondrial function; a transgenic approach.</td>
<td>Maastricht University</td>
<td>April 20, 2011</td>
<td>Prof. J Maessen, Prof. E Oomen, Prof. J Maessen, Prof. T Delhaa</td>
</tr>
<tr>
<td>Steinbusch LKM</td>
<td>CD 36; a target to restore cardiac function in type 2 diabetes.</td>
<td>Maastricht University</td>
<td>October 13, 2011</td>
<td>Prof. J Maessen, Prof. E Oomen, Prof. J Maessen, Prof. T Delhaa</td>
</tr>
<tr>
<td>Stevens KNJ</td>
<td>Blood-contacting biomaterials for critical clinical applications.</td>
<td>Maastricht University</td>
<td>December 15, 2011</td>
<td>Prof. J Maessen, Prof. E Oomen, Prof. J Maessen, Prof. T Delhaa</td>
</tr>
<tr>
<td>Verkaar F</td>
<td>Pharmacological characterization of wrt/frizzled signaling.</td>
<td>Maastricht University</td>
<td>February 10, 2011</td>
<td>Prof. J Maessen, Prof. E Oomen, Prof. J Maessen, Prof. T Delhaa</td>
</tr>
<tr>
<td>Verstraeten V</td>
<td>Nuclear structure at the crossroad of premature aging and lipodystrophy.</td>
<td>Maastricht University</td>
<td>March 3, 2011</td>
<td>Prof. J Maessen, Prof. E Oomen, Prof. J Maessen, Prof. T Delhaa</td>
</tr>
</tbody>
</table>

**PHD THESES, EXTERNALLY PREPARED**

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>University</th>
<th>Date</th>
<th>Promotores</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kats S</td>
<td>Alkaline phosphatase. An old enzyme newly discovered.</td>
<td>RWTH Aachen</td>
<td>January 21, 2011</td>
<td>Prof. J Maessen, Prof. E Oomen, Prof. J Maessen, Prof. T Delhaa</td>
</tr>
<tr>
<td>Soliman Hamad M</td>
<td>Surgical revascularization in patients with left ventricular dysfunction, management and predictors of outcome.</td>
<td>University of Utrecht</td>
<td>November 25, 2011</td>
<td>Prof. J Maessen, Prof. E Oomen, Prof. J Maessen, Prof. T Delhaa</td>
</tr>
</tbody>
</table>

**PHD THESES 2012**

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>University</th>
<th>Date</th>
<th>Promotores</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bolderman R</td>
<td>Epicardial amiodarone therapy for atrial fibrillation.</td>
<td>Maastricht University</td>
<td>April 20, 2012</td>
<td>Prof. J Maessen, Prof. E Oomen, Prof. J Maessen, Prof. T Delhaa</td>
</tr>
<tr>
<td>Corsten M</td>
<td>MicroRNAs in the heart: micromanagers and sentinels of cardiac disease.</td>
<td>Maastricht University</td>
<td>September 14, 2012</td>
<td>Prof. J Maessen, Prof. E Oomen, Prof. J Maessen, Prof. T Delhaa</td>
</tr>
<tr>
<td>Dirk E</td>
<td>Protein kinase Dr: At the crossroad of cardiac function and metabolism.</td>
<td>Maastricht University</td>
<td>February 3, 2012</td>
<td>Prof. J Maessen, Prof. E Oomen, Prof. J Maessen, Prof. T Delhaa</td>
</tr>
<tr>
<td>Eckstein J</td>
<td>The three-dimensional substrate of Atrial Fibrillation in the goat.</td>
<td>Maastricht University</td>
<td>January 18, 2012</td>
<td>Prof. J Maessen, Prof. E Oomen, Prof. J Maessen, Prof. T Delhaa</td>
</tr>
<tr>
<td>Gaajetaan G</td>
<td>Limiting viral infections with immunomodulating agents.</td>
<td>Maastricht University</td>
<td>November 29, 2012</td>
<td>Prof. J Maessen, Prof. E Oomen, Prof. J Maessen, Prof. T Delhaa</td>
</tr>
<tr>
<td>Gerards M</td>
<td>Unraveling genetic defects and pathophysiologial mechanisms in OXPHOS disease.</td>
<td>Maastricht University</td>
<td>December 12, 2012</td>
<td>Prof. J Maessen, Prof. E Oomen, Prof. J Maessen, Prof. T Delhaa</td>
</tr>
<tr>
<td>Goossens P</td>
<td>A fatal attraction: Macrophage recruitment to the atherosclerotic plaque.</td>
<td>Maastricht University</td>
<td>February 15, 2012</td>
<td>Prof. J Maessen, Prof. E Oomen, Prof. J Maessen, Prof. T Delhaa</td>
</tr>
</tbody>
</table>
Heijman J -
Computational analysis of β-adrenergic stimulation and its effects on cardiac ventricular electrophysiology. 
Promotores: Prof. H Crijns; Prof. R Peeters. Co-promotores: Dr P Volders; Dr R Westra. 
Maastricht University, April 27, 2012

Huberts W -
Personalized computational modeling of vascular access creation. 
Promotores: Prof. F van den Vosse, Prof. T Delhaas Co-promotores: Dr E Bosboom, Dr J Tordoir. 
Maastricht University, March 1, 2012

Jacobs L -
The release of cardiac troponin: when, where and how. 
Promotor: Prof. M van Dieijen-Visser Co-promotor: Dr W Wodzig. 
Maastricht University, February 3, 2012

La Meir M -
Hybrid thoracoscopic epicardial and transvenous endocardial catheter ablation of atrial fibrillation. 
Maastricht University, November 30, 2012

Manusama R -
The value of catheter-based cryoablation for the management of cardiac arrhythmias. 
Promotor: Prof. H Crijns. Co-promotor: Dr C Timmermans. 
Maastricht University, March 16, 2012

Mingels A -
High-sensitivity cardiac troponin assays; Laboratory and clinical aspects. 
Promotor: Prof. M van Dieijen-Visser Co-promotor: Dr W Wodzig. 
Maastricht University, February 3, 2012

Pisters R -
Antithrombotic management of patients with atrial fibrillation. 
Promotor: Prof. H Crijns. 
Maastricht University, March 23, 2012

Pulinx B -
Protein biomarkers in chronic disease. Proteomics-driven discovery. 
Promotores: Prof. M van Dieijen-Visser, Prof. G Schurink. Co-promotor: Dr W Wodzig. 
Maastricht University, October 3, 2012

Salic K -
MicroRNAs: small directors with crucial powers in heart failure. 
Maastricht University, November 21, 2012

Van Almen G -
Pleiotropic effects of non-structural matrix proteins in the stressed heart. ECM remodeling in cardiotoxicity, aging and cardiac allograft rejection. 
Promotor: Prof. S Heymans. Co-promotor: Dr B Schroen. 
Maastricht University, May 16, 2012

Van Geldorp I -
Improving ventricular pacing in adults and children; to treat or to avoid dyssynchrony-induced cardiac failure. 
Promotores: Prof. T Delhaas, Prof. F Prinzen, Prof. J Janousek. 
Maastricht University, November 16, 2012

Voets A -
New pathophysiological concepts and potential therapeutic targets for oxidative phosphorylation disorders. 
Promotor: Prof. H Smeets. Co-promotor: Dr I de Coo. 
Maastricht University, May 24, 2012

Weijs B -
Clinical implications of idiopathic atrial fibrillation. 
Promotor: Prof. H Crijns. Co-promotor: Dr R Pisters. 
Maastricht University, September 21, 2012
IF 2.011

IF 2.377

IF 12.629

Jacobs L, Gerards M, Chinnery P, Dumoulin J, de Coo I, Geraedts JPM, Smeets HJM - mtDNA point mutations are present at various levels of heteroplasmia in human oocytes. Mol Hum Reprod 2007; 13(3): 914
IF 2.760

IF 2.011

IF 3.015

IF 3.724

IF 1.979

IF 2.051

IF 26.681

IF 3.777

IF 5.739

IF 10.940


IF 1.953

IF 7.286

IF 3.514

IF 5.247

IF 2.615

IF 7.286


REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31. Brain 2008; 31(Pt 4): 1076-86
IF 8.568
Benton CR, Holloway GP, Campbell SE, Yoshida Y, Tandon NN, Glatz JF, Luiken JJFP, Spriet LL, Bonen A –
Rosiglitazone increases fatty acid oxidation and fatty acid translocase (FAT/CD36) but not carnitine palmitoyltransferase I in rat muscle mitochondria. J Physiol-London 2008; 586: 1755-1766
IF 4.58
Benton CR, Nickerson JG, Lally J, Han XX, Holloway GP, Glatz JF, Luiken JJFP, Graham TE, Heikila JJ, Bonen A –
IF 5.581
Bhargava K, Kler TS, Wellsens HJJ –
IF 1.069
Bijlsma MF, Leenders PJ, Janssen BJA, Peutz-Kootstra CJ, van de Schans VA, ter Horst IF 2.986
2008; 10: 281-90
Treatment of atrial fibrillation. Heart 2008; 94(10): 1342-9
IF 4.141
Blauw Y, Crijns HJGM –
Treatment of atrial fibrillation. Heart 2008; 94(10): 1342-9
IF 4.141
Blankstein WM, van de Schans VA, ter Horst P, Smits JFM –
IF 9.61
De Boeck BWL, Meine M, Leenders GE, Teske E, Noble FAC, Ahmed A, Glatz JF, Nicolaides KH, Gratacos E –
Cardiac dysfunction and cell damage across clinical stages of severity in growth-restricted foetuses. Am J Obstet Gynecol 2008; 199: 2541-8
IF 4.48
Van den Borne SWM, Narula J, Voncken JW, Lijnen PM, Vervoorts-Peters HT, Dahlmans VE, Smits JFM, Daemen MJAP, Blankstein WM –
Defective intercellular adhesion complex in myocardium predisposes to infarct rupture in humans. J Am Coll Cardiol 2008; 51(22): 2184-92
IF 11.054
IF 28.638
Bredenoord AL, Dondorp WJ, Pennings G, de Die-Smulders CEM, de Wert GMWR –
IF 3.543
Bredenoord AL, Pennings G, Smeets HJM, de Wert GMWR –
IF 3.543
IF 1.62
Chun HJ, Narula J, Hofstra L, Wu JC –
Intracellular and extracellular targets of molecular imaging in the myocardium. Nat Clin Pract Cardiol 2008; 5(2): 533-41
IF 4.743
Cobbaut CM, Neykamp CW, Michielsen E, Baadenhuisen J, van Dieijen-Visser MP –
IF 4.903
IF 4.903
Die-Smulders CEM, de Wert GMWR –
IF 3.543
IF 6.807

IF 1.8

IF 2.424

IF 2.424

IF 12.755

IF 3.973

IF 3.613

IF 2.619

IF 4.003

IF 4.374

IF 1.915

IF 1.525

IF 2.953

IF 2.338

IF 3.973

IF 52.589

IF 3.973

IF 2.346

IF 6.014

IF 4.333

Huyrh M, Luiken JJFP, Courmans WA, Bell RC – Dietary fructose during the suckling period increases body weight and fatty acid uptake into skeletal muscle in adult rats. Obesity 2008; 16: 1755-1762
IF 1.52

IF 3.493

IF 1.561

IF 5.009

IF 3.903

IF 3.973

IF 3.493

IF 2.346

IF 6.014

IF 4.333


Sorens NYP, Axelsson AD, Stleys A, Loos RJ, Stassen AP, Giuliani M, Smeets HJM, Beunen G Fagard R, Derom C Vlietinck R, Geraedts JPM, Zeegers MPJ – Common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNPs in LEP and LEPR associated with common SNP...
Letter to the editor

IF 52.589

IF 1.602

IF 26.372

IF 1.602


IF 26.372


IF 0

IF 1.126

IF 26.372


IF 0

IF 1.126

IF 26.372
IF 2.5

IF 3.272

IF 4.409

IF 3.643

IF 3.925

IF 16.559

IF 16.559

IF 0

IF 7.033

IF 1.956

IF 5.114

IF 9.089

IF 1.436

IF 3.121

IF 1.12

IF 3.134

IF 5.947

IF 1.126

IF 4.285

Habets DDJ, Thumond DC, Coumans WA, Bonen A, Glazt JF, Luiken JFF – Munc18c is not rate-limiting for glucose and long-chain fatty acid uptake in the heart. Mol Cell Biochem 2009; 321(2): 81-6
IF 1.764

IF 4.564

IF 0

Self-evaluation 2007-2012
CARIM 51

IF 5.132


IF 3.398

Hohnloser SH, Crijns HJGM, van Eickels M, IF 3.398


IF 3.264


IF 4.964


IF 5.101


IF 1.917


IF 3.905


IF 1.764


IF 3.121


IF 0


IF 3.002


IF 3.129


IF 1.788


IF 6


IF 4.371

Luiken JJPF – Sarcolemmal fatty acid uptake vs. mitochondrial beta-oxidation as target to regress cardiac insulin resistance. Appl Physiol Nutr Me 2009; 34(3): 473-8

IF 1.591


IF 2.605

IF 2.181


IF 2.689


IF 5.407


IF 14.595


IF 14.595


IF 7.033


IF 2.131


IF 3.64


IF 4.622


IF 4.697

Stevens KN, Knetisch MLW, Sen A, Sambhy V, Koole LH – Disruption and Activation of Blood Platelets in Contact with an Antimicrobial Composite Coating Consisting of a Pyridinium Polymer and AgBr Nanoparticles. ACS Appl Mater Interfaces 2009; 1(9): 2049-64

IF 0


IF 6.646


IF 4.329


IF 14.595


IF 1.961

Van der Vusse GJ – Albumin as fatty acid transporter. Drug Metab Pharmacok 2009; 24: 300-307

IF 2.541


IF 7.033


IF 3.4


IF 1.700


IF 1.03


IF 11.438


Constantinedis C, Mean R, Janssen B – Heart rate and blood pressure variability effects as a result of oxygen and nitrous oxide administration in the anesthetized mouse. IEEE Eng Med Biol 2010; 1: 2529-2532 IF 1.081

Cox M, van der Smagt JJ, Doevendans PA, van Tintelen P, Wilde AAM –
Avontuurlijke reis naar het verleden: een trip door de geschiedenis.
IF 4.162

IF 3.859

IF 3.859

IF 4.752

IF 1.91

IF 1.392

Hermans MCE, Pinto YM, Merkies ISJ, de Dieu Smulders CEM, Crijns H, Faber CG – A Repressor of Myocardin Activity. Journal of Biological Chemistry 2010; 285(2): 122-130
IF 4.965

IF 37.05

IF 1.208

Korsten A, de Coo IFM, Spruijt L, de Wit LEA, Smeets HMJ, Sluijer W – Patients with Leber hereditary optic neuropathy fail to compensate impaired oxidative phosphorylation. Biochimica Et Biophysica Acta-Bioenergetics 2010; 1797(2): 197-203
IF 3.688

IF 1.902

IF 13.66

IF 6.961

Laeremans H, Rensen SS, Ottenheim HCJ, Smits JFM, Blankensteijn WM – V/ß signaling modulates the migration and differentiation of immortalized cardiac fibroblasts. Cardiovascular Research 2010; 87(3): 514-523
IF 5.801

IF 7.235

IF 3.575

IF 5.328


Impaired recruitment of HHT-1 mononuclear cells to the ischaemic heart is due to an altered CXCR4/CD26 balance. Cardiovascular Research 2010; 85(3): 494-502
IF 5.801

The Impact of New and Emerging Clinical Data on Treatment Strategies for Atrial Fibrillation. Journal of Cardiovascular Electrophysiology 2010; 21(8): 946-958
IF 3.703

IF 3.4

Cardiac Rac1 overexpression in mice creates a substrate for atrial arrhythmias characterized by structural remodelling. Cardiovascular Research 2010; 87(3): 485-493
IF 5.801

IF 2.643

IF 1.062

Rother J, Crijns H –
IF 3.535

Safety and T Cell Modulating Effects of High Dose Vitamin D-3 Supplementation in Multiple Sclerosis. Plos One 2010; 5(12): 1-9
IF 4.351

IF 4.802

Gonadal function in male and female patients with classic galactosemia. Human Reproduction Update 2010; 16(2): 177-188
IF 7.042

Adult Basic Life Support Chapter Collaborators.
IF 14.816

Replacement and reactive myocardial fibrosis in idiopathic dilated cardiomyopathy: comparison of magnetic resonance imaging with right ventricular biopsy. European Journal of Heart Failure 2010; 12(3): 227-231
IF 3.706

Syndecan-1 Amplifies Angiotensin II-Induced Cardiac Fibrosis. Hypertension 2010; 55(2): 249-56
IF 7.042

Schotten U, Verheule S, Kerfant BG, Greiser M –
Pulse Conductance and Flow-Induced Hemolysis During Pulsatile Cardiopulmonary Bypass. Artificial Organs 2010; 34 (4): 289-294
IF 1.827

IF 3.859

IF 6.579

Simons AP, Lance MD, Reesink KD, van der Veen FH, Weerwind PW, Maessen JG –
Quantitative assessment of cardiac load responsiveness during extracorporeal life support: case and rationale. Journal of Cardiothoracic Surgery 2010; 5: 4
IF 0.737

Simons AP, Reesink KD, Lance MD, van der Nagel T, van der Veen FH, Weerwind PW, Maessen JG –
IF 0.642

Simons AP, Wortel P, van Kan RAT, van der Veen FH, Weerwind PW, Maessen JG –
IF 2.074

Different distribution of the genetic subtypes of the Prader-Vili syndrome in the elderly. European Journal of Human Genetics 2010; 18(9): 993-998
IF 3.564

Smedts F, Ramaekers FCS, Hopman AHN –
IF 2.074

IF 1.518

Heart failure patients with a lower educational level and better cognitive status benefit most from a self-management group programme. Patient Education and Counseling 2010; 81(2): 214-221
IF 1.975

IF 6.579
IF 5.751

IF 4.013

IF 4.722

IF 6.573

IF 9.214

IF 3.703

IF 4.559

IF 1.317

IF 3.713

IF 3.703

IF 0

IF 1.392

IF 2.175

Van Dommelens L, Verbon A, van Doorn HR, Goossens VJ – Acute hepatitis B virus infection with simultaneous high HBsAg and high anti-HBs signals in a previously HBV vaccinated healthy 1-positive patient. Journal of Clinical Virology 2010; 43(7): 293-296
IF 3.124

IF 3.4

IF 4.565

IF 1.871

IF 3.575

IF 2.376

IF 6.614

IF 9.214

IF 2.935

IF 4.365

IF 3.4

IF 2.777

Verkaar F, Blanksteijn WM, Smits JFM, Zaman QR – Beta-Galactosidase enzyme fragment complementation for the measurement of Wnt/beta-catenin signaling. Faseb Journal 2010; 7(1): 30-37
IF 6.401

Verkaar F, Zaman QR – A model for signaling specificity of Wnt/Frizzled combinations through co-receptor recruitment. Feds Journal 2010; 2(4): 1205-1217
IF 6.401

IF 3.644

Volders PGA – Novel insights into the role of the sympathetic nervous system in cardiac arrhythmogenesis. Heart Rhythm 2010; 7(12): 1900-1906
IF 4.359

IF 2.442

SELF-EVALUATION 2007-2012 CARIM 61


Weis J, Smulders MW, Alzand BSN – Water leakage” in an oxygenator; a suspected unexpected phenomenon. Perfusion-Uk 2010; 25(1): 242 IF 0.642


Publications in scientific journals (wi-2)


Letter to the editor


Van Gelder IC, Crijns H, Van den Berg MP – Lenient versus Strict Rate Control in Atrial Fibrillation REPLY. New England Journal of Medicine 2010; 363(4): 393-394 IF 47.05


Janssen DJA, Spruit MA, Uszko-Lencer NH, Schols J, Wouters EF – Symptoms, Comorbidities, and Health Care in Advanced Chronic Obstructive Pulmonary Disease or Chronic Heart Failure. Journal of Palliative Medicine 2011; 14(6): 735-743 IF 2.245


IF 14.432


IF 4.246


IF 0.557


IF 14.432


IF 4.925


IF 1.109


IF 0.557


IF 14.432


IF 4.925


IF 1.109

Lenthal ME, Denhaerynck K, Brunner-La Roca HP, Burnd B, Conca A, Bernasconi AT, Mahrer-Imhof R, Froelicher ES, De Geest S – Swiss Interventional Management Programme for Heart Failure (SWMM-HF), Swiss Medical Weekly 2011; 141: 10

IF 1.823


IF 4.328


IF 0.862


IF 4.246

Linz D, Schotten U, Neuberger HR, Bohm M, Wirth K – Negative tracheal pressure during obstructive respiratory events promotes atrial fibrillation by vagal activation. Heart Rhythm 2011; 8(8): 1436–1443

IF 4.246


IF 2.493


IF 0.650


IF 4.877


IF 4.701


IF 5.328


IF 2.146


IF 0.050


IF 0.050


IF 5.499


IF 1.772


IF 2.146


IF 3.601


IF 5.439


IF 2.493


IF 4.246

IF 1.790


IF 3.761


IF 3.681


IF 4.050


IF 1.735


IF 3.368


IF 3.781


IF 2.872


IF 3.964


IF 14.432


IF 5.224


IF 4.050


IF 3.368


IF 3.676


IF 0.745


IF 1.735


IF 14.233


IF 2.901


IF 4.411

Schravana-Hinderling VB, Meex RCR, Hesselink MKC, van de Weijer T, Leiner T, Schrarpen PV, Kool ME – Cardiac lipid content is unresponsive to a physical activity training intervention in type 2 diabetic patients, despite improved ejection fraction. Cardiovascular Diabetology 2011; 10: 7

IF 2.720


IF 3.801


IF 2.586

Sep SJS, Schreurs MPH, Bekkers S, Kruse AJ, Smits LJ, Peeters LLH – Early-pregnancy changes in cardiac diastolic function in women with recurrent pre-eclampsia and in previously pre-eclamptic women without recurrent disease. BJOG-an International Journal of Obstetrics and Gynecology 2011; 118(9): 1112-1119

IF 3.349


IF 0.745


IF 1.735


IF 14.233


IF 2.901


IF 4.411

SELF-EVALUATION 2007-2012

CARIM 67
Exercise related ventricular arrhythmias are related to cardiac fibrosis in hypertrophic cardiomyopathy due to sarcomeric mutations. Netherlands Heart Journal 2011; 19(4): 168-174
IF 1.447

Van Tienen FJH, van der Kallen CJH, Lindsey PJ, Wanders RJ, van Groenenboom MM, Smeets HJM –
IF 5.125

Intrathoracic Impedance Monitoring, Audible Patient Alerts, and Outcome in Patients With Heart Failure. Circulation 2011; 124(16): 1719-26
IF 14.432

IF 3.681

Vanhees K, Coort S, Ruijters EJB, Godschalck RWW, van Schooten FJ, van Doorn-Khosrovani SBV –
Epigenetics: prenatal exposure to genistein leaves a permanent signature on the hematopoietic lineage. Faseb Journal 2011; 25(2): 797-807
IF 6.515

Cerebral Accumulation of Dietary Derivable Plant Sterols does not Interfere with Memory and Anxiety Related Behavior in Aobg^-/- Mice. Plant Foods for Human Nutrition 2011; 66(2): 149-156
IF 2.463

IF 4.727

IF 4.727

Large scale miRNA sequencing reveals sequence and functional conservation as major determinants of homoplasmic mtDNA variant distribution. Mitochondrion 2011; 11(6): 964-972
IF 3.238

Voogdt-Pruis HR, Beusmans G, Gorgels APM, van Ree JW –
IF 1.540

Voogdt-Pruis HR, van Ree JW, Gorgels APM, Beusmans G –
IF 2.103

IF 4.411

Wann LS, Curtis AB, Crijns H, Yancy CW –
IF 14.432

Wecke L, van Deursen CJM, Bergfeldt L, Prinzen FW –
Regulation changes in patients with heart failure receiving cardiac resynchronization therapy-signs of cardiac memory. Journal of Electrocardiology 2011; 44(5): 590-598
IF 1.109

Patients using vitamin K antagonists show increased levels of coronary calciumification: an observational study in low-risk atrial fibrillation patients. European Heart Journal 2011; 32(20): 2555-2562
IF 10.052

Weijls B, de Voos CB, Tielemans RG, Pisters R, Cheriex EC, Prins MH, Crijns H –
Clinical and echocardiographic correlates of intra-atrial conduction delay. Europace 2011; 13(12): 1681-1687
IF 1.842

Wellens HJ, Gorgels APM –
IF 14.432

Weseler AR, Ruijters EJ, Dritty - Reijnders MJ, Reesink KD, Haenen GRMM, Bast A –
Pleiotropic benefit of monomeric and oligomeric flavonols on vascular health – a randomized controlled clinical pilot study. PLoS One 2011; 6(12): e28460
IF 4.411

IF 3.792
Publications in scientific journals (wi–2)

Accord R, Maessen J –
Endoscopic vein harvesting for coronary bypass grafting: A blessing or a trojan horse? Cardiol Res Pract 2011; 2011: 813512

Donker DW, Peeters L, van Mook WNKA –

Glazt JFC –
Challenges in fatty acid and lipid physiology. Frontiers Physiol 2011; 2: 45-201

Hermeling E, Reneman RS, Hoeks AP, Reesink KD –
Advances in arterial stiffness research. Artery Research 2011; 5: 130-136

A comparison between the mechanical behaviour of steel wires and ultra high molecular weight poly ethylene cables for sternum closure. Materials Sciences and Applications 2011: 1367-1374


Reesink KD, Hermeling E, Ong KT, Brouwers MC, Reneman RS, Bouytourie P, Hoeks AP –

Letter to the editor

Bramer S, van Straten AHM, Hamad MAS, Berrekleuwe E, Martens EJ, Maessen JG –


Crijns HJ, Schotten U, Moens AL –
Is NOS uncoupling the missing link between atrial fibrillation and chronic non-Ischaemic cardiomyopathy? Cardiovascular Research (Letter) 2011; 91(3): 556-556

Crijns HJ, Straus SM, de Jong-van den Berg LT –
Oral isotretinoin and pregnancy prevention programs: reply from authors. Brit J Dermatol 2011; 164(2): 238-244

Da Costa Martins PA, De Windt LJ –
Letter concerning: “Enhanced expression of OPRM1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo”. Cardiovascular Research (letter) 2011; 91(4): 742-743

Denner R, Alzand BSN, Crijns H –

Geelen CC, Bouman EA, Roekaerts PM, Breedveld P, Strauch U, Van Garsee L, Weerwind PW, Donker DW –

Goossens VJ, Wolfs PF, Bruggeman CA –

Juni RP, Blom Hj, Schmidt HH, Moens AL –
Folic acid enlarges the armamentarium for the treatment of coronary vasospasm. J Cell Physiol 2011; 228(7): 1627-8

IF 3.986

Ketelsdorren R, Kietselaer BL, Schmidt H, Moens AL –
Role of tetrahydrobiopterin (BH4) in hyperhomocysteinemia-induced endothelial dysfunction: new indication for this orphan-drug? American Journal of Physiology-Endocrinology and Metabolism (Letter) 2011; 300(6): E1175-E1176

Kirchhof C, Crijns H, van Gelder IC –
Propafenone contraindicated in the elderly? Heart (Letter) 2011; 97(3): 292-292

Octavia Y, Wingler K, Schmidt HH, Moens AL –

Patberg KW, de Groot JR, Blauw Y-

Pisters R, Lane DA, Nieuwlaat R, Crijns H, Lip GYH –

Pisters R, Nieuwlaat R, Lane DA, Crijns H, Lip GYH –

Prinzen FW –
Cardiac Resynchronization Therapy in Heart Failure (book review). Circulation 2011; 123: e416-e417

IF 14.432
Publications in scientific journals 2012

**Altenhofer S, Kleikers PWM, Rademaker KA, Scheurer P, Hermans JJR, Schillers P, Ho HD, Wingler K, Schmidt HH –**
The NOX toolbox: validating the role of NADPH oxidases in physiology and disease. CML-CELL, Molecular Life Sciences 2012; 69(14): 2327-2343
IF 8.57

CD36 inhibition prevents lipid accumulation and contractile dysfunction in rat cardiomyocytes. Biochemical Journal 2012; 448: 49-53
IF 4.897

**Arts T, Lumens J, Kroon W, Dehaas T –**
Control of Whole Heart Geometry by Intramyocardial Mechano-Feedback: A Model Study. Plos Computational Biology 2012; 8(2): e1002369
IF 5.215

**Arts T, Reesink K, Kroon W, Dehaas T –**
Simulation of adaptation of blood vessel geometry to flow and pressure: Implications for arterio-venous impedance. Mechanics Research Communications 2012; 42: 15-21
IF 1.273

**Babiker FA, van Golde J, Vanagt WY, Prinzen FW –**
IF 2.611

**Bacharova L, Szathmary V, Potse M, Mateasik A –**
Computer simulation of ECG manifestations of left ventricular electrical remodeling. Journal of Electrocardiology 2012; 45(6): 630-634
IF 1.141

The (pro)renin receptor (P)RR can act as a repressor of Wnt signalling. Biochim Pharmacol 2012; 84(12): 1643-50
IF 4.705

LDL Receptor Knock-Out Mice Are a Physiological Model Particularly Vulnerable to Study the Onset of Inflammation in Non-Alcoholic Fatty Liver Disease. Plos One 2012; 7(1): e30658
IF 4.092

Specific immunization strategies against oxidized low-density lipoprotein: A novel way to reduce nonalcoholic steatohepatitis in mice. Hepatology 2012; 56(3): 894-903
IF 11.665

IF 4.092

IF 3.653

IF 1.141

**Bode AS, Huberts W, Bosboom EMH, Kroon W, van der Linden WPM, Planken RN, van de Vosse FN, Torod LRH –**
IF 4.092

Myelin-Derived Lipids Modulate Macrophage Activity by Liver X Receptor Activation. Plos One 2012; 7(9)
IF 1.98

IF 1.38

**Borissioff JL, Joozen IA, Versteylen MO, Sprock HM, ten Cate H, Hofstra L –**
Accelerated in vivo thrombin formation independently predicts the presence and severity of CT angiographic coronary atherosclerosis. JACC-CARDIOVASC IMAG 2012; 5(12): 1201-10
IF 5.431

**Bosch YPJ, Weerwind PW, Nelemans PJ, Maessen JG, Mochtar B –**
IF 1.64

IF 8.286

The lipid droplet coat protein perilipin 5 also modulates to muscle mitochondria. Histochemistry and Cell Biology 2012; 137(2): 205-216
IF 2.588


Hermans MCE, Faber CG, Bekkers SC, de Die 2013; 14: 48 IF 3.717


IF 4.746


IF 5.423


IF 5.166


IF 4.092

Papageorgiou AP, Heymans S – Interactions between the extracellular matrix and inflammation during viral myocarditis. Immunology 2012; 121(5): 503-510

IF 3.205


IF 6.064


IF 6.207


IF 8.833


IF 1.98


IF 14.156


IF 1.98


IF 4.102


IF 5.215


IF 1.273


IF 2.611


IF 1.98


IF 2.664


IF 4.746


IF 5.686


IF 10.478


IF 4.896


IF 35.532


IF 2.664


IF 1.98


IF 0.304

Self-Evaluation 2007-2012 CARIM 77

Schoen B, Heymans S – Small but smart-micro-RNAs in the centre of inflammatory processes during cardiovascular diseases, the metabolic syndrome, and ageing. Cardiovascular Research 2012; 93(4); 605-613. IF 6.054


Swendsen M, Prinzen FW, Das MK, Berwick Z, Rybka M, Tune JD, Combs W, Berbari EJ, Kassab GS – Bi-ventricular pacing improves pump function only with adequate myocardial perfusion in canine hearts with pseudo-left bundle branch block. Experimental Biology and Medicine 2012; 237(6); 644-651. IF 2.525

Ter Bekke RMA, Volders PGA – Arrhythmogenic mecano-electric heterogeneity in the long-QT syndrome. Progress in Biophysics & Molecular Biology 2012; 1102-3; 347-358. IF 3.203

Ter Horst P, Smits JFM, Blankenstein WM – The Wnt/Briskzled pathway as a therapeutic target for cardiac hypertrophy: where do we stand. Acta Physiologica 2012; 204(1); 110-117. IF 3.307


Sternick EB, Gerken L, Correa FS, Wellens HJ – Progressive Widening of the QRS Complex During Tachycardia: What Are The Underlying Rhythms?. Journal of Cardiovascular Electrophysiology 2012; 23(10); 1146-1148. IF 3.064


Sternick EB, Gerken L, Correa FS, Wellens HJ – Progressive Widening of the QRS Complex During Tachycardia: What Are The Underlying Rhythms?. Journal of Cardiovascular Electrophysiology 2012; 23(10); 1146-1148. IF 3.064

Strogovskis M, Rikvendovs L, Kuznetsov A – Geometrical models for cardiac MRI in rodents: comparison of quantification of left ventricular volumes and function by various geometrical models with a full-volume MRI data set in rodents. American Journal of Physiology-Heart and Circulatory Physiology 2012; 302(3); H709-H715. IF 3.708


Van den Bosch BJ, Gerard M, Salah G, Meijboom H – An age-related increase in diastolic function with superior exercise capacity in highly trained athletes. Nitric Oxide-Biology and Chemistry 2012; 20(7); 75-81. IF 3.548

Vaaarhors AAM, Lu YC, Heijmans BT, Dole MET, Bohringer S, Putter H, Imholz S, Merry AHV, van Greevenbroek MM, Jukema JW, Gorgels APM, van den Brandt PA, Muller M, Schouten LJ, Feskens EJM, Boer JMA, Slagboom PE – Literature-Based Genetic Risk Scores for Coronary Heart Disease The Cardiovascular Registry Maastricht (CAREMA) Prospective Cohort Study. Circulation-Cardiogenic Genes 2012; 45(8); e43178. IF 4.092


Van Tienen FJH, Praet SFE, de Feyter HM, van den Broek NM, Lindsey PJ, Schoonderwoerd KGC, de Coo IFM, Nicolay K, Prompers JJ, Smeets HJM, van Loon LJC – Physical Activity Is the Key Determinant of Skeletal Muscle Mitochondrial Function in Type 2 Diabetes. Journal of Clinical Endocrinology & Metabolism 2012; 97(9): 3261-3269 IF 5.987


Voets AM, Huigsloot M, Lindsey PJ, Leenders AM, Koopman WJH, Willems P, Rodenburg RJ, Smeets HJM – Transcriptional changes in OXPHOS complex I deficiency are related to anti-oxidant pathways and could explain the disturbed calcium homeostasis. Biochimica Et Biophysica Acta-Molecular Basis of Disease 2012; 1822(7): 1161-1168 IF 5.387


Letter to the editor

Bons JAP, Havekes B, Volders PGA, de Zwaan C, Kema IP, Pryzmak W, Menheere P –


C

ADDENDUM I

GRANTS SUPPORTING RESEARCH IN MAIN THEME III
<table>
<thead>
<tr>
<th>YEAR</th>
<th>TITLE</th>
<th>TYPE</th>
<th>COMPANY BASE/ORGANISATION</th>
<th>COUNTRY</th>
<th>SUPPORT (K€) from: NWO/STW foundations contracts</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>Study on the use of intermittent ventricular pacing for the prevention of heart failure</td>
<td>Contract</td>
<td>Cardiac Pacemakers/ Boston Scientific USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Validation of Cathepsin C</td>
<td>Contract</td>
<td>(Organon) Schering Plough The Netherlands</td>
<td></td>
<td>97</td>
</tr>
<tr>
<td></td>
<td>Validation of S1P4/EDG6 and CMKLR1</td>
<td>Contract</td>
<td>(Organon) Schering Plough The Netherlands</td>
<td></td>
<td>87</td>
</tr>
<tr>
<td></td>
<td>Validation of targets for collateralisation</td>
<td>Contract</td>
<td>(Organon) Schering Plough The Netherlands</td>
<td></td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>Rheos Pivotal Trial</td>
<td>Contract</td>
<td>CTCM The Netherlands</td>
<td></td>
<td>406</td>
</tr>
<tr>
<td></td>
<td>DEBuT-HET drug withdrawal protocol</td>
<td>Contract</td>
<td>CTCM The Netherlands</td>
<td></td>
<td>137</td>
</tr>
<tr>
<td></td>
<td>Health care innovation for painful diabetic neuropathy</td>
<td>Contract</td>
<td>CTCM The Netherlands</td>
<td></td>
<td>149</td>
</tr>
<tr>
<td></td>
<td>Consultancy Agreement</td>
<td>Contract</td>
<td>CTCM The Netherlands</td>
<td></td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Evaluate the Efficacy and Safety of Belimumab etc</td>
<td>Contract</td>
<td>CTCM The Netherlands</td>
<td></td>
<td>203</td>
</tr>
<tr>
<td></td>
<td>Shockwave treatment for advanced angina in Maastricht (SWAAM)</td>
<td>Contract</td>
<td>CTCM The Netherlands</td>
<td></td>
<td>27</td>
</tr>
<tr>
<td></td>
<td>Study of azd6140 compared with clopidogrel for prevention of vascular events in patients with non-ST or ST elevation etc</td>
<td>Contract</td>
<td>CTCM The Netherlands</td>
<td></td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>Study Of The Mar-Tyn Cobalt Chromium Tin-Coated Balloon-Expandable Stent In The Treatment Of Patients With De Novo Coronary Artery Lesions</td>
<td>Contract</td>
<td>CTCM The Netherlands</td>
<td></td>
<td>66</td>
</tr>
<tr>
<td></td>
<td>The role of (auto)-immunity in pulmonary arterial hypertension</td>
<td>Contract</td>
<td>Actelion Pharmaceuticals Nederland BV</td>
<td>The Netherlands</td>
<td>180</td>
</tr>
<tr>
<td></td>
<td>Finding and validation of transmembrane targets in late atherosclerotic plaques</td>
<td>Contract</td>
<td>BRACCO Italy</td>
<td></td>
<td>662</td>
</tr>
<tr>
<td></td>
<td>Validation of CCR5 receptor as target of plaques instability</td>
<td>Contract</td>
<td>BRACCO Italy</td>
<td></td>
<td>378</td>
</tr>
<tr>
<td></td>
<td>Plaque tissue biomarker discovery</td>
<td>Contract</td>
<td>BG Medicine USA</td>
<td></td>
<td>400</td>
</tr>
<tr>
<td></td>
<td>VIDI E. Lutgens ASPASIA</td>
<td>Grant</td>
<td>ZonMw The Netherlands</td>
<td></td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>VIDI E. Lutgens Revival of CD40(L) as a therapy for atherosclerosis: exploration of downstream pathways as novel therapeutic options</td>
<td>Grant</td>
<td>ZonMw The Netherlands</td>
<td></td>
<td>405</td>
</tr>
<tr>
<td></td>
<td>Translational Regenerative Medicine (TerM)</td>
<td>Grant</td>
<td>NWO The Netherlands</td>
<td></td>
<td>770</td>
</tr>
<tr>
<td></td>
<td>Kootstra Fellowship S. Meex</td>
<td>Grant</td>
<td>UM/FHML The Netherlands</td>
<td></td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>Kootstra Fellowship K. Wouters</td>
<td>Grant</td>
<td>UM/FHML The Netherlands</td>
<td></td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>Is N-(carboxymethyl)lysine in plasma a predictor of poor outcome in patients with diabetes?</td>
<td>Grant</td>
<td>tUL The Netherlands</td>
<td></td>
<td>200</td>
</tr>
<tr>
<td></td>
<td>Ti-Pharma Exploitation of toll-like receptors in drug discovery</td>
<td>Grant</td>
<td>TTI The Netherlands</td>
<td></td>
<td>430</td>
</tr>
<tr>
<td></td>
<td>Ti-Pharma Endothelium-derived peptides in cardiovascular diseases</td>
<td>Grant</td>
<td>TTI The Netherlands</td>
<td></td>
<td>940</td>
</tr>
<tr>
<td></td>
<td>INTACT Regenerative medicine using autologous stem cell technologies for treatment of cardiovascular diseases</td>
<td>Grant</td>
<td>Provincie Limburg/ Ministry of Economic Affairs The Netherlands</td>
<td></td>
<td>240</td>
</tr>
<tr>
<td></td>
<td>Cerebral microbleeds: a marker of hypertensive cerebral target-organ damage?</td>
<td>Grant</td>
<td>Novartis Foundation The Netherlands</td>
<td></td>
<td>88</td>
</tr>
<tr>
<td></td>
<td>Chemokine receptor CXCR4: a protective factor in atherothrombosis?</td>
<td>Grant</td>
<td>NHS The Netherlands</td>
<td></td>
<td>130</td>
</tr>
<tr>
<td></td>
<td>An intact endothelial glycocalyx is required for adequate shear stress induced arteriogenesis</td>
<td>Grant</td>
<td>NHS The Netherlands</td>
<td></td>
<td>178</td>
</tr>
<tr>
<td></td>
<td>Marie Curie Fellowship A. Zernecke Structuring the European research area: Dendritic cells in the pathogenesis of atherosclerosis</td>
<td>Grant</td>
<td>EU Belgium</td>
<td></td>
<td>157</td>
</tr>
<tr>
<td></td>
<td>Integrated Genomics, Clinical Research and Care in Hypertension (Ingenious Hypercare)</td>
<td>Grant</td>
<td>EU Belgium</td>
<td></td>
<td>331</td>
</tr>
<tr>
<td></td>
<td>The role of insulin-mediated glycocalyx modulation in insulin sensitivity</td>
<td>Grant</td>
<td>Diabetes Foundation The Netherlands</td>
<td></td>
<td>270</td>
</tr>
<tr>
<td></td>
<td>Consultancy agreement</td>
<td>Grant</td>
<td>BG Medicine USA</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td>1,275</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3,015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2,958</td>
</tr>
<tr>
<td>YEAR</td>
<td>TITLE</td>
<td>TYPE</td>
<td>COMPANY BASE/ ORGANISATION</td>
<td>COUNTRY</td>
<td>SUPPORT (K€) from: contracts</td>
</tr>
<tr>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------</td>
<td>-----------------------------</td>
<td>-------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>2008</td>
<td>Diagnostic value of novel biomarkers in patients with chest pain of suspected cardiac origin</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>232</td>
</tr>
<tr>
<td></td>
<td>The effects of RO4697381 on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acuty Coronary Syndrome (ACS)</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>180</td>
</tr>
<tr>
<td></td>
<td>Mesenchymal cardiopoietic stem cells for the treatment of chronic heart failure secondary to ischemic cardiomyopathy</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>69</td>
</tr>
<tr>
<td></td>
<td>Effect of Olmesartan Medoxomil on Arterial Stiffness and Thickness in Subjects with Metabolic Syndrome</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td>To evaluate the efficacy and safety of fragmin in the treatment of chronic neuroischaemic foot ulcers in diabetic patients</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td>Phase II/III study with atacicept given subcutaneously to subjects having recently experienced a flare of systemic lupus erythematosus (SLE)</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>65</td>
</tr>
<tr>
<td></td>
<td>Research to therapy loyalty patients</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Collaboration agreement Fresenius Medical Care</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>150</td>
</tr>
<tr>
<td></td>
<td>Clinical performance of the endeavor resolute zotarolimus-eluting stent system in a Real-World patient population</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td>Collaboration agreement</td>
<td>Contract</td>
<td>Medtronic</td>
<td>The Netherlands</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>The CD40/CD40L axis in arterial neoimtima formation</td>
<td>Grant</td>
<td>NWO/DFG</td>
<td>The Netherlands</td>
<td>198</td>
</tr>
<tr>
<td></td>
<td>Microarray-based molecular diagnostic method to determine site of origin of Cancers of Unknown Primary (CUP)</td>
<td>Grant</td>
<td>STW</td>
<td>The Netherlands</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>VENI K. Reesink Non-invasive model-based assessment of individual cardiovascular interaction</td>
<td>Grant</td>
<td>STW/NWO</td>
<td>The Netherlands</td>
<td>208</td>
</tr>
<tr>
<td></td>
<td>Renal mechanisms in the progression of systemic atherosclerosis; renal artery stenosis as a model</td>
<td>Grant</td>
<td>CARIM</td>
<td>The Netherlands</td>
<td>180</td>
</tr>
<tr>
<td></td>
<td>CTMM PREDICT Diabetes Glycocalyx</td>
<td>Grant</td>
<td>CTMM</td>
<td>The Netherlands</td>
<td>438</td>
</tr>
<tr>
<td></td>
<td>CTMM Circulating cells: The natural sensors of plaque and patient destabilization</td>
<td>Grant</td>
<td>CTMM</td>
<td>The Netherlands</td>
<td>336</td>
</tr>
<tr>
<td></td>
<td>CTMM PREDICT</td>
<td>Grant</td>
<td>CTMM</td>
<td>The Netherlands</td>
<td>621</td>
</tr>
<tr>
<td></td>
<td>Patient specific image-based computational modelling for improvement of short- and long-term outcome of vascular access in patient on hemodialysis therapy</td>
<td>Grant</td>
<td>EU/ARCH</td>
<td>Belgium</td>
<td>1,019</td>
</tr>
<tr>
<td></td>
<td>Marie Curie Fellowship B. Bermudez The arterial adventitia: a critical actor in atheroscrotic plaque progression and stability?</td>
<td>Grant</td>
<td>EU</td>
<td>Belgium</td>
<td>160</td>
</tr>
<tr>
<td></td>
<td>The mechanisms of cardiovascular risks after low radiation doses</td>
<td>Grant</td>
<td>EU/CARDIORISK</td>
<td>Belgium</td>
<td>292</td>
</tr>
<tr>
<td></td>
<td>Health Foundation Limburg</td>
<td>Grant</td>
<td>Health Foundation Limburg</td>
<td>The Netherlands</td>
<td>200</td>
</tr>
<tr>
<td></td>
<td>Happy project</td>
<td>Grant</td>
<td>IMG</td>
<td>The Netherlands</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>Role of the endothelial glycocalyx in renal glomerular and tubular function</td>
<td>Grant</td>
<td>Kidney Foundation</td>
<td>The Netherlands</td>
<td>120</td>
</tr>
<tr>
<td></td>
<td>Established investigator M. De Winther Macrophage subpopulation in atherosclerosis</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>500</td>
</tr>
<tr>
<td></td>
<td>Student travel grant</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Study to validate the use of alphavbeta(3) integrin imaging to predict scar formation and adverse remodelling after myocard infarction in patients</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>180</td>
</tr>
<tr>
<td></td>
<td>VEGF-receptor downstream signalling ADAM10 as a novel metalloprotease involved in angiogenesis and atherosclerosis</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>234</td>
</tr>
<tr>
<td></td>
<td>MRI molecular imaging of (inflammatory) macrophages as a predictor of abdominal aortic aneurysm progression</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>245</td>
</tr>
<tr>
<td></td>
<td>Role of endothelial arginine metabolism in endothelial dysfunction</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>210</td>
</tr>
<tr>
<td>YEAR</td>
<td>TITLE</td>
<td>TYPE</td>
<td>COMPANY BASE/ ORGANISATION</td>
<td>COUNTRY</td>
<td>SUPPORT (K€) from:</td>
</tr>
<tr>
<td>------</td>
<td>-------</td>
<td>------</td>
<td>-----------------------------</td>
<td>---------</td>
<td>-------------------</td>
</tr>
<tr>
<td>2008</td>
<td>Morphological and functional characterization of therapeutically induced neovasculature by magnetic resonance imaging</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>104</td>
</tr>
<tr>
<td></td>
<td>Interreg IV-A Alma-In-Silico project</td>
<td>Grant</td>
<td>Provincie Limburg</td>
<td>The Netherlands</td>
<td>600</td>
</tr>
<tr>
<td></td>
<td>Parelsnoer Diabetes Maastricht</td>
<td>Grant</td>
<td>SenterNovem</td>
<td>The Netherlands</td>
<td>521</td>
</tr>
<tr>
<td></td>
<td>The role of tissue factor pathway inhibitor in the onset and progression of ischemic cerebral injuries by cerebral micro-angiopathy</td>
<td>Grant</td>
<td>Dutch Thrombosis Foundation</td>
<td>The Netherlands</td>
<td>67</td>
</tr>
<tr>
<td></td>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td></td>
<td><strong>431</strong></td>
</tr>
<tr>
<td>2009</td>
<td>Fellowship agreement: Medical training of the fellow in the field of CardioVascular and participation in the day-to-day activities of the Hart &amp; Vaat Centrum at the Medical Institution</td>
<td>Contract</td>
<td>Medtronic</td>
<td>The Netherlands</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>Renin-angiotensin system blockade beyond angiotensin II</td>
<td>Contract</td>
<td>Ti Pharma</td>
<td>The Netherlands</td>
<td>917</td>
</tr>
<tr>
<td></td>
<td>Study of hydrochlorothiazide in subjects with moderate to severe hypertension etc</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>71</td>
</tr>
<tr>
<td></td>
<td>Effects of angiotensin-receptor blockade with olmesartan on carotid atherosclerosis etc</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>Long term safety profile of the PRO-Kinetic Energy coronary stent system in daily clinical practice</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>Pro-Kinetic Energy Reimbursement Registry</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>From Targets to Novel Drugs</td>
<td>Grant</td>
<td>Bayer Healthcare</td>
<td>Germany</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Inhibition of co-stimulation to induce plaque stabilization: indentifying downstream pathways and cell-type specific functions of CD40(L) in atherosclerosis</td>
<td>Grant</td>
<td>Universitätsklinikum Aachen</td>
<td>Germany</td>
<td>225</td>
</tr>
<tr>
<td></td>
<td>BMM project IVALVE</td>
<td>Grant</td>
<td>BMM</td>
<td>The Netherlands</td>
<td>639</td>
</tr>
<tr>
<td></td>
<td>BMM project PENT</td>
<td>Grant</td>
<td>BMM</td>
<td>The Netherlands</td>
<td>531</td>
</tr>
<tr>
<td></td>
<td>Circulating cells</td>
<td>Contract</td>
<td>CTMM</td>
<td>The Netherlands</td>
<td>870</td>
</tr>
<tr>
<td></td>
<td>The assessment of the Plaque AT RISK by non-invasive (molecular) imaging and modelling (PARISk)</td>
<td>Contract</td>
<td>CTMM</td>
<td>The Netherlands</td>
<td>596</td>
</tr>
<tr>
<td></td>
<td>Dynamic contrast-enhanced MRI for the quantification of neovascularisation in atherosclerotic plaque</td>
<td>Contract</td>
<td>CTMM</td>
<td>The Netherlands</td>
<td>1,115</td>
</tr>
<tr>
<td></td>
<td>PARISk WP</td>
<td>Contract</td>
<td>CTMM</td>
<td>The Netherlands</td>
<td>350</td>
</tr>
<tr>
<td></td>
<td>PARISk WP 5</td>
<td>Contract</td>
<td>CTMM</td>
<td>The Netherlands</td>
<td>162</td>
</tr>
<tr>
<td></td>
<td>Maastricht studie</td>
<td>Grant</td>
<td>EFRO</td>
<td>The Netherlands</td>
<td>8,000</td>
</tr>
<tr>
<td></td>
<td>Endothelial progenitor cells in ANCA associated vasculitis</td>
<td>Grant</td>
<td>Kidney Foundation</td>
<td>The Netherlands</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>Student travel grant</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Predictive value of high-resolution MRI, Annexin 5 imaging and microemboli detection for the occurrence of stroke in symptomatic patients with 50-69% carotid stenosis</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>112</td>
</tr>
<tr>
<td></td>
<td>Magnetic resonance imaging (MRI) of microvascular blood volume recruitment capacity in the heart: indicator of coronary endothelial glycocalyx loss and associated microvascular dysfunction?</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>210</td>
</tr>
<tr>
<td></td>
<td>Established investigator E. Lutgens</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>500</td>
</tr>
<tr>
<td></td>
<td>Kootstra Fellowship T. Mulders</td>
<td>Grant</td>
<td>UM/FHML</td>
<td>The Netherlands</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>Kootstra Fellowship J. Sluimer</td>
<td>Grant</td>
<td>UM/FHML</td>
<td>The Netherlands</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td></td>
<td><strong>0</strong></td>
</tr>
<tr>
<td>YEAR</td>
<td>TITLE</td>
<td>TYPE</td>
<td>COMPANY BASE/ORGANISATION</td>
<td>COUNTRY</td>
<td>SUPPORT (K€) from:</td>
</tr>
<tr>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------</td>
<td>----------------------------</td>
<td>---------------</td>
<td>-------------------</td>
</tr>
<tr>
<td></td>
<td>The role of (auto)-immunity in pulmonary arterial hypertension</td>
<td>Contract</td>
<td>Actelion Pharmaceuticals Nederland BV</td>
<td>The Netherlands</td>
<td>NWO/STW foundations</td>
</tr>
<tr>
<td>2010</td>
<td>Novation agreement Monash University</td>
<td>Contract</td>
<td>Servier</td>
<td>France</td>
<td>162</td>
</tr>
<tr>
<td></td>
<td>Validation of NADPH oxidases as cardiovascular targets</td>
<td>Contract</td>
<td>Actelion Pharmaceuticals Nederland BV</td>
<td>The Netherlands</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>The role of (auto)-immunity in pulmonary arterial hypertension</td>
<td>Contract</td>
<td>Esaote</td>
<td>Italy</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>Use of duloxetine or pregabalin in monotherapy versus combination therapy of both drugs in patients with painful diabetic neuropathy</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>Study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in type 2 diabetes mellitus patients etc</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>Lisinaglutide effect and action in Diabetes: evaluation of cardiovascular etc</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>Study of BI 10773 (10 mg and 25 mg administered orally once daily) as add on to pre-existing antidiabetic therapy etc</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>XR-1 BAT (Baroreflex activation) verification study</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>121</td>
</tr>
<tr>
<td></td>
<td>Evaluation of the Vascutek Ltd. Thoracic Endo-vascular Stent Graft System Thoracic Aorta</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>Study of the efficacy and safety of KIACTA in preventing renal function decline in patients with AA Amyloidosis</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>37</td>
</tr>
<tr>
<td></td>
<td>Rules Parel CVA</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>39</td>
</tr>
<tr>
<td></td>
<td>Cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce etc.</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>85</td>
</tr>
<tr>
<td></td>
<td>Regulation of foam cell formation</td>
<td>Grant</td>
<td>ZonMw via VU</td>
<td>The Netherlands</td>
<td>169</td>
</tr>
<tr>
<td></td>
<td>VICI C. Weber Structure-function analysis of platelet chemokine interactions in atherosclerosis</td>
<td>Grant</td>
<td>ZonMw</td>
<td>The Netherlands</td>
<td>1.250</td>
</tr>
<tr>
<td></td>
<td>VENI 2010 Hypoxia in atherosclerotic plaque macrophages: choking off clearance of dead cells?</td>
<td>Grant</td>
<td>ZonMw</td>
<td>The Netherlands</td>
<td>250</td>
</tr>
<tr>
<td></td>
<td>CTMM EMINENCE</td>
<td>Contract</td>
<td>CTMM EMINENCE</td>
<td>The Netherlands</td>
<td>2.174</td>
</tr>
<tr>
<td></td>
<td>Maastricht studie</td>
<td>Grant</td>
<td>EFRO/ Maastricht studie</td>
<td>The Netherlands</td>
<td>8.000</td>
</tr>
<tr>
<td></td>
<td>Student travel grant</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Parel Kidney Failure</td>
<td>Grant</td>
<td>Parelsnoer Initiatif</td>
<td>The Netherlands</td>
<td>174</td>
</tr>
<tr>
<td></td>
<td>Marie Curie Reintegration grant Free Radical Pharmacology: Generators, Targets and Therapeutic Implications</td>
<td>Grant</td>
<td>EU/FP7</td>
<td>Belgium</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>CVA Parelnoor</td>
<td>Grant</td>
<td>SENTER/NOVEM</td>
<td>The Netherlands</td>
<td>276</td>
</tr>
<tr>
<td></td>
<td>The classical, the lectin and the alternative pathways of complement activation and risk of cardiovascular disease</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>248</td>
</tr>
<tr>
<td></td>
<td>The effects of vitamine K2 supplementation on the progression of Coronary Artery Calcification</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>241</td>
</tr>
<tr>
<td></td>
<td>The role of type I interferons in atherosclerosis development and plaque stability</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>250</td>
</tr>
<tr>
<td></td>
<td>Collaboration Royal Embassy of Saudi Arabia</td>
<td>Grant</td>
<td>Royal Embassy of Saudi Arabia</td>
<td>Saudi Arabia</td>
<td>54</td>
</tr>
<tr>
<td></td>
<td>Graduation Fund</td>
<td>Grant</td>
<td>Academic Hospital Maastricht</td>
<td>The Netherlands</td>
<td>172</td>
</tr>
<tr>
<td></td>
<td>Graduation Fund</td>
<td>Grant</td>
<td>Academic Hospital Maastricht</td>
<td>The Netherlands</td>
<td>85</td>
</tr>
</tbody>
</table>

**Total**: 1,669 **11,777** **627**
<table>
<thead>
<tr>
<th>YEAR</th>
<th>TITLE</th>
<th>TYPE</th>
<th>COMPANY BASE/ ORGANISATION</th>
<th>COUNTRY</th>
<th>SUPPORT (K€) from: foundations contracts</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>The new hamburger, and ... the new steak</td>
<td>Contract</td>
<td>Bin Brin</td>
<td>Wojciki Foundation</td>
<td>USA</td>
</tr>
<tr>
<td></td>
<td>The production of the first lab grown hamburger</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>Tolerability of the TAK-491 and Chlorthalidone Fixed-Dose Combination Versus Olmesartan Medoxomil and Hydrochlorothiazide Fixed-Dose Combination in Hypertensive etc</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>159</td>
</tr>
<tr>
<td></td>
<td>Randomized Heart Failure Trial</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>172</td>
</tr>
<tr>
<td></td>
<td>The Randomized Phase</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>51</td>
</tr>
<tr>
<td></td>
<td>Treatment with Trafermin 0.01% Spray in patients with diabetic foot ulcer of neuropathic origin</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td>A Study Comparing the Analgesic Efficacy and Safety of ABT-639 to Placebo in Subjects with Diabetic Neuropathic Pain</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Evaluate Efficacy and Safety of Treatment with CNTO 136 Administered Intravenously in Subjects with Active Lupus Nephritis</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>CCX168 in Subjects with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Renal Vasculitis on Background Cyclophosphamide Treatment</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Trial of Gusperimus versus Conventional Therapy in Relapse of Granulomatosis with Polyangitis (Wegener’s Granulomatosis)</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Consulting services regarding Informatics Products</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Conduction of Fellowships Programmes</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Insulin resistance, beta-cell dysfunction and cognitive impairment (samenwerking Maastricht Studie en UMC Utrecht)</td>
<td>Grant</td>
<td>ZonMw</td>
<td>The Netherlands</td>
<td>95</td>
</tr>
<tr>
<td></td>
<td>VENI Kristiaan Wouters The obesity-induced macrophage: a new player in atherosclerosis development</td>
<td>Grant</td>
<td>ZonMw</td>
<td>The Netherlands</td>
<td>250</td>
</tr>
<tr>
<td></td>
<td>Arteriograph equipment for measurements in the context of TIP Metalloproteases and novel targets in endothelial dysfunction</td>
<td>Grant</td>
<td>Abbott products GmbH</td>
<td>Germany</td>
<td>63</td>
</tr>
<tr>
<td></td>
<td>Cardiovascular Health: Relevance of cardiovascular function markers</td>
<td>Grant</td>
<td>TIFN</td>
<td>The Netherlands</td>
<td>890</td>
</tr>
<tr>
<td></td>
<td>Collaboration agreement</td>
<td>Grant</td>
<td>aCGB</td>
<td>The Netherlands</td>
<td>240</td>
</tr>
<tr>
<td></td>
<td>Collaboration agreement</td>
<td>Grant</td>
<td>TIFN</td>
<td>The Netherlands</td>
<td>440</td>
</tr>
<tr>
<td></td>
<td>CTMM EMINENCE</td>
<td>Grant</td>
<td>CTMM</td>
<td>The Netherlands</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>Early determinants of atherosclerosis and arterial stiffness: a life-course analysis</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>138</td>
</tr>
<tr>
<td></td>
<td>Effect modification of thrombolysis for acute ischemic stroke by hemostatic activation</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>200</td>
</tr>
<tr>
<td></td>
<td>ERC - Advanced Grant Radical Medicine: Refining Oxidative Stress</td>
<td>Grant</td>
<td>EU / RadMed</td>
<td>Belgium</td>
<td>2,298</td>
</tr>
<tr>
<td></td>
<td>Interreg IV Maas Rijn</td>
<td>Grant</td>
<td>EU</td>
<td>Belgium</td>
<td>506</td>
</tr>
<tr>
<td></td>
<td>Methylglyoxal: a propagating factor contributing to accelerated atherosclerosis in diabetes</td>
<td>Grant</td>
<td>EFSD/Sanofi</td>
<td>Germany</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>Pieken in de Delta</td>
<td>Grant</td>
<td>Academic Hospital Maastricht</td>
<td>The Netherlands</td>
<td>230</td>
</tr>
<tr>
<td></td>
<td>Student travel grant</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>TIFN</td>
<td>Grant</td>
<td>TIFN</td>
<td>The Netherlands</td>
<td>450</td>
</tr>
<tr>
<td></td>
<td>UPMI: Ultrasound perfluorohexane-loaded monocyte imaging. A non-invasive technique for comprehensive detection of liver inflammation</td>
<td>Grant</td>
<td>MLDS</td>
<td>The Netherlands</td>
<td>60</td>
</tr>
</tbody>
</table>

**Total** | 345 | 5,638 | 1,616
<table>
<thead>
<tr>
<th>YEAR</th>
<th>TITLE</th>
<th>TYPE</th>
<th>COMPANY BASE/ ORGANISATION</th>
<th>COUNTRY</th>
<th>SUPPORT (K€) from: foundations contracts</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>Collaboration agreement</td>
<td>Contract</td>
<td>Abbott Laboratories</td>
<td>USA</td>
<td>253</td>
</tr>
<tr>
<td></td>
<td>Collaborative research agreement</td>
<td>Contract</td>
<td>Boehringer Ingelheim</td>
<td>Germany</td>
<td>144</td>
</tr>
<tr>
<td></td>
<td>Liraglutide with or without NEAT in type 2 diabetes mellitus. Effects on HbA1c, weight, blood pressure, quality of life and health care costs</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>225</td>
</tr>
<tr>
<td></td>
<td>Reducing with MetfOmin Vascular Adverse Lesions in type 1 diabetes study</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>175</td>
</tr>
<tr>
<td></td>
<td>Research agreement</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>Research agreement</td>
<td>Contract</td>
<td>Glucox Biotech AB</td>
<td>Sweden</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Collaboration agreement</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>300</td>
</tr>
<tr>
<td></td>
<td>Master agreement</td>
<td>Contract</td>
<td>CTCM</td>
<td>The Netherlands</td>
<td>300</td>
</tr>
<tr>
<td></td>
<td>Mozak grant C.E. Zhang Blood-brain barrier permeability in cerebral small vessel disease: a dynamic contrast-enhanced MRI study</td>
<td>Grant</td>
<td>NWO</td>
<td>The Netherlands</td>
<td>200</td>
</tr>
<tr>
<td></td>
<td>Complementation of the CODAM cohort with GWAS data</td>
<td>Grant</td>
<td>NWO - BBMRI-NL</td>
<td>The Netherlands</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>Impaired neurogenic inflammation in diabetic polyneuropathy</td>
<td>Grant</td>
<td>Diabetes Research Foundation</td>
<td>The Netherlands</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>MacObesity Marie Curie Grant K. Wouters The obesity-induced macrophage: a new player in atherosclerosis development</td>
<td>Grant</td>
<td>EU/PEOPLE</td>
<td>Belgium</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>Support for training and career development of researchers (Marie Curie: Micro-and Macrocirculation Coupling: a cross sectional investigation of the cross-talk between the two circuits in insulin resistance states)</td>
<td>Grant</td>
<td>EU/MMC</td>
<td>Belgium</td>
<td>217</td>
</tr>
<tr>
<td></td>
<td>Fellowship K. Radermacher Inhibition of NADPH oxidases as a new mechanistic approach to promote recovery in stroke: Validation by non-invasive brain redox imaging</td>
<td>Grant</td>
<td>Brain Foundation</td>
<td>The Netherlands</td>
<td>150</td>
</tr>
<tr>
<td></td>
<td>Defining the roles of NOX1 and NOX4 in diabetes-induced renal diseases - preventive and therapeutic implications</td>
<td>Grant</td>
<td>Kidney Foundation</td>
<td>The Netherlands</td>
<td>99</td>
</tr>
<tr>
<td></td>
<td>Student travel grant</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>ADAM10 and ADAM 17: Complementary sheddases with gate keeper and immune-modulatory functions regulating atherosclerotic plaque progression and stability</td>
<td>Grant</td>
<td>NHS</td>
<td>The Netherlands</td>
<td>382</td>
</tr>
<tr>
<td></td>
<td>The role of disturbed Microcirculation in the relationship with the onset of diabetes and associated disorders</td>
<td>Grant</td>
<td>Foundation Sint Annadal</td>
<td>The Netherlands</td>
<td>200</td>
</tr>
<tr>
<td></td>
<td>Kootstra Fellowship K. Gabriels</td>
<td>Grant</td>
<td>UM/FHML</td>
<td>The Netherlands</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td></td>
<td><strong>300 1,229 1,414</strong></td>
</tr>
</tbody>
</table>
Addendum III
Output of Main Theme I in 2007 - 2012

1. List of PhD theses 2007 – 2012
2. List of publications 2007 – 2012
C_
ADDENDUM II
OUTPUT OF
MAIN THEME III
IN 2007-2012

1. LIST OF PHD THESES 2007 – 2012
2. LIST OF PUBLICATIONS 2007 – 2012
**PHD THERSES 2007**

**Baumann M** – 
Transient prehypertensive treatment: an additive option against hypertension. 
Promotores: Prof. H Struijkjier Boudier, Prof. J Smits. 
Maastricht University, October 31, 2007

**Beeks E** – 
Functional correlates of the alpha adrenergic polymorphism. 
Promotor: Prof. P de Leeuw. Co-promotores: Dr A Kroon, Dr M van der Klauw. 
Maastricht University, July 6, 2007

**Cappendijk V** – 
MRI of atherosclerosis. Identification and quantification of carotid plaque components. 
Promotores: Prof. J van Engelshoven, Prof. M Daemen. Co-promotores: Dr E Kooi, Dr S Heeneman. 
Maastricht University, March 23, 2007

**Van Cleef K** – 
Molecular biology of rat cytomegaloivirus: genome-wide transcriptional program and molecular mimicry. 
Promotor: Prof. C Bruggeman. Co-promotor: Dr C Vink. 
Maastricht University, March 2, 2007

**Ezzahiri R** – 
Infection and inflammation in progression of atherosclerosis: the role of Chlamydia pneumonia infection in different mouse models. 
Promotores: Prof. P Kitislaar, Prof. C Bruggeman. Co-promotores: Dr H Kersvers, Dr F Stassen. 
Maastricht University, November 23, 2007

**Hermans M** – 
Arterial wall abnormalities in chronic kidney disease. 
Maastricht University, November 16, 2007

**Huugen D** – 
Myleoperoxidase and anti-myleoperoxidase autoantibodies in renal inflammation. 
Maastricht University, October 5, 2007

**Lutgens S** – 
Functional genomics in atherosclerosis: focus on calhepin K. 
Promotor: Prof. M Daemen. Co-promotores: Dr K Cleutjens, Dr S Heeneman. 
Maastricht University, October 19, 2007

**Van Neer P** – 
The role of incompetent perforating veins in varicose veins. 
Maastricht University, May 4, 2007

**Nijenhuis R** – 
Non-invasive imaging of spinal cord blood supply. 
Maastricht University, June 22, 2007

**Van Onna M** – 
Diagnostic and therapeutic strategies in renal artery stenosis. 
Promotor: Prof. P de Leeuw. Co-promotores: Dr A Kroon, Dr A Houben. 
Maastricht University, November 30, 2007

**Planken N** – 
Hemodialysis vascular access imaging. 
Promotores: Prof. P Kitislaar, Prof. J van Engelshoven. Co-promotores: Dr J Tordoir, Dr T Leiner. 
Maastricht University, June 1, 2007

**Schapira K** – 
Atherosclerotic plaque stability: identification and validation of key regulators. 
Maastricht University, September 6, 2007

**Slot M** – 
ANCA-Associated vasculitis: Factors involved in disease. Induction, survival and long-term complications. 
Maastricht University, March 9, 2007

**Smook M** – 
Promotores: Prof. J Cohen Tervaert, M Daemen. Co-promotores: Dr P Heeringa, Dr E Lutgens. 
Maastricht University, June 29, 2007

**Tintu A** – 
Promotores: Prof. M Jacobs, Prof. F le Noble. Co-promotores: Dr W Lamers, Dr E Rouwet. 
Maastricht University, September 13, 2007

**PHD THERSES, EXTERNALLY PREPARED**

**De Jongh R** – 
Microvascular dysfunction: metabolic and cardiovascular causes and consequences. 
Promotor: Prof. C Stehouwer. Co-promotores: Dr E Serné, Dr R Uzerman. 
Free University Amsterdam, November 9, 2007

**Thewissem M** – 
The role of immunosenesence and CD4+ CD28null T cells in autoimmune disease. 
Promotor: Prof. P Stijnissen. 
University Diepenbeek, May 31, 2007

**PHD THERSES 2008**

**Brouwers M** – 
Hepatic steatosis in familial combined hyperlipidemia. 
Promotores: Prof. T de Bruin, Prof. C Stehouwer. Co-promotores: Dr M van Greevenbroek, Dr C van der Kallen. 
Maastricht University, March 7, 2008

**Driessen R** – 
Adaptive remodeling of cardiomyocytes under stress. 
Promotores: Prof. F Ramaekers, Prof. M Borgers. Co-promotor: Dr F Verheyen. 
Maastricht University, March 20, 2008

**Gamboa Vilela D** – 
Analysis of gene expression in the Leishmania Life Cycle: Leishmania (Vannia) braziliensis and Leishmania (Vianna) peruviana model. 
Promotor: Prof. C Bruggeman. Co-promotores: Dr J Dujardin, Dr G van Eys. 
Maastricht University, September 4, 2008

**Henskens L** – 
High blood pressure and target-organ damage of the brain. 
Promotores: Prof. P de Leeuw, Prof. J Lodder. Co-promotores: Dr A Kroon, Dr R van Oostenbrugge. 
Maastricht University, November 27, 2008

**Keuter X** – 
Promotores: Prof. P Kitislaar, Prof. A Hoeks. Co-promotor: Dr J Tordoir, Dr F van der Sande. 
Maastricht University, June 27, 2008

**Kisters N** – 
Heterogeneity in human atherosclerotic gene expression profiles: from man to macrophages. 
Maastricht University, December 5, 2008

**Meex S** – 
Novel insights in the pathophysiology of insulin resistance-a molecular genetic approach. 
Promotores: Prof. T de Bruin, Prof. C Stehouwer. Co-promotores: Dr M van Greevenbroek, Dr CJH van der Kallen. 
Maastricht University, March 7, 2008

**Megens R** – 
Vital imaging of large arteries using Two-Photon laser scanning microscopy: Focus on the arterial wall. 
Promotores: Dr Slaaf. Co-promotores: Dr M van Zandvoort, Dr M Oude Egbrink. 
Maastricht University, March 14, 2008

**Niessen P** – 
Smoothalin and smooth muscle contractility. 
Maastricht University, April 11, 2008

**Prompers L** – 
Diabetic Foot Disease in European Perspective. 
Maastricht University, May 29, 2008

**Sluimer J** – 
Hypoxia, HIF and angiogenesis in atherosclerosis. 
Maastricht University, May 14, 2008

**Wouters K** – 
Non-Alcoholic Steatohepatitis: Second Hit or Strike Out? 
Promotor: Prof. M Hofker. Co-promotor: Dr M van Bitsen van, Dr R Shirl-Sverdlov. 
Maastricht University, December 3, 2008

**PHD THERSES, EXTERNALLY PREPARED**

**Czepluch F** – 
Der Effekt einer Cholesterinserung mithilfe von Statinen auf die Verbesserung der Monozytenfunktion. Die VERAACD-STAT-Studie. 
Promotor: Prof. J Walterberger. 
Ulm, February 14, 2008, summa cum laude

**Halm V van der** – 
Cerebrovascular risk and inflammation: focusing on rheumatoid arthritis and ankylosing spondylitis. 
Promotores: Prof. B Dijkmans, Prof. C Stehouwer. Co-promotores: Dr M Nurmohamed, Dr A Volkuy. 
Free University Amsterdam, September 19, 2008
PHD THESSES 2009

Beuk R –
Experimental ischemia and reperfusion of the small bowel: focus on microvascular events.
Maastricht University, June 12, 2009

Bonne van den S –
Myocardial infarct healing: Rupture and remodeling.
Maastricht University, April 17, 2009

Chi Yuen Simon Cheung –
Use of tacrolimus in Chinese renal transplant recipients.
Promotor: Prof. J van Hoof. Co-promotores: Dr M Christiaans, Mr C Li.
Maastricht University, December 10, 2009

PHD THESSES 2010

Bai L –
Immunosuppressive and anti-proteolytic therapy in vascular diseases.
Promotores: Prof. M Daemen and Prof. E Biessen. Co-promotor: Dr S Heeneman.
Maastricht University, March 10, 2010

Brands J –
Agonist-induced modulation of glyocalyx barrier properties in the microcirculation.
Promotores: Prof. H Vink and Prof. J Spaan (University of Amsterdam). Co-promotor: Dr J van Teefelen.
Maastricht University, October 29, 2010

De Jager J –
Hemodialysis Access-Induced Distal Ischemia (HAIDI); diagnosis and surgical management.
Maastricht University, May 28, 2010

De Jager J –
The effects of metformin on metabolism and Cardiovascular disease in type 2 diabetes.
Promotor: Prof. C Stehouwer. Co-promotor: Dr A Kooi.
Maastricht University, May 27, 2010

Kromann L –
Molecular imaging of large arteries by ultrasound - Quantitative ultrasound imaging in carotid atherosclerosis.
Promotor: Prof. M Daemen and Prof. F van de Vosse. Co-promotores: Dr H Spronk and Dr E Bosboom.
Maastricht University, September 16, 2010

Kwede C –
Imaging of carotid atherosclerosis.
Promotores: Prof. D Wildberger and Prof. W Mess. Co-promotores: Dr E Kooi and Dr R van Oostenbrugge.
Maastricht University, December 13, 2010

PHD THESSES, EXTERNALLY PREPARED

Arbouw M –
Assessment of drug therapy in Parkinson’s disease.
Promotores: Prof. A Egberts (Enschede), Prof. H Guchelaar and Prof. C Neef. Co-promotor: Dr K Movig.
Utrecht University, June 29, 2010
Bakker W – Vascular Insulin Resistance Through Fat. Intracellular Signaling, Genetic Interferences and Hemodynamics.
Promotores: Prof. V van Hinsbergh and Prof. C Stehouwer. Co-promotores: Dr P Sipkema and Dr E Eringa.
Free University Amsterdam, May 20, 2010

Ketel I – Vascular function and insulin sensitivity in lean obese women with PCOS.
Promotores: Prof. C Lambalk and Prof. C Stehouwer. Co-promotores: Dr E Serné and Dr P Homburg.
Free University Amsterdam, November 17, 2010

Leguy C – On the clinical estimation of the hemodynamical and mechanical properties of the arterial tree.
Promotores: Prof. F van den Vosse and Prof. A Hoeks. Co-promotor: Dr E Bosboom.
Eindhoven University of Technology, October 4, 2010

Lopata R – 2D And 3D ultrasound strain imaging. Methods and in vivo applications.
Promotores: Prof. J Thijssen and Prof. R de Groot. Co-promotores: Dr C de Korte and Dr L Kapusta.
Radboud University Nijmegen, December 3, 2010

Van Vliet Y – Revealing the genetic roots of obesity and type 2 diabetes.
Promotores: Prof. M Hofker and Prof. C Wijmenga. University of Groningen, July 7, 2010

Schalkwijk, Maastricht University, April 1, 2011

Groeneweg HM – Macrophages and modified lipoproteins: modulation of inflammation?
Maastricht University, May 20, 2011

Hanssen SJP – Hemolysis, microcirculatory changes and organ injury induced by cardiovascular surgery
Promotores: Prof. M Jacobs, Prof. W Bauman. Maastricht University, September 30, 2011

Promotor: Prof. C Stehouwer. Co-promotores: Dr M van Gervenbroek, Dr C van der Kallen.
Maastricht University, September 29, 2011

Promotor: Prof. M Post. Co-promotores: Dr W Backes, Dr T Leiner.
Maastricht University, September 9, 2011

Jonk AM – Microvascular actions of insulin: studies on the interaction with angiotensin II and on the postprandial state.
Maastricht University, December 15, 2011

Loon van MM – Cannulation practise and complications in hemodialysis vascular access.
Promotor: Prof. P Kitslaar. Co-promotores: Dr J Tordoir, Dr F van der Sande.
Maastricht University, May 26, 2011

Meens MJPMT – Interactions between ET-1 and CGRP in resistance arteries.
Promotor: Prof. J De Mey. Maastricht University, October 19, 2011

Moret K – The role of technological advances in sodium prescription and adequate assessment during hemodialysis.
Maastricht University, January 21, 2011

Rennenberg R – Vascular calcifications and matrix Gla protein in hypertensive subjects.
Promotor: Prof. P de Leeuw. Co-promotores: Dr A Kroon, Dr L Schurgers.
Maastricht University, July 6, 2011

Stevens KNJ – Blood-contacting biomaterials for critical clinical applications.
Promotores: Prof. J Maassen, Prof. L Koole. Maastricht University, December 15, 2011

Verjans JWH – Molecular imaging of acute and healing myocardial infarction.
Promotor: Prof. L Hofstra. Maastricht University, December 14, 2011

PHD THESES 2011

Bekkers SCAM – Assessment of injury in reperfused acute myocardial infarction using cardiovascular magnetic resonance imaging.
Promotores: Prof. A Gorgels, Prof. J Waltenberger. Maastricht University, June 1, 2010

Brouwers O – Intracellular glycation and endothelial dysfunction; role of methylglyoxal.
Promotores: Prof. C Stehouwer, Prof. J De Mey. Co-promotor: Dr C Schalkwijk. Maastricht University, May 18, 2011

Casolo V – VEGF and NOTCH in blood vessels, an intricate and fascinating interplay.

Dennert R – Idiopathic cardiomyopathies: the role of virus persistence and immune-mediated disease.
Maastricht University, November 28, 2012

Gaens K – The Ne(c) Carboxymethyllysine-RAGE axis; Implications for the pathogenesis of obesity-related complications.
Promotor: Prof. C Stehouwer. Co-promotor: Dr C Schalkwijk.
Maastricht University, April 1, 2011

Groeneweg HM – Macrophages and modified lipoproteins: modulation of inflammation?
Maastricht University, May 20, 2011

Hanssen SJP – Hemolysis, microcirculatory changes and organ injury induced by cardiovascular surgery
Promotores: Prof. M Jacobs, Prof. W Bauman. Maastricht University, September 30, 2011

Promotor: Prof. C Stehouwer. Co-promotores: Dr M van Gervenbroek, Dr C van der Kallen.
Maastricht University, September 29, 2011

Promotor: Prof. M Post. Co-promotores: Dr W Backes, Dr T Leiner.
Maastricht University, September 9, 2011

Jonk AM – Microvascular actions of insulin: studies on the interaction with angiotensin II and on the postprandial state.
Maastricht University, December 15, 2011

Loon van MM – Cannulation practise and complications in hemodialysis vascular access.
Promotor: Prof. P Kitslaar. Co-promotores: Dr J Tordoir, Dr F van der Sande.
Maastricht University, May 26, 2011

Meens MJPMT – Interactions between ET-1 and CGRP in resistance arteries.
Promotor: Prof. J De Mey. Maastricht University, October 19, 2011

Moret K – The role of technological advances in sodium prescription and adequate assessment during hemodialysis.
Maastricht University, January 21, 2011

Rennenberg R – Vascular calcifications and matrix Gla protein in hypertensive subjects.
Promotor: Prof. P de Leeuw. Co-promotores: Dr A Kroon, Dr L Schurgers.
Maastricht University, July 6, 2011

Stevens KNJ – Blood-contacting biomaterials for critical clinical applications.
Promotores: Prof. J Maassen, Prof. L Koole. Maastricht University, December 15, 2011

Verjans JWH – Molecular imaging of acute and healing myocardial infarction.
Promotor: Prof. L Hofstra. Maastricht University, December 14, 2011

PHD THESES, EXTERNALLY PREPARED

Sarabi A – Structural and functional characterization of the interactions of platelet-derived chemokines CCL5, CXCL4 and CXCL4L1.
RWTH Aachen, January 31, 2011

PHD THESES 2012

Preoperative imaging techniques and computational modeling.
Promotor: Prof. P Kitslaar. Co-promotores: Dr J Tordoir, Dr T Leiner.
Maastricht University, June 1, 2012

Cnossen T – New Developments in Peritoneal Dialysis.
Promotor: Prof. K Leunissen. Co-promotores: Dr J Kooman, Dr C Koning.
Maastricht University, March 29, 2012

Crees S – Staphylococcus aureus biofilm.
Promotores: Prof. C Bruggeman; Prof Dr C Neef. Co-promotor: Dr E Stobberingh.
Maastricht University, April 27, 2012

Daisansomrt I – Peri- and extravascular inflammation: impact on Atherosclerosis.
Promotor: Prof. E Biessen. Maastricht University, April 13, 2012

Engel D – Caveolin-1 and CD40L-CD40-TRAF interactions in vascular and metabolic disease.
Promotores: Prof. E Lutgens, Prof. E Biessen. Maastricht University, October 12, 2012

Promotores: Prof. C Stehouwer, Prof. C Schalkwijk. Co-promotor: Dr I Fiererra.
Maastricht University, October 12, 2012

Hazewindus M – Toxins as functional food.
Promotores: Prof. A Bast, Prof. G Haenen. Maastricht University, December 6, 2012

Hellenthal F – Prediction of Abdominal Aortic Aneurysm progression.
Promotor: Prof. G Schurink. Co-promotores: Dr W Wodzig; Dr S Heeneman.
Maastricht University, November 28, 2012

Hermoen I – Adrenocortical carcinoma.
Promotores: Prof. C Stehouwer, Prof. J Romijn (University of Amsterdam). Co-promotor: Dr H Haak, MMC Eindhoven.
Maastricht University, December 13, 2012

Huberts W – Personalized computational modeling of vascular access creation.
Promotores: Prof. F van den Vosse, Prof. T Delhaas. Co-promotores: Dr E Bosboom, Dr J Tordoir.
Maastricht University, March 1, 2012
Knottnerus I -
Vascular endothelial function and genetic epidemiology in lacunar stroke subtypes.
Promotores: Prof. R van Oostenbrugge, Prof. H ten Cate, Prof. J Lodder.
Maastricht University, March 2, 2012

Nin J -
Advanced glycation and type 1 diabetes.
Promotores: Prof. C Stehouwer, Prof. C Schalkwijk.
Co-promotor: Dr I Ferreira.
Maastricht University, June 7, 2012

Pijpers E -
Morbidity and mortality risk of aging diabetic and psychogeriatric patients.
Promotores: Prof. A Nieuwenhuijzen Kruseman, Prof. A Stehouwer. Co-promotor: Dr I Ferreira.
Maastricht University, May 25, 2012

Pulinx B -
Protein biomarkers in chronic disease. Proteomics-driven discovery.
Promotores: Prof. M van Dieijen-Visser, Prof. G Schurink. Co-promotor: Dr W Wodzig.
Maastricht University, October 3, 2012

Reitsma S -
The endothelial glycocalyx in early atherogenesis. Role in platelet adhesion?
Promotores: Prof. D Slaaf, Prof. M van Zandvoort, Prof. M oude Egbrink.
Maastricht University, June 7, 2012

Rooijens P -
Primary vascular access for hemodialysis treatment.
Promotor: Prof. P Kitslaar. Co-promotores: Dr J Tordoir; Dr T Yo (Rotterdam).
Maastricht University, September 13, 2012

Rouhi R -
Cerebral Small Vessel Disease: Endothelial Progenitor Cells and Markers of Vascular Inflammation.
Promotores: Prof. J Lodder, Prof. J Cohen Tervaert, Prof. R van Oostenbrugge.
Maastricht University, March 2, 2012

Ruiter M -
Reactivity, recruitment and remodeling of collateral arteries in diabetes.
Promotores: Prof. N Schaper, Prof. C Stehouwer. Co-promotores: Dr M Huijberts; Dr J van Golde.
Maastricht University, September 6, 2012

Sigala F -
The role of neovascularization and oxidative stress in human carotid atherosclerotic lesions.
Promotor: Prof. M Jacobs. Co-promotores: Dr V Gorgoulis, Dr A Kotsinas (Athens, Greece).
Maastricht University, December 10, 2012

Van Onzenoort H -
Treatment adherence in hypertension. Methodological aspects and new strategies.
Promotores: Prof. P de Leeuw, Prof. C Neef. Co-promotores: Dr P van der Kuy, Dr W Verberk.
Maastricht University, June 27, 2012

Vermeulen Windsant I -
Connecting hemosysis and visceral injury during cardiovascular surgery; studies on the causes, effects, and treatment of hemolysis-induced organ injury.
Promotores: Prof. W Buurman, Prof. M Jacobs.
Maastricht University, September 28, 2012

Zhu F -
Application of Bioimpedance to study body composition in dialysis patients.
Promotores: Prof. K Leunissen, Prof. N Levin, Prof. P Kotanko (Renal Research Institute, New York).
Maastricht University, December 13, 2012
Publications in scientific journals 2007

Publications in scientific journals (wi-1)


IF 3.685


IF 10.940


IF 2.484


IF 2.322


IF 0.998


IF 1.400


IF 10.940

Bodeo B, Franke C, Weizen V, van Oostenbrugge RJ - Estimating the number of stroke patients eligible for thrombolytic treatment if delay could be avoided. Cerebrovasc Dis 2007; 23: 294-8

IF 2.003


IF 2.116


IF 2.229

Brandwijk RJ, Griffioen AW, Thijssen VLJL - Contribution of high-resolution correlative imaging techniques in the study of the liver sieve in three dimensions. Microsc Res Tchnq 2007; 70: 230-242

IF 1.895


IF 1.890


IF 2.242


IF 4.459


IF 4.459


IF 4.459


IF 2.363


IF 1.093


IF 9.158


IF 1.703


IF 0.837


IF 2.694


IF 5.999


IF 1.975


IF 2.116


IF 4.459


IF 4.459


IF 4.459


IF 2.363


IF 1.093


IF 9.158


IF 1.703


IF 0.837
IF 2.784

IF 1.930

Coleman MD, Rimmer GSE, Haenen GRMM - Effects of lipoic acid and dihydrolipoic acid on total erythrocytic thiol under conditions of restricted glucose in vitro. Basic Clin Pharmacol 2007; 100(2): 139-144
IF 1.788

IF 1.478

IF 4.730

IF 1.930

IF 6.562

Damaoiseaux JGMC, Rijkers G, Cohen Tervaert JW - Pneumococcal vaccination does not increase circulating levels of IgM antibodies to oxidized LDL in humans and therefore precludes an antiatherogenic effect. Atherosclerosis 2007; 190: 10-11
IF 3.811

IF 1.605

Van Dijk CN, de Leeuw PW - Imaging from an orthopaedic point of view. Imaging the hyproxie surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiolother Oncol 2007; 83(3): 367-373
IF 3.970

Eringa EC, Bakker W, Smulders YM, Serné EH, Yudkin JS, Stehouwer CDA - Regulation of vascular function and insulin sensitivity by adipose tissue: focus on perivascular adipose tissue. Microlcirculation 2007; 14: 389-402
IF 2.405

IF 4.123

IF 4.724

IF 7.920

IF 4.021

IF 3.311

IF 7.912

IF 5.138

IF 1.880

IF 5.767

Dubois LJ, Douma K, Supuran CT, Chiu RK, van Zandvoort MAMJ, Pastoreková S, Scozzafava A, Wouters BG, Lombin P - Pneumococcal vaccination does not increase circulating levels of IgM antibodies to oxidized LDL in humans and Therefore precludes an anti-atherogenic effect. Atherosclerosis 2007; 190: 10-11
IF 3.811

IF 1.478

IF 4.730

Damaoiseaux JGMC, Rijkers G, Cohen Tervaert JW - Pneumococcal vaccination does not increase circulating levels of IgM antibodies to oxidized LDL in humans and Therefore precludes an anti-atherogenic effect. Atherosclerosis 2007; 190: 10-11
IF 3.811


De Leeuw PW - Measuring the blood pressure in both arms is subject to discussion. Neth J Med 2007; 151(27): 1498-9 IF 1.162

Leiner T, Herborn CU, Goyen M - Nephrogenic systemic fibrosis is not exclusively associated with gadodiamide. Eur Radiol 2007; 17(8): 1951-3 IF 2.554


De Leeuw PW - Measuring the blood pressure in both arms is subject to discussion. Neth J Med 2007; 151(27): 1498-9 IF 1.162

Leiner T, Herborn CU, Goyen M - Nephrogenic systemic fibrosis is not exclusively associated with gadodiamide. Eur Radiol 2007; 17(8): 1951-3 IF 2.554


Lodder J - Poststroke cognition and the fight against the hard problem: Vascular neurologists enter the arena! Stroke 2007; 38: 7-8 IF 5.391


Nanayakkara PWB, van Guldener C, Prasad K, Koelewijn CW, Krol J - Effect of a treatment strategy consisting of pravastatin vitamin E and homocysteine lowering on carotid intima-media thickness endothelial function and renal function in patients with mild to moderate chronic kidney disease Results from the Arch Intern Med 2007; 167: 1262-70 IF 7.920

IF 5.247

Nijenhuis RJ, Backes WH - Inlet arteres or outlet veins of the spinal cord? Am J Roentgenol 2007; 189(1): W45
IF 2.117

IF 3.311

IF 3.311

IF 1.400

IF 1.930

Pasterkamp G, Daemen MJAP - Stabilizing the vulnerable plaque; the search for the magic bullet. Curr Pharm Design 2007; 13: 979-82
IF 5.270

IF 9.701

IF 3.772

IF 7.912

IF 3.668

IF 2.005

IF 3.902

IF 1.242

IF 5.270


IF 7.912

IF 7.912

IF 3.811

IF 2.484

SELF-EVALUATION 2007-2012
CARIM 99

IF 2.556


IF 1.534


IF 1.253

Schurgers LJ, Spronk HMH, Soute BAM, Schifters PMH, De Mey JGR, Vermeer C - Regression of arterial medial calcification after high intake of vitamin K. Blood 2007; 109: 2823-2831

IF 10.370

Sermé EH, de Jongh RT, Eringa EC, Izjerman RG, Stehouwer CDA - Microvascular dysfunction: a potential pathophysiological role in the metabolic syndrome. Hypertension 2007; 50: 204-11

IF 6.007


IF 2.960


IF 2.747


IF 7.678


IF 6.643


IF 4.782


IF 1.309


IF 2.342


IF 5.204


IF 2.855


IF 7.463


IF 7.286


IF 5.341


IF 1.188


IF 7.286


IF 5.204


IF 2.855


IF 7.463


IF 7.286


IF 5.204


IF 1.979


IF 4.724

IF 1.493


IF 5.270


IF 3.154


IF 2.156

Verberk WJ, de Leeuw PW - The trained observer better predicts daytime ambulatory blood pressure measurement diastolic blood pressure in hypertensive patients than does an automated (Omron) device. Blood Press Monit 2007; 12(1): 57

IF 1.424


IF 3.116


IF 5.247


IF 5.917


IF 7.696


IF 2.086


IF 2.156


IF 3.116


IF 4.773


IF 1


IF 1.477


IF 4.773


IF 1


IF 3.287


IF 5.365
Publications in scientific journals (wi-2)


Bot I, van Berkel ThJC, Biessen EAL - Viral serine protease inhibitors as anti-atherosclerotic therapy. Current Opinion in Investigational Drugs 2007; 8: 729-735


Van Gulden C, Stehouwer CDA - Homocysteine and large arteries. Adv Cardiol 2007; 44: 278-301


De Leeuw PW - Review: medical treatment and revascularization may be similar in atherosclerotic renal artery stenosis. ACP J Club 2007; 146(3): 59


Leiner T - Peripheral magnetic resonance angiography with blood pool agents. European Cardiovascular Disease. European Cardiovascular Disease 2007; 1: 68-71


Rensen SSM, Doevendans PA, van Eys GJM - Regulation and characteristics of vascular smooth muscle cell phenotypic diversity. Neth Heart J 2007; 15(3): 100-8

Schwitters B, Achanta G, van der Vlies D, Morisset H, Bast A, Hanekamp JC - The European regulation of food supplements and food fortification intended normal use – The ultimate tool in organising level playing field markets and regulations or how to break the fairy ring around “other substances”. Env Law Management 2007; 19: 19-23


**Letter to the editor**

Lodder J -
Size criterion for lacunar infarction. Cerebrovasc Dis 2007; 24: 156
IF 2.003

Schalkwijk CG -
IF 2.776

Waltenberger JL -
Letter to the editors. Clin Res Cardiol 2007; 96(11): 832

---

## Publications in scientific journals 2008

On behalf of the International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes (DACO) investigators. Determinants of the ambulatory arterial stiffness index in 7604 subjects from 6 populations. Hypertension 2008; 52: 1038-1044
IF 7.194

Determinants of the ambulatory arterial stiffness index in 7604 subjects from 6 populations. Hypertension 2008; 52(8): 1038-44
IF 7.194

### Adriaanse MC, Dekker JM, Heine RJ, Snoek FJ, Beekman AJ, Stenhower CDA, Bouter LM, Nijepels G Ploover F –
IF 2.97

### Adriaanse MC, Ploover F, Dekker JM, Nijepels G, Stenhower CDA, Heine RJ, Snoek FJ –
Diabetes-related symptom distress in association with glucose metabolism and co-morbidity: the Hoorn Study. Diabetes Care 2008; 31: 2268-70
IF 7.851

### Aarden L, van Raak E, Borca AMHP, Kessels AG, Lodder J –
IF 2.517

### Aerts HJ, van Riel NA, Backes WH –
IF 3.131

### Agren P, van der Sterren S, Cogolludo AL, Frazziano G, de Mey JGR, Blanco CE, Villamor EI –
Developmental changes in endothelium-dependent relaxation of the chicken ductus arteriosus. J Physiol Pharmacol 2008; 59: 55-76
IF 4.468

### Apelqvist J, Bakker K, van Houtum WH, Schaper NC –
IF 3.087

### Apelqvist J, Bakker K, van Houtum WH, Schaper NC –
IF 3.087

### Astrup AS, Tarnow L, Pietraszek L, Schalkwijk CG, Stenhower CDA, Parving H, Rossing P –
Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years Association with mortality and decline of glomerular filtration rate. Diabetes Care 2008; 31: 1170-6
IF 7.851

### Van Baardwijk AA, Bosmans GHK, van Suylen RJ, van Kroonenburgh MJPG, Hochstenbag MCM, Geskes GG, Lambin P, de Rysscher DKM –
IF 4.074

### Backes WH, Nijenhuis RJ –
IF 2.338

### Backes WH, Nijenhuis RJ, Mess WH, Wilmink FA, Schurink GWH, Jacobs MJH –
IF 3.272

### Bakker W Sipkema P, Stenhower CDA, Serne EH, Smulders YM, van Hinsbergh VWM, Eerina EC –
IF 8.261

### Balguid A, Diessen NSB, Mol A, Schmitz JP, Verheyen F, Boute JVC, Baaijens FPT –
IF 2.397

### Baumann M, Bartholome R, Peutz-Kootstra CJ, Smits JFM, Struyker Boudier HA –
IF 3.102

### Baumann M, Stenhower CDA, Scheijen J, Heemann U, Struyker Boudier HA, Schalkwijk CG –
N(epsilon)-(carboxymethyl)lysine during the early development of hypertension. Am NY Acad Sci 2008; 1126: 201-4
IF 1.731

Myocardial deformation imaging based on ultrasonic pixel tracking to identify reversible myocardial dysfunction. J Am Coll Cardiol 2008; 51: 1473-81
IF 11.054
Corstens CSJ, Saralidze K, Knesch MLW, Emanus PJ, de Haan MW, Magusin PC, Mezari B, Kerre LH.
IF 4.169

Curfs DMJ, Ghesquiere SA, Vergouwe MN, van der Made I, Gijbels MJJ, Greaves DR, Verbeek JS, Hofker MH, de Winther MPJ –
Macrophage secretory phospholipase A2 group X enhances anti-inflammatory responses promotes lipid accumulation and contributes to aberrant lung pathology. J Biol Chem 2008; 283: 21640-21648
IF 5.581

Czepluch FS, Waltenberger JL –
Monocyte function rather than number is a prerequisite for the stimulation of collateral growth. Atherosclerosis 2008; 196: 485-6
IF 4.287

Van Dam EA, Dans SM, Peters GW, Rutten MC, Schurink GWH, Buth J, de Vosse FN –
IF 2.604

IF 1.773

IF 3.405

Dechering DG, van der Steen MS, Adiyaman A Thijis L, Deinum J Li Y Dolan E, Akkersmans RPM, Richart T, Hansen TW, Kikuya M Wang J, O'Brien E Thien T, Staesens JAH –
IF 4.384

Dekker JM, Funahashi T Nijpels G Pilz S, Stehouwer CDA, Snijder MB, Bouter LM, Matsuzawa Y Shimmura I, Heine RJ.
IF 7.194

Van Deutekom AW, Niessen HW, Schalkwijk CG, Heine RJ, Simsek S –
IF 3.239

Van Dommelen L, Smisman A, Goossens VJ, Damoiseaux J, Bruggeman CA, van Tiel FH, Hoebe C.
Evaluation of a rapid one-step immunochromatographic test and two immunoenzymatic assays for the detection of anti- treponema pallidium antibodies. Sex Transm Infect 2008; 84: 230-6
IF 2.616

Dorhout Mees SM, van Oostendenbrugge RJ –
IF 1.917

Glycemic index and glycemic load in relation to food and nutrient intake and metabolic risk factors in a Dutch population. Am J Clin Nutr 2008; 87(3): 655-61
IF 6.503

Duits A, Munne com T, van Heughten C, van Oostendenbrugge RJ –
Cognitive complaints in the early phase after stroke are not indicative of cognitive impairment. J Neurol Neurosour Ps 2008; 79(2): 143-6
IF 3.857

Van Eijndhoven HW, Jansen GM, Aardenburg R, Spaan derman ME, Peeters LHL, de Mey JGR –
IF 2.463

IF 1.412

Van Grievenbroek MMJ, Zhang J, van der Kallen C, Schif fers PMH, Feskens EJM, de Bruin TW –
IF 2.419

Griffioen AW –
New entry in angiostatic cancer therapy. Blood 2008; 111: 1755-1756
IF 10.896

Griffioen AW –
IF 3.728

Modification of LDL with oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (oxPAPC) results in a novel form of minimally modified LDL that modulates gene expression in macrophages. BB A-Genera Subjects 2008; 171: 336-343
IF 2.371

Interobserver agreement of scoring of histopathological characteristics and classification of lupus nephritis. Nephrol Dial Transplant 2008; 23: 223-230
IF 3.167

IF 8.261
IF 1.422

Hanevark JC, Bast A – Why RDAs and ULs are incompatible standards in the U-shape micronutrient model: a philosophically oriented analysis of micronutrients’ standardizations. Risk Anal 2008; 28(6): 1639-1652
IF 1.784

IF 7.194

IF 7.446

IF 3.067

IF 5.246

IF 2.989

Van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K, Van Heerebeek L, Hamdani N, Handoko ML, Musters RJ, Kupreishvili K – Intracoronary infusion of autologous mononuclear bone marrow cells in patients with acute myocardial infarction treated with primary PCI: CCL3 (MIP-1α) levels are elevated during acute coronary syndromes and show strong prognostic power for future ischemic events. J Mol Cell Cardiol 2008; 45(3): 446-452
IF 5.246

IF 7.194

IF 4.364

Henskens LHG, van Oostenbrugge RJ, Kroon AA, de Leeuw PW, Lodder J – Brain microbleeds are associated with ambulatory blood pressure levels in a hypertensive population. Hypertension 2008; 51: 62-68
IF 7.194

IF 4.364

Hermeling E, Reesink KD, Reneman RS, Hoeks APG – Confluence of incident and reflected waves interferes with systolic foot detection of the carotid artery distension waveform. J Hypertens 2008; 26: 2374-2380
IF 4.364

IF 4.29

IF 3.087

IF 5.246

IF 4.377

IF 2.099

IF 7.194

IF 2.647


CARIM 107
IF 5.423

IF 3.405

IF 2.532

IF 2.55

IF 3.084

IF 4.003

Molin DGM, van den Akker NMS, Post MJ – Affirmative action of osteopontin on endothelial progenitors. Arterioscl Throm Vas 2008; 29(12): 2099-100
IF 7.221

IF 3.084

IF 3.167

IF 3.981

IF 4.045

IF 3.632

IF 7.672

Nyberg JL, Kiers L, Eagan LA, Rabe KG, van der Heijde DM – Efficacy of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant. Pharmacogenet Genom 2008; 18: 631-6
IF 5.775

Oett EB, van den Akker NMS, Saksalis PA, Gittenberger-de Groot AC, Te Velthuis AJ, Pasman WK, Bagowski CP – The lip domain only protein 7 is important in zebrashift heart development. Dev Dynam 2008; 237(12): 3940-52
IF 3.084

IF 2.47

IF 4.364

IF 7.924

IF 4.922

IF 1.235

IF 3.151

IF 5.775

IF 8.261
Compromised CD4+CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunoology 2008; 123: 79-89
IF 3.398

Verberk WJ, Kessels AG, de Leeuw PW –
IF 3.102

IF 4.003

Vlooswijk MC, Jansen JF, Reijis RP, de Krom MC, Koil ME, Majioe HJM, Hofman PAM, Backes WH, Aldenkerkerer AP –
IF 1.553

IF 11.054

Vos MR, Bornans PH, Frederik PM, Sommerdijk NA –
IF 1.996

Wijnen PA, Drent M, Nelemans PJ, Kuipers PMJC, Koek GH, Neef C –
Role of cytochrome p450 polymorphisms in the development of pulmonary drug toxicity: a case-control study in the Netherlands. Drug Safety 2008; 31(12):1125-34
IF 3.536

Wisse E, Jacobs F, Topal B, Frederik PM, de Geest B –
IF 4.812

Short-term and long-term repeatability of the morning blood pressure in older patients with isolated systolic hypertension. J Hypertens 2008; 26: 1329-35
IF 3.364

Increased release of sMD-e during human endotoxemia and sepsis: a role for endothelial cells. Mol Immunol 2008; 45(11): 3268-3277
IF 3.742

Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of NASH. Hepatology 2008; 48: 474-486
IF 10.734

Xanthoulea SA, Gijbels MJJ, van der Made I, Mijucic H, Thelen M, Vergouwe MN, Ambagts MH, Hofker MH, de Winther MPJ –
IF 6.127

IF 4.901

Zafarman MH, Franx A, Sabour S, van der Schouw YT, Grobbee DE, de Leeuw PW, Bots ML –
The M235T variant of the angiotensinogen gene is related to development of self-reported hypertension during pregnancy: the Prospect-EPIC cohort study. Hypertens Res 2008; 31:1299-305
IF 2.951

Zafarman MH, van der Schouw YT, Grobbee DE, de Leeuw PW, Bots ML –
IF 11.054

Zafarman MH, Franx A, Sabour S, van der Schouw YT, Grobbee DE, de Leeuw PW, Bots ML –
IF 6.603

Zemse SM, Hilgers RHP, Slmkins GB, Rudic RD, Webb RC –
IF 1.587

IF 9.721

Zhang L, Qiao O, Tumilieho J, Hammar N, Alberti KG, Eliaason M, Heine RJ, Stenhower CDA, Ruotolo G –
IF 1.823


Croes S, Deurenberg RHCA, Boumans MLL, Beisser PSF, Neef C, Stoberbinger EE – Staphylococcus aureus biofilm formation at the carotid plaque analysis: comparison of dual-source computed tomography (CT) findings and histopathological correlation. Eur J Vasc Endovasc 2009; 39: 14-9 IF 3.007


Hellenthal FAMVI, Buurman WA, Wodzig KWH, Schurink GWH –
IF 0
IF 6.288
An optimized flow cytometry protocol for analysis of angiogenic monocytes and endothelial progenitor cells in peripheral blood. Cytometry Part A 2009; 75: 848-53
IF 3.269
Hyper-intensive low-density lipoprotein cholesterol as a marker of subclinical atherosclerosis in the European Prospective Investigation Into Cancer and Nutrition (EPIC) study. Atherosclerosis 2009; 208: 58-63
IF 3.704
IF 6.754
A low-density lipoprotein cholesterol index improves the association with inflammatory markers. Atherosclerosis 2009; 207: 76-81
IF 3.704
The association of low-density lipoprotein cholesterol with markers of inflammation and arterial stiffness in the EPIC study. Atherosclerosis 2009; 208: 58-63
IF 3.704
Low-density lipoprotein cholesterol as a marker of subclinical atherosclerosis in the European Prospective Investigation Into Cancer and Nutrition (EPIC) study. Atherosclerosis 2009; 208: 58-63
IF 3.704
IF 6.754
A low-density lipoprotein cholesterol index improves the association with inflammatory markers. Atherosclerosis 2009; 207: 76-81
IF 3.704
Low-density lipoprotein cholesterol as a marker of subclinical atherosclerosis in the European Prospective Investigation Into Cancer and Nutrition (EPIC) study. Atherosclerosis 2009; 208: 58-63
IF 3.704
A low-density lipoprotein cholesterol index improves the association with inflammatory markers. Atherosclerosis 2009; 207: 76-81
IF 3.704
Low-density lipoprotein cholesterol as a marker of subclinical atherosclerosis in the European Prospective Investigation Into Cancer and Nutrition (EPIC) study. Atherosclerosis 2009; 208: 58-63
IF 3.704
A low-density lipoprotein cholesterol index improves the association with inflammatory markers. Atherosclerosis 2009; 207: 76-81
IF 3.704
Low-density lipoprotein cholesterol as a marker of subclinical atherosclerosis in the European Prospective Investigation Into Cancer and Nutrition (EPIC) study. Atherosclerosis 2009; 208: 58-63
IF 3.704
Low-density lipoprotein cholesterol as a marker of subclinical atherosclerosis in the European Prospective Investigation Into Cancer and Nutrition (EPIC) study. Atherosclerosis 2009; 208: 58-63
IF 3.704
Low-density lipoprotein cholesterol as a marker of subclinical atherosclerosis in the European Prospective Investigation Into Cancer and Nutrition (EPIC) study. Atherosclerosis 2009; 208: 58-63
IF 3.704
Low-density lipoprotein cholesterol as a marker of subclinical atherosclerosis in the European Prospective Investigation Into Cancer and Nutrition (EPIC) study. Atherosclerosis 2009; 208: 58-63
IF 3.704
Low-density lipoprotein cholesterol as a marker of subclinical atherosclerosis in the European Prospective Investigation Into Cancer and Nutrition (EPIC) study. Atherosclerosis 2009; 208: 58-63
IF 3.704
Low-density lipoprotein cholesterol as a marker of subclinical atherosclerosis in the European Prospective Investigation Into Cancer and Nutrition (EPIC) study. Atherosclerosis 2009; 208: 58-63
IF 3.704


CARIM


Pons D, Monraats PSJ, Zwijnder HA, de Maat MP, Doevendans PA, de Winter RJ, Tio RA, Jukema JW – Metabolic background determines the importance of NO3 polymorphisms in restenosis after percutaneous coronary intervention: A study in patients with and without the metabolic syndrome. Dis Markers 2009; 26: 75-83 IF 2.303


Punt IM, Cleutjens JPM, de Bruin T, Willems PCPH, Kurtz SM, Van Rhijn LW, Schurink GWH – Periprosthetic tissue reactions observed at revision of total intervertebral disc arthroplasty. Biomaterials 2009; 30(11): 2079-84 IF 6.646


Struyker Boudier HAJ, Blacher J, Levy BI, Safar ME – Introduction to the seventh international workshop on structure and function of the vascular system. Hypertension 2009; 54: 373-374 IF 7.368


IF 5.947

IF 0

IF 1.958

IF 0

IF 3.178

IF 31.718

IF 4.409

IF 7.188

Van Helvoort-Postulart D, Dirksen CD, Kessels AGH, Van Engelshoven JMA, Hunink MG – A comparison between willingness to pay and willingness to give up time. Eur J Health Econ 2009; 10: 81-91
IF 0

IF 11.438

IF 2.303

IF 5.371

IF 6.787

IF 3.77

IF 5.947

Van den Berg BM, Spana JA, Vink H – Impaired glycolycalex barrier properties contribute to enhanced intimal low-density lipoprotein accumulation at the carotid artery bifurcation in mice. Pflugers Archiv-Eur J Physiol 2009; 457(6): 1199-206
IF 3.526

IF 3.149


Weditck NM, Snijder MB, Dekker JM, Heine RJ, Stouwheuer CDA, Nijpels G, Van Dam RM – Prospective investigation of metabolic characteristics in relation to weight gain in older adults: the Hoom Study. Obesity 2009; 17: 1609-14 IF 2.762

Publications in scientific journals (wi-2)


De Mey JGR, Compeer MG, Meens JPMPT – Endothelin-1, an endogenous irreversible agonist in search of an allelicoster inhibitor. Mol Cell Pharmacol 2009; 1: 246-257


Letter to the editor


Brouwers MC, Van GReekenbroek MJM, Cantor RM – Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009; 137(4): 1536 IF 12.591

Daemen MJP, Kool ME – Bridging the gap: Intraplaque hemorrhage identified as a stimulator of episodic growth of advanced but non-symptomatic atherosclerotic lesions. JACC Cardiovasc Imaging 2009; 2: 1390-1392


Publications in scientific journals 2010


IF 2.643


IF 4.522


IF 2.77


IF 9.973


IF 4.451


IF 2.544


IF 2.697


IF 8.111


IF 3.306


IF 1.373


IF 2.645


IF 7.235


IF 3.589


IF 12.64


IF 2.548


IF 7.365

SELF-EVALUATION 2007-2012

CARIM 123


IF 4.523

IF 2.074

IF 2.871

IF 3.998

IF 4.351

IF 2.473

IF 3.306

IF 2.265

IF 4.592

IF 3.396

IF 2.576

IF 0.4182

IF 2.704

IF 1.792

IF 47.05

IF 6.202

IF 3.032

IF 2.425

IF 30.758
Koenen RR, Weber C –
IF 3.549
Koeppel TA, Mess WH, Jacobs MJ –
IF 1.247
Kommann LM, Reesink KD, Reneman RS, Hoeks APG –
IF 2.021
IF 4.965
Kristensen PL, Pedersen-Bjaergaard U, Schalkwijk C, Olsen NV, Thorsteinsson B –
IF 3.559
IF 2.607
Association Between Left Ventricular Mass and Systolic and diastolic left ventricular dysfunction: from risk factors to overt heart failure. Expert Rev Cardiovasc Ther 2010; 8: 251-258
IF 5.589
Kuznetsova T, Herbots L, Jin Y, Stolarz-Skrzypek K, Staessen JA –
Systolic and diastolic left ventricular dysfunction: from risk factors to overt heart failure. Expert Rev Cardiovasc Ther 2010; 8: 251-258
IF 5.589
Kwee RM –
Kwee RM –
IF 3.517
Kwee RM –
Kwee RM –
Carotid Plaques in Transient Ischemic Attack and Stroke Patients One-Year Follow-up Study by Magnetic Resonance Imaging. Investigative Radiology 2010; 45(12): 803-809
IF 4.85
Langelaan MLP, Boonen KJMJ, Polak RB, Baaijens FPT, Post MJ, Van der Schaft DWJ –
Meet the new meat: tissue engineered skeletal muscle. Trends in Food Science & Technology 2010; 21(2): 59-66
IF 4.051
Capture of endothelial progenitor cells by a bispeciﬁc protein/monoclonal antibody molecule induces reendothelialization of vascular lesions. Journal of Molecular Medicine-Jmm 2010; 88(7): 687-699
IF 5.004
IF 0.5
Chronic kidney disease aggravates arteriogenous fistula damage in rats. Kidney International 2010; 78(12): 1312-1321
IF 6.193
IF 7.235
Lauret AM, Mingels AMA, Winkens MHM, Roozen I, Schellings MWM, Leiner T, Wildberger JE, Narula J, Van Diejen-Visser MP, Hofstra -
The Extent of Coronary Atherosclerosis is Associated With Increasing Circulating Levels of High Sensitive Cardiac Troponin T. Arteriosclerosis Thrombosis and Vascular Biology 2010; 30(6): 1269-1275
IF 7.235
Regulation of Cardiac Gene Expression by KLF15, a Repressor of Myocardin Activity. Journal of Biological Chemistry 2010; 285(35): 27449-27456
IF 5.328
Legay C, Bosboom EM, Gelderblom H, Hoeks APG, Van de Vosse FH –
Estimation of distributed arterial mechanical properties using a wave propagation model in a reverse way. Medical Engineering & Physics 2010; 32(9): 957-967
IF 1.674
IF 6.424
IF 8.202
Kietadisorn R, Schmidt HH, Moens AL –
Folic Acid as a cardiovascular drug: dose matters. Am J Cardiol 2010; 106(11): 1673-4
IF 3.575
Post-Stroke Inhibition of Induced NADPH Oxidase Type 4 Prevents Oxidative Stress and Neurodegeneration. Plos Biology 2010; 8(9): 13 IF 12.916
Klinkhammer K, Bockelmann J, Simitzis C, Brook GA, Graafhend D, Groll J, Moller M, De Mey JGR, Klee D –
Functionalization of electropun fibers of polycaprolactone with star shaped NCO-poly(epsilon-caprolactone) with star shaped NCO-poly(epsilon-caprolactone) with star shaped NCO-poly(epsilon-caprolactone) with star shaped NCO-poly(epsilon-caprolactone) for neuronal cell guidance. Journal of Materials Science-Materials in Medicine 2010; 21(9): 2637-2651
IF 1.955
Kluza E, Van der Schaft DWJ, Hautvast PAI, Mulder WJMJ, Mayo KH, Griffioen AW, Strijkers GJ, Niclasy K –
IF 9.991
Knetsh MLW, Koole LH –
IF 2.816
IF 7.041
Koenen RR, Weber C –
IF 3.214
Koenen RR, Weber C –
IF 29.059


Machshyn I, Bovendeerd PHM, Van de Vosse FF - Stability against dynamic by remodeling of an arterial tissue. J Eng Math 2010; 67: 175-192 IF 0.691


Signalling pathways in vasculogenic mimicry. Paulis YWJ, Soetekouw P, Verheul HMW, Tjan-779-785


Vooren JD, Van der Ven A, Mulder M, Lodder J, Steinbusch HWM, Bruggerman CA – Chlamydia pneumoniae infection enhances microglial activation in atherosclerotic mice. Neurobiology of Aging 2010; 31(10): 1766-1773 IF 5.937


Whitehead DS – Intranasal Fentanyl in Patients Undergoing Drain Removal After Breast Reduction or Augmentation Surgery: A Prospective, Randomized, Double-blind, Placebo-Controlled Study. Clinical Therapeutics 2010; 32(7): 1427-1436 IF 3.25


Strijkers GJ, Van Tilborg GA, Geelen T, Reutelingsperger CP, Nicolay K – Current applications of nanotechnology for magnetic resonance imaging: the effect of sampling frequency and duration. Physics in Medicine and Biology 2011; 56(17): 5655-5678


IF 3.064


IF 1.791


IF 2.526


IF 2.789


IF 4.944


IF 3.532


IF 3.072


IF 4.086

Brouwers M, van Greevenbroek MMJ, Troutt JS, Freeman AG, Lu A, Schaper NC, Konrad RJ, Stehouwer CDA – Plasma propionate convertase subtilisin kexin type 9 is a heritable trait of familial combined hyperlipidemia. Clinical Science 2011; 121(9-10): 397-403

IF 4.613


Bussel BCT, Henry RMA, Schalkwijk CG, Ferreira I, Feskens EJM, Strepel MT, Smulders YM, Twisk JWR, Stehouwer CDA – Fish Consumption in Healthy Adults Is Associated with Decreased Circulating Biomarkers of Endothelial Dysfunction and Inflammation during a 6-Year Follow-Up. Journal of Nutrition 2011; 141(9): 1719-25 IF 4.295


De Mey JGR, Compeer MG, Lemkens P, Meens M – ETA-receptor antagonists or allosteric modulators?. Trends in Pharmacological Sciences 2011; 32(6): 345-351 IF 11.05

De Mooij YM, van den Akker NMS, Bekker MN, Bartelings MM, van Vugt JMG, Gitteiner-de Grood AC – Abluminal lymphatic development in euploid fetuses with increased nuchal translucency including Noonan syndrome. Prenatal Diagnosis 2011; 31(2): 159-166 IF 2.152


Hoff EL, Steinbusch HWM, van Oostenbrugge RJ, Garret L, Otte WM, van der Marel K, Dijkhuizen RM – Alterations in the cholinergic system after forebrain contusion in rat brain: Pharmacological magnetic resonance imaging of muscarinic receptor responsiveness and stereological analysis of cholinergic forebrain neurons. Neurobiolology of Disease 2011; 43(5): 625-634 IF 5.121


Jonk AM, Houben AJ, Schaper NC, de Leeuw PW, Serne EH, Smulders YM, Stehouwer CD – Obesity is associated with impaired endothelial function in the postprandial state. Microvascular Research 2011; 82(3): 570-575 IF 4.646


Jonk AM, Houben AJ, Schaper NC, de Leeuw PW, Serne EH, Smulders YM, Stehouwer CD – Meal-Related Increases in Microvascular Vasomotion Are Impaired in Obese Individuals A potential mechanism in the pathogenesis of obesity-related insulin resistance. Diabetes Care 2011; 34: S342-S348 IF 7.141


SELF-EVALUATION 2007-2012


Rationale and design of the Newer Versus Older Antiplatelet Agents in African Hypertensive Patients (NOAH) trial. Blood Pressure 2011; 20(5): 256-266

IF 1.256

Olieslagers S, Pardi D, Tchaikovski V, ten Dijke P, Waltenberger J –

TGF-beta 1/ALK5-induced monocyte migration involves PI3K and p38 pathways and is not negatively affected by diabetes mellitus. Cardiovascular Research 2011; 91(3): 510-518

IF 6.051


Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants [the STOP-BPD study]; a multicenter randomized placebo controlled trial. BMC Pediatr 2011; 11: 102

IF 1.904


MRA of renal oxygenation and function after normothermic ischemia-reperfusion injury. Nmr in Biomedicine 2011; 24(2): 194-200

IF 3.064

Peppelensbosch AG, de Haan MW, Daemen J, Schurink GWH –


IF 2.942

Peters SA, Palmer MK, Grobbée DE, Crouse JR 3rd, Evans GW, Raichlen JS, Bots ML, Staessen JA –


IF 3.872


IF 2.872

Reijmer YD, van den Berg E, Dekker JM, Nijpels G, Stehouwer CDA, Kappelle LJ, Biessels GJ –


IF 4.086

Reijmer YD, van den Berg E, sonsbeek S, Dekker JM, Nijpels G, Stehouwer CDA, Kappelle JL, Biessels GJ –

Dementia Risk Score Predicts Cognitive Impairment after a Period of 15 Years in a Non-Demented Population. Dementia and Geriatric Cognitive Disorders 2011; 31(2): 152-157

IF 2.455

Reitsma S, Oude Egbrink M, Heijnen VVT, Megens RTA, Engels W, Vink H, Slaaf DW, van Zandvoort M –

Endothelial glyocalyx thickness and platelet-vessel wall interactions during atherosclerosis. Thrombosis and Haemostasis 2011; 106(5): 939-945

IF 4.701


IF 3.129

Roijers RB, Debernardi N, Cleutjens JP, Schwurig LJ, Mutsaers PH, van der Vusse GJ –

Cardiac lipid content is unresponsive to a physical activity training intervention in type 2 diabetic patients, despite improved exercise faction. Cardiovascular Diabetology 2011; 10: 7

IF 2.72

Schreinemacher MH, Bloemen JG, van der Heijden SJ, Gijbels MJ, Dejongh CH, Bouvy ND –

Collagen fibers do not improve colonic anastomotic strength but increase bowel obstructions in an experimental rat model. International Journal of Colorectal Disease 2011; 26(8): 729-735

IF 2.645

Schreinemacher MHH, Vijgen G, Dagenelle PC, Bloemen JG, Huizinga BF, Bouvy ND –


IF 4.5


IF 1.719

Scholten RR, Sep S, Peeters L, Hopman MTE, Lotgering FK, Spaanderman MEA –


IF 4.392

Schouten F, Twisk JW, de Boer MR, Stehouwer CD, Smeulders YM, Ferreira I –

Increases in central fat mass and decreases in peripheral fat mass are associated with accelerated arterial stiffening in healthy adults: the Amsterdam Growth and Health Longitudinal Study. American Journal of Clinical Nutrition 2011; 94(1): 40-48

IF 6.806


Cardiac lipid content is unresponsive to a physical activity training intervention in type 2 diabetic patients, despite improved exercise faction. Cardiovascular Diabetology 2011; 10: 7

Schrauwren-Mer, Vijgen G, Dagenelle PC, Bloemen JG, Huizinga BF, Bouvy ND –


IF 4.5


IF 1.719

Sep S, Rijvers C, Smits L, van Bilsen M, Bekers O, Peeters L –


IF 2.353
Young adulthood is associated with higher arterial JWR, Ferreira I – Van de Laar RJJ, Stehouwer CDA, Boreham CA, Pinto YM, Schroen B, Carmeliet P, Heymans S – Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy. Journal of Molecular and Cellular Cardiology 2011; 51(3): 318-328

EF 5.499


EF 1.842


EF 4.512


IF 3.381


IF 2.539


IF 1.909


IF 6.051


IF 4.411


IF 1.842


IF 6.525


IF 3.162


IF 4.512


IF 3.381


IF 2.539


IF 1.909


IF 6.051


IF 4.411


IF 1.842


IF 6.525


IF 3.162


IF 4.512


IF 3.381


IF 2.539


IF 1.909

van der Zwan LP, Scheffer PG, Dekker JM, Stehouwer CDA, Heine RJ, Teerlink T – Systemic inflammation is linked to low arginine and high ADMA plasma levels resulting in an unfavourable NO substrate-to-inhibitor ratio: the Hoorn Study. Clinical Science 2011; 121(1-2-2012): 71-78

IF 4.613

Van der Zwan LP, Scheffer PG, Dekker JM, Stehouwer CDA, Heine RJ, Teerlink T – Systemic inflammation is linked to low arginine and high ADMA plasma levels resulting in an unfavourable NO substrate-to-inhibitor ratio: the Hoorn Study. Clinical Science 2011; 121(1-2-2012): 71-78

IF 4.613


Ter Bekke RMA, Crijns HJ, Kroon AA, Gorgels APM –
Pheochromocytoma-induced ventricular tachycardia and reversible cardiomyopathy.
International Journal of Cardiology (Letter) 2011; 147(1): 145-146

Van Domenen DR, Koster A, Harris TB –

Van Overbeek EC, van Oostenbrugge RJ –
932-932

Xu TY, Li Y, Fan WX, Li FH, Zou J, Gao PJ, after Intravenous Thrombolysis. Cerebrovascular Middle Cerebral Artery Sign and Stroke Outcomes

Adriansen ME, Jailillard M, Eijssen LMT, Mayer CD, Evelo CTA –
An evaluation of two-channel ChIP-on-chip and DNA methylation microarray normalization strategies. BMC Genomics 2012; 13: 42
IF 4.073

Albert-Weissenberger C, Stetter C, Mouth SG, Gübel K, Bader M, Siren AL, Kleinschnitz C –
Blocking of bradykinin receptor B1 protects from focal closed head injury in mice by reducing axonal damage and astroglia activation. J Cerebr Blood F Met 2012; 32: 1747-56
IF 5.008

Effect of Benfotamine on Advanced Glycation Endproducts and Markers of Endothelial Dysfunction and Inflammation in Diabetic Nephropathy. Plos One 2012; 7(7): e40427
IF 4.092

Sustained acute voltage-dependent blood pressure decrease with prolonged carotid baroreflex activation in therapy-resistant hypertension. Journal of Hypertension 2012; 30(8): 1685-1670
IF 4.021

Alsa M, Guest PC, Schwarz E, Re A, Kettel-Schneider S, Spain M, Rahmouve H, Bahn S –
Analysis of serum and plasma identities differences in molecular coverage, measurement variability, and candidate biomarker selection. Proteom Clin Appl 2012; 6(5-6): 297-303
IF 1.97

Allesma M, Newson RS, Bakker SJL, Stenhouver CBA, Heymans MW, Nijpels G, Hilleges HL, Hofman A, Witteman JCM, Gansevoort RT, Dekker JM –
One Risk Assessment Tool for Cardiovascular Disease, Type 2 Diabetes, and Chronic Kidney Disease. Diabetes Care 2012; 35(4): 741-748
IF 8.087

The NOX toolbox: validating the role of NADPH oxidases in molecular coverage, measurement variability, and candidate biomarker selection. Proteom Clin Appl 2012; 6(5-6): 297-303
IF 1.97

CD36 inhibition prevents lipid accumulation and contractile dysfunction in rat cardiomyocytes. Biochemical Journal 2012; 448: 43-53
IF 4.897

Aparicio-Vergara M, Shirli-Sverdlov R, Koonen DPY, Hofker MH –
Bone marrow transplantation as an established approach for understanding the role of macrophages in atherosclerosis and the metabolic syndrome. Current Opinion in Lipidology 2012; 23(2): 111-121
IF 6.086

Arnoldussen CW, Toonder I, Wittens CH –
An imaging approach to deep vein thrombosis and the lower extremity thrombosis classification. Phlebology 2012; 27(1): 143-8
IF 2.072

Arnoldussen CW, Wittens CH –
A novel scoring system for lower-extremity venous pathology analysed using magnetic resonance venography and duplex ultrasound. Phlebology 2012; 27(1): 163-70
IF 2.072

Hypertension Outcome T –
Hypertension Objective T –
Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertension Research 2012; 35(11): 1102-1110
IF 2.576

Mother-offspring aggregation in home versus home blood pressure. Hypertension Research 2012; 35(11): 1102-1110
IF 2.576

Hypertension Outcome T –
Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertension Research 2012; 35(11): 1102-1110
IF 2.576

IF 0.605

Austen S, Punt IM, Cleutjens JP, Willems PC, Kurtz SM, MacDonald DW, van Rijn LW, van Ooj A –
Clinical, radiological, histological and retrieval findings of Activ-L and Mobidisc total disc replacements: a study of two patients. Eur Spine J 2012; 21(4): 513-520
IF 1.965

Bachmair EM, Bots ML, Mennen LI, Kelder T, Evelo CT, Horgan GW, Ford I, de Roos B –
IF 4.301

Baetke SC, Adriansen ME, Seigneuric R, Evelo CT, Eijssen LMT –
IF 4.092
NASH and atherosclerosis are two aspects of a shared disease: Central role for macrophages.


IF 1.45


IF 3.373


IF 5.289


IF 4.092


IF 4.092


IF 5.431


IF 4.156


IF 5.431


IF 4.092


IF 5.431


IF 5.431


IF 4.459


IF 4.092


IF 14.739


IF 3.026


IF 2.546


IF 2.382


IF 4.773


IF 4.022


IF 4.077


IF 4.578


IF 4.092


IF 14.739


IF 6.368


IF 6.368


IF 6.207


IF 13.689


IF 6.207


IF 5.58


IF 9.264


IF 4.092


IF 5.044


IF 2.346


IF 2.73


IF 5.227


IF 5.227

IF 2.566


2.897


IF 4.092


IF 0.236


IF 3.153


IF 11.08


IF 5.895


IF 4.092


IF 9.663


IF 8.087


IF 8.087


IF 1.895


IF 9.489

Hanssen NMJ, Huijbers MS, Schalkwijk CG, Nijpels G, Dekker JM, Stehouwer CDA – Associations Between the Ankle-Brachial Index and Cardiovascular and All-Cause Mortality Are Similar in Individuals Without and With Type 2 Diabetes Nineteen-year follow-up of a population-based cohort study. Diabetes Care 2012; 35(8): 1731-1735

IF 8.087


IF 0.882


IF 2.305


IF 6.814


IF 5.729


IF 3.373


IF 5.227


IF 1.771


IF 2.123
Self-Evaluation 2007-2012


Kleinschitz C, Plesniak N - Experimental therapy approaches for ischemic stroke. Nervenarzt 2012; 83(1): 1275-1281


IF 3.396

IF 4.409

IF 38.278

IF 4.092

IF 2.598

IF 2.203

IF 6.368

IF 2.205

IF 13.069

IF 2.527

IF 2.576

IF 3.423

IF 6.814

IF 3.346

IF 2.496

IF 3.597

IF 3.731

Pinto LA, Vandewalle E, De Clerck E, Marques-Neves C, Stalmans I – Ophthalmic artery Doppler waveform changes associated with increased damage in glaucoma patients. Invest Ophth Vis Sci 2012; 53: 2448-2453
IF 3.597

IF 2

Pijpers E, Ferreira I, de Jongh RT, Deeg DJ, Lips P, Stehouwer CDA, Nieuwenhuijzen Kruseman CA – Older individuals with diabetes have an increased risk of recurrent falls: analysis of potential mediating factors: the longitudinal Ageing Study Amsterdam. Age and Ageing 2012; 41(3): 358-365
IF 3.09

IF 4.243

IF 2.275

IF 6.368

IF 2.775

IF 4.992

IF 2.775

IF 1.977
Reiberi M, Verburg FA, Palmowski M, Krohn T, Pletsch H, Kuhl CK, Mottaghy FM, Behrendt FF –
Multiphase CT scanning and Different Intraoperative contrast media concentrations in combined F-18-
81(8): E862-E869
IF 2.606

Meta-analysis argues for a female-specific role of MAAO-αVNR in panic disorder in four European populations. Am J Med Genet B 2012; 159B(7): 786-793
IF 3.705

Reijmer YD, van den Berg E, Dekker JM, Nijpels G, Stehouwer CDA, Kappelle LJ, Biessels GJ –
Development of Vascular Risk Factors over 15 Years in Relation to Cognition: The Hoorn study.
American Journal of the Geriatric Societies 2012; 60(8): 1426-1433
IF 3.737

Lelong physical activity in maintaining bone health in older men and women of the Age, Gene
Environment Susceptibility-Reykjavik Study. Osteoporosis Int 2012; 23(9): 2303-2312
IF 4.58

IF 2.385

An association study of sequence variants in the forkhead box P2 (FOXP2) gene and adulthood attention-deficit/hyperactivity disorder in two European samples. Psychol Genet 2012; 22(4): 155-160
IF 3.581

Rocha MC, Santos LMB, Bagatin E, Cohen Tervaert JW, Damoiseaux J, Lido AV, Longhini AL, Torello CO, Queiroz MLS –
Genetic polymorphisms and surface expression of CTLA-4 and PD-1 on T cells of silica-exposed workers. International Journal of Hygiene and Environmental Health 2012; 215(8): 562-569
IF 3.809

Erythrocytophaphersis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial. Transfusion 2012; 52(3): 476-477
IF 3.217

Ronen RA, Houben A, Teneerink T, Bakker JA, Bierau J, Stehouwer CDA, de Leeuw PW, Kroon AA –
Reduced renal plasma clearance does not explain increased plasma asymmetric dimethylarginine in hypertensive subjects with mild to moderate renal insufficiency. American Journal of Physiological- Renal Physiology 2012; 303(1): F149-F156
IF 3.682

IF 6.189

IF 5.729

IF 2.606

Tissue Doppler indexes of left ventricular systolic function in relation to the pulsatillity and steady components of blood pressure in a general population. Journal of Hypertension 2012; 30(3): 403-410
IF 4.021

Tissue Doppler indexes of left ventricular systolic function in relation to the pulsatillity and steady components of blood pressure in a general population. Journal of Hypertension 2012; 30(3): 403-410
IF 4.021

IF 35.532

Schalkwijk CJ, Miyata T –
IF 3.248

Schaper NC –
Lessons from eurodiale. Diabetes-Metabolism Research and Reviews 2012; 28: 21-26
IF 3.373

Diagnosis and treatment of peripheral arterial disease in diabetic patients with a foot ulcer. A progress report of the International Working Group on the Diabetic Foot. Diabetes-Metabolism Research and Reviews 2012; 28: 218-224
IF 3.373

Schaper NC, Apeqijst J, Bakker K –
IF 6.814

Schelten M, Bijnings C –
IF 1.2

Scheijen J, Hanssen NMJ, van de Waarenburg MPH, Jonkers D, Stehouwer CDA, Schalkwijk CG –
L(+) and D(-) Lactate Are Increased in Plasma and Urine Samples of Type 2 Diabetes as Measured by a Simultaneous Quantification of L(+) and D(-) Lactate by Reversed-Phase Liquid Chromatography Tandem Mass Spectrometry. Experimental Diabetes Research 2012; 2012: 234812
IF 1.0

Scheltering M, Brienckins CAM –
Haemodialysis access induced distal ischemia is caused by hypotension and not by steal. Eur J Vasc Endovasc 2012; 43(2): 218-223
IF 2.591

1.757

Myocardial regeneration by transplantation of modified endothelial progenitor cells expressing SDF-1 in a rat model. Journal of Cellular and Molecular Medicine 2012; 16(10): 2311-2320
IF 4.125
IF 4.092

IF 6.207

IF 4.773

IF 5.58

IF 6.368

IF 4.73

IF 3.794

IF 12.539

IF 3.794

Strooijker-Boudier HAJ, Heijnen BFJ, Liu YP, Staessen JA – Phenotyping the microcirculation. Hypertension 2012; 60(2): 523-527
IF 6.207

IF 2.382

IF 2.606

Teunissen-Beekman KFM, Dopheide J, Geleijnse JM, Bakker SJJL, Brink EJ, de Leeuw PW, van Baak MA – Protein supplementation lowers blood pressure in overweight adults: effect of dietary proteins on blood pressure (PROPROPES), a randomized trial. American Journal of Clinical Nutrition 2012; 95(4): 986-971
IF 6.669

IF 4.2

IF 6.207

Touwslager RHN, Houben A, Gielen M, Zeegers MP, Stehouwer CDA, Zimmermann LJ, Sagen IF 3.794

IF 1.494

IF 1.091

IF 5.227

IF 3.386

IF 6.105

IF 2.391

IF 4.092

IF 4.092

IF 2.606

IF 2.606

IF 2.606

Wildberger JE, Fink C, Henzler T – Quantification of left and right ventricular function and myocardial mass: Comparison of love-radiation dose 2nd generation dual-source CT and cardiac MRI. European Journal of Radiology 2012; 81(4): E598-E604
IF 2.606

**Atherosclerosis**


IF 1.987


**Journal of Cardiology**

Vitamin D in relation to myocardial structure and function after eight years of follow-up: the Hoorn study. Annals of Nutrition and Metabolism 2012; 60(1): 69-77

IF 2.257

Van Buszel BCT, Henry RMA, Chawalik CG, Dekker JM, Nijpels G, Stehouwer CDA –

**Cardiovascular Physiology**

Low grade inflammation, but not endothelial dysfunction, is associated with greater carotid stiffness in the elderly; the Hoorn Study. Journal of Hypertension 2012; 30(4): 744-752

IF 4.021


**Diabetes and Vascular Endoscopy Surgery**


IF 8.087


**Arthritis Research & Therapy**


IF 9.38


**Arteriosclerosis Thrombosis and Vascular Biology**


IF 2.991

Van der Vorst EPc, Keijbeck AA, de Winther MPJ, Donners M –

**American Journal of Hypertension**

A disintegrin and metalloproteases: Molecular scissors in angiogenesis, inflammation and atherosclerosis. Atherosclerosis 2012; 224(2): 302-308

IF 3.794

Van Dijk JW, Manders RJF, Tummers K, Bonomi CA, Stehouwer CDA, Hartgens F, van Loon LJC –

**Diabetes Care**

Both resistance- and endurance-type exercise reduce the prevalence of hyperglycemia in individuals with impaired glucose tolerance and in insulin-treated and non-insulin-treated type 2 diabetic patients. Diabetologia 2012; 55(5): 1273-1282

IF 6.814

Van Dijk JW, Tummers K, Stehouwer CDA, Hartgens F, van Loon LjC –

**Arthritis Research & Therapy**

Exercise therapy in type 2 diabetes is daily exercise required to optimize glycemic control?. Diabetes Care 2012; 35(5): 948-954

IF 8.087

Van Dijk S, Van den Beukel TO, Dekker FW, le Cessie S, Kaptein AA, Honig A, Siegent CE, Boeschoten EW, Krediet RT –

**Rheumatology**

Different type of carotid arterial wall remodeling – comparison of quantication of left ventricular thickness and disease progression. Rheucom Archiv 2012; 46(1): 441-448

IF 2.491


**Vascular Cell Culture**


IF 6.368

Van Onzenoorth HA, Neef C, Verberk WW, Van Iperen HP, de Leeuw PW, van der Kuy PH –

**Journal of Endocrinology, Metabolism and Cardiovascular Diseases**

Determining the feasibility of objective adherence measurement with blister packaging smart technology. American journal of health-system pharmacy 2012; 69(10): 872-9

IF 1.962

Van Onzenoorth HAW, Verberk WJ, Kroon AA, Kessels AGH, Neef C, van der Kuy PHM, de Leeuw PW –

**American Health-System Pharmacist**


IF 3.181


**International Arterial Wall Remodeling in Rheumatoid Arthritis Compared with Healthy Subjects: A Case-Control Study. Journal of Rheumatology**


IF 3.695

Van Sloten TT, Pijpers E, Stehouwer CDA, Brouwer M –

**Metabolism**


IF 2.754


**The CoDAM study. Nutrition Metabolism and Cardiovascular Diseases**

Comparison of fatty acid proportions in serum cholesteryl esters among people with different glucose tolerance status. The CoDAM study. Nutrition Metabolism and Cardiovascular Diseases 2012; 22(2): 133-140

IF 3.731


**Hypertension**

Stations accelerate the onset of collagen type II-induced arthritis in mice. Arthritis Research & Therapy 2012; 14(2): R90

IF 4.445

**Journal of Clinical Endocrinology & Metabolism**

Differentiation of Antibodies against the Thrombin-Generation of Antigenic Conjugates by VEGF and Notch: An act by VEGF and Notch. Differentiation 2012; 84(1): 62-78

IF 3.731

Van der Steenhoven TJ, Bosman W, Tersteeg C, Jacobs Mj, Moll FL, de Groot PG, Heyligers JMM –

**Arteriosclerosis Thrombosis and Vascular Biology**


IF 2.991

Van der Vorst EPc, Keijbeck AA, de Winther MPJ, Donners M –

**American Journal of Hypertension**

A disintegrin and metalloproteases: Molecular scissors in angiogenesis, inflammation and atherosclerosis. Atherosclerosis 2012; 224(2): 302-308

IF 3.794

Van Dijk JW, Manders RJF, Tummers K, Bonomi CA, Stehouwer CDA, Hartgens F, van Loon LjC –

**Arthritis Research & Therapy**

Exercise therapy in type 2 diabetes is daily exercise required to optimize glycemic control?. Diabetes Care 2012; 35(5): 948-954

IF 8.087

Van Dijk S, Van den Beukel TO, Dekker FW, le Cessie S, Kaptein AA, Honig A, Siegent CE, Boeschoten EW, Krediet RT –

**NECOSAD Study Group**

Metformin-associated lactic acidosis in a patient with normal kidney function. Diabetes Research and Clinical Practice 2012; 96(3): E57-E58

IF 2.754


**The CoDAM study. Nutrition Metabolism and Cardiovascular Diseases**

Comparison of fatty acid proportions in serum cholesteryl esters among people with different glucose tolerance status. The CoDAM study. Nutrition Metabolism and Cardiovascular Diseases 2012; 22(2): 133-140

IF 3.731